WO2013014567A1 - Indazoles - Google Patents

Indazoles Download PDF

Info

Publication number
WO2013014567A1
WO2013014567A1 PCT/IB2012/053546 IB2012053546W WO2013014567A1 WO 2013014567 A1 WO2013014567 A1 WO 2013014567A1 IB 2012053546 W IB2012053546 W IB 2012053546W WO 2013014567 A1 WO2013014567 A1 WO 2013014567A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluoro
ethyl
indazol
tetrahydro
imidazo
Prior art date
Application number
PCT/IB2012/053546
Other languages
French (fr)
Inventor
Jotham Wadsworth Coe
Christoph Martin Dehnhardt
Peter Jones
Steven Wade Kortum
Yogesh Anil Sabnis
Florian Michel WAKENHUT
Gavin Alistair Whitlock
Original Assignee
Pfizer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46826868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2013014567(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR1020147001773A priority Critical patent/KR20140026627A/en
Priority to JP2014522177A priority patent/JP5579351B1/en
Priority to UAA201400660A priority patent/UA108442C2/en
Priority to AU2012288491A priority patent/AU2012288491A1/en
Priority to EA201490357A priority patent/EA201490357A1/en
Priority to BR112014001801A priority patent/BR112014001801A2/en
Priority to CA2841882A priority patent/CA2841882A1/en
Priority to AP2014007372A priority patent/AP2014007372A0/en
Priority to MDA20140002A priority patent/MD20140002A2/en
Priority to CN201280037293.XA priority patent/CN103717599B/en
Priority to GEAP201213360A priority patent/GEP20156398B/en
Priority to EP12756557.0A priority patent/EP2736907B1/en
Priority to MX2014001004A priority patent/MX2014001004A/en
Application filed by Pfizer Limited filed Critical Pfizer Limited
Publication of WO2013014567A1 publication Critical patent/WO2013014567A1/en
Priority to TNP2014000033A priority patent/TN2014000033A1/en
Priority to IL230662A priority patent/IL230662A0/en
Priority to MA36716A priority patent/MA35285B1/en
Priority to CU2014000009A priority patent/CU20140009A7/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to indazoles, pharmaceutical compositions comprising such compounds and their use as medicaments. More particularly, the present invention provides 6- phenyl-1 H-indazole derivatives which are Janus Kinase (JAK) inhibitors and useful for the treatment of allergic and respiratory conditions, particularly chronic obstructive pulmonary disease.
  • JK Janus Kinase
  • COPD chronic obstructive pulmonary disease
  • JAK Janus kinase
  • JAK 2 The Janus kinase family of receptor associated tyrosine kinases, JAK 1 , JAK 2, JAK 3 and tyrosine kinase 2 (TYK2), are involved in signal transduction associated with a variety of inflammatory cytokines.
  • JAK kinases can function as either hetero or homo-dimers, phosphorylating STAT transcription factors which regulate inflammatory gene transcription.
  • Oral JAK 1/JAK 3 inhibitors such as CP-690550 have shown impressive anti-inflammatory activity in inflammatory diseases such as rheumatoid arthritis and psoriasis.
  • JAK dependent cytokines are thought to play key roles in the pathology of COPD which involves the interplay of multiple inflammatory cells such as T lymphocytes, neutrophils, macrophages and lung epithelium.
  • T lymphocytes T lymphocytes
  • neutrophils neutrophils
  • macrophages macrophages
  • lung epithelium a cell that influences the production of neutrophils.
  • JAK 1 and JAK 2 play an important role in IL-13 mediated inflammatory signaling in macrophages, which is thought to link acute inflammatory events to chronic progressive disease.
  • JAK 1 , JAK 2 and TYK 2 also play an important role in signaling mediated by IFNy, a cytokine associated with the chronic inflammation observed in COPD, which modulates the activity of T cells, epithelium and macrophages whilst not being modulated by corticosteroids.
  • Macrophage phagocytosis of bacteria is impaired in the lungs of COPD patients, potentially in part due to high local IFNy levels.
  • JAK inhibitors increase phagocytotic rate in the presence of IFNy. Consequently, as well as exerting a direct anti-inflammatory effect, JAK inhibitors may also increase the ability of the lung to maintain a sterile environment.
  • JAK inhibitors are therefore likely to have utility in the treatment of a range of inflammatory diseases, including lung diseases such as COPD, asthma and pulmonary vascular disease.
  • lung diseases such as COPD, asthma and pulmonary vascular disease.
  • Compounds which have a broad inhibitory activity across the range of Janus kinases, in particular, are likely to have a potent anti-inflammatory effect.
  • such a selectivity profile can also lead to undesirable side-effects in systemically circulating compounds, particularly anemia and neutropenia associated with JAK 2 inhibition.
  • JAK inhibitors that are potent, selective inhibitors of Janus kinases with appropriate metabolic stability and pharmacokinetic properties, particularly compounds which can be administered by inhalation and are active in lung tissue whilst having poor systemic penetration or high systemic lability.
  • R 1 is halo
  • R 2 is C-
  • X is a bond, -CO-, -S0 2 - or -CH 2 -;
  • R 3 is Aryl 1 , Het 1 or Het 2 , each of which is optionally substituted by 1 substituent -Y-R 4 and/or 1-4 substituents each independently selected from R 5 ; n is 1 or 2;
  • Aryl 1 is phenyl or naphthyl
  • Het 1 is (i) a 6-membered aromatic heterocycle containing 1 -3 N atoms or (ii) a 5-membered aromatic heterocycle containing either (a) 1-4 N atoms or (b) 1 O or S atom and 0-3 N atoms;
  • Het 2 is (i) a 10-membered bicyclic aromatic heterocycle containing 1-4 N atoms or (ii) a 9- membered bicyclic aromatic heterocycle containing either (a) 1-4 N atoms or (b) 1 O or S atom and 0-3 N atoms or (iii) an 8-membered bicyclic aromatic heterocycle containing (a) 1-4 N atoms or (b) 1 O or S atom and 1 -3 N atoms or (c) 2 O or S atoms and 0-2 N atoms; Y is a bond or -0-;
  • R 4 is Aryl 2 or Het 3 ;
  • R 5 is Ci-C 6 alkyl, C 3 -C 8 cycloalkyl, halo, -CN, -OR 6 , -NR 7 R 8 , -SR 6 , -SOR 9 , -S0 2 R 9 , -COR 6 , - OCOR 6 , -COOR 6 , -NR 6 COR 6 , -CONR 7 R 8 , -NR 6 S0 2 R 9 , -S0 2 NR 7 R 8 , -NR 6 CONR 7 R 8 , - NR 6 COOR 9 or -NR 6 S0 2 NR 7 R 8 ;
  • R 6 is H, d-C 6 alkyl or C 3 -C 8 cycloalkyl, said d-C 6 alkyl;
  • R 7 and R 8 are each independently H, C-
  • R 9 is Ci-C 6 alkyl or C 3 -C 8 cycloalkyl
  • Aryl 2 is phenyl or naphthyl, said phenyl and naphthyl being optionally substituted with 1-5 substituents selected from d-C 6 alkyl, C 3 -C 8 cycloalkyl, halo, -CN, -OR 6 , -NR 7 R 8 , -SR 6 , -SOR 9 , -S0 2 R 9 , -COR 6 , -OCOR 6 , -COOR 6 , -NR 6 COR 6 , -CONR 7 R 8 , -NR 6 S0 2 R 9 , -S0 2 NR 7 R 8 , - NR 6 CONR 7 R 8 , -NR 6 COOR 9 and -NR 6 S0 2 NR 7 R 8 ; and
  • Het 3 is a 3 to 8-membered saturated or partially unsaturated monocyclic heterocycle, containing 1 or 2 heteroatoms selected from O and N, said heterocycle being optionally substituted by 1-5 substituents selected from Ci-C 6 alkyl, C 3 -C 8 cycloalkyl, halo, oxo, -OR 6 , -NR 7 R 8 , -SR 6 , -SOR 9 , -S0 2 R 9 , -COR 6 , -OCOR 6 , -COOR 6 , -NR 6 COR 6 , -CONR 7 R 8 , -NR 6 S0 2 R 9 , -S0 2 NR 7 R 8 , - NR 6 CONR 7 R 8 , -NR 6 COOR 9 and -NR 6 S0 2 NR 7 R 8 .
  • the invention also provides, as embodiment E2, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R 2 , n, X and R 3 are as defined in embodiment E1 and R 1 is fluoro.
  • the invention also provides, as embodiment E3, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R 1 is as defined in either of embodiments E1 or E2, n, X and R 3 are as defined in embodiment E1 and R 2 is -CH 2 CH 3 or -
  • the invention also provides, as embodiment E4, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R 1 is as defined in either of embodiments E1 or E2, R 2 is as defined in either of embodiments E1 or E3, X and R 3 are as defined in embodiment E1 and n is 1.
  • the invention also provides, as embodiment E5, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R 1 is as defined in either of embodiments E1 or E2, R 2 is as defined in either of embodiments E1 or E3, X and R 3 are as defined in embodiment E1 and n is 2.
  • the invention also provides, as embodiment E6, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R 1 is as defined in either of embodiments E1 or E2, R 2 is as defined in either of embodiments E1 or E3, n is defined in any one of embodiments E1 , E4 or E5, R 3 is as defined in embodiment E1 and X is a bond.
  • the invention also provides, as embodiment E7, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R 1 is as defined in either of embodiments E1 or E2, R 2 is as defined in either of embodiments E1 or E3, n is defined in any one of embodiments E1 , E4 or E5, R 3 is as defined in embodiment E1 and X is -CO-.
  • the invention also provides, as embodiment E8, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R 1 is as defined in either of embodiments E1 or E2, R 2 is as defined in either of embodiments E1 or E3, n is defined in any one of embodiments E1 , E4 or E5, R 3 is as defined in embodiment E1 and X is -CH 2 -.
  • the invention also provides, as embodiment E9, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R 1 is as defined in either of embodiments E1 or E2, R 2 is as defined in either of embodiments E1 or E3, n is defined in any one of embodiments E1 , E4 or E5, R 3 is as defined in embodiment E1 and X is -S0 2 -.
  • the invention also provides, as embodiment E10, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R 1 is as defined in either of embodiments E1 or E2, R 2 is as defined in either of embodiments E1 or E3, n is as defined in any one of embodiments E1 , E4 or E5, X is as defined in any one of embodiments E1 , E6, E7, E8 or E9 and R 3 is is phenyl, thiazolyl, quinolinyl, pyrimidinyl, [1 ,8]naphthyridinyl or pyridyl, each of which is optionally substituted by 1 substituent -Y-R 4 and 1-4 substituents each independently selected from R 5 .
  • R 1 is as defined in either of embodiments E1 or E2
  • R 2 is as defined in either of embodiments E1 or E3
  • n is as defined in any one of embodiments
  • the invention also provides, as embodiment E1 1 , a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R 1 is as defined in either of embodiments E1 or E2, R 2 is as defined in either of embodiments E1 or E3, n is as defined in any one of embodiments E1 , E4 or E5, X is as defined in any one of embodiments E1 , E6, E7, E8 or E9 and R 3 is phenyl, thiazolyl, quinolinyl, pyrimidinyl, [1 ,8]naphthyridinyl or pyridyl, each of which is optionally substituted by 1 substituent selected from piperdininyl, (fluorophenyl)oxy, phenyloxy and morpholinyl and 1-2 substituents each independently selected from fluoro, chloro, cyano, methoxy and hydroxy.
  • R 1 is as defined in
  • the invention also provides, as embodiment E12, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R 1 is as defined in either of embodiments E1 or E2, R 2 is as defined in either of embodiments E1 or E3, n is as defined in any one of embodiments E1 , E4 or E5, X is as defined in any one of embodiments E1 , E6, E7, E8 or E9 and R 3 is fluorophenyl, methoxyphenyl, thiazolyl, hydroxyphenyl, phenyl, quinolinyl, [1 ,8]naphthyridinyl, (piperidinyl)pyridyl, (piperidinyl)pyrimidinyl, ((fluorophenyl)oxy)pyrimidinyl, (phenyloxy)pyridyl, (morpholinyl)pyridyl, chloropyridyl
  • the invention also provides, as embodiment E13, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R 1 is as defined in either of embodiments E1 or E2, R 2 is as defined in either of embodiments E1 or E3, n is defined in any one of embodiments E1 , E4 or E5, and -X-R 3 is (fluorophenyl)carbonyl, (thiazolyl)carbonyl, benzyl, ((piperidinyl)pyrimidinyl)carbonyl, ((phenoxy)pyridyl)carbonyl, ((morpholinyl)pyridyl)sulphonyl, ((phenoxy)pyridyl)sulphonyl, (chloropyridyl)carbonyl, (cyanopyridyl)carbonyl, (fluorophenyl)carbonyl, (thiazolyl)carbonyl, (fluorophen
  • the invention also provides, rmula:
  • X is as defined in any one of embodiments E1 , E6, E7, E8 or E9 and R 3 is as defined in any one of embodiments E1 , E10, E1 1 or E12 or -X-R 3 is as defined in embodiment E13.
  • Particularly preferred compounds of formula (I) include:
  • the present invention also provides: a method of treating a disease for which a JAK inhibitor is indicated, in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt; the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, for the manufacture of a medicament for treating a disease or condition for which a JAK inhibitor is indicated; a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use as a medicament; a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, for use in the treatment of a disease or condition for which a JAK inhibitor is indicated; a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said
  • the disease or condition for which a JAK inhibitor is indicated is preferably an allergic or respiratory condition such as allergic rhinitis, nasal congestion, rhinorrhea, perennial rhinitis, nasal inflammation, asthma of all types, chronic obstructive pulmonary disease (COPD), chronic or acute bronchoconstriction, chronic bronchitis, small airways obstruction, emphysema, chronic eosinophilic pneumonia, adult respiratory distress syndrome, exacerbation of airways hyperreactivity consequent to other drug therapy, pulmonary vasulcar disease (including pulmonary arterial hypertension), acute lung injury, bronchiectasis, sinusitis, allergic conjunctivitis, idiopathic pulmonary fibrosis or atopic dermatitis, particularly asthma or chronic obstructive pulmonary disease, most particularly chronic obstructive pulmonary disease.
  • COPD chronic obstructive pulmonary disease
  • inflammation including neuroinflammation
  • arthritis including rheumatoid arthritis, spondyloarthropathies, systemic lupus erythematous arthritis, osteoarthritis and gouty arthritis
  • pain fever
  • pulmonary sarcoisosis silicosis
  • cardiovascular disease including atherosclerosis, myocardial infarction, thrombosis, congestive heart failure and cardiac reperfusion injury
  • cardiomyopathy including stroke, ischaemia, reperfusion injury, brain edema, brain trauma, neurodegeneration, liver disease, inflammatory bowel disease (including Crohn's disease and ulcerative colitis), nephritis, retinitis, retinopathy, macular degeneration, glaucoma
  • diabetes including type 1 and type 2 diabetes
  • diabetic neurorpathy viral and bacterial infection
  • myalgia endotoxic shock
  • toxic shock syndrome autoimmune disease
  • osteoporosis multiple sclerosis
  • endometrios endometrios
  • Types of asthma include atopic asthma, non-atopic asthma, allergic asthma, atopic bronchial IgE-mediated asthma, bronchial asthma, essential asthma, true asthma, intrinsic asthma caused by pathophysiologic disturbances, extrinsic asthma caused by environmental factors, essential asthma of unknown or inapparent cause, bronchitic asthma, emphysematous asthma, exercise- induced asthma, allergen induced asthma, cold air induced asthma, occupational asthma, infective asthma caused by bacterial, fungal, protozoal, or viral infection, non-allergic asthma, incipient asthma, whez infant syndrome and bronchiolytis.
  • the treatment of asthma includes palliative treatment for the symptoms and conditions of asthma such as wheezing, coughing, shortness of breath, tightness in the chest, shallow or fast breathing, nasal flaring (nostril size increases with breathing), retractions (neck area and between or below the ribs moves inward with breathing), cyanosis (gray or bluish tint to skin, beginning around the mouth), runny or stuffy nose, and headache.
  • the present invention also provides any of the uses, methods or compositions as defined above wherein the compound of formula (I), or pharmaceutically acceptable salt thereof, or pharmaceutically acceptable solvate of said compound or salt, is used in combination with another pharmacologically active compound, particularly one of the functionally-defined classes or specific compounds listed below.
  • the compounds of the combination will be administered together as a formulation in association with one or more pharmaceutically acceptable excipients.
  • Suitable agents for use in combination therapy with a compound of formula (I), or pharmaceutically acceptable salt thereof, or pharmaceutically acceptable solvate of said compound or salt, particularly in the treatment of respiratory disease include: a 5-lipoxygenase activating protein (FLAP) antagonist;
  • FLAP 5-lipoxygenase activating protein
  • LTRA leukotriene antagonist
  • LTC 4 an antagonist of LTB 4 , LTC 4 , LTD 4 , LTE 4 , CysLT- ⁇ or CysLT 2 , e.g. montelukast or zafirlukast;
  • a histamine receptor antagonist such as a histamine type 1 receptor antagonist or a histamine type 2 receptor antagonist, e.g. loratidine, fexofenadine, desloratidine, levocetirizine, methapyrilene or cetirizine;
  • an a1 -adrenoceptor agonist or an a2-adrenoceptor agonist e.g. phenylephrine, methoxamine, oxymetazoline or methylnorephrine;
  • a muscarinic M3 receptor antagonist e.g. tiotropium or ipratropium
  • a PDE inhibitor such as a PDE3 inhibitor, a PDE4 inhibitor or a PDE5 inhibitor, e.g. theophylline, sildenafil, vardenafil, tadalafil, ibudilast, cilomilast or roflumilast;
  • a cyclooxygenase (COX) inhibitor such as a non-selective inhibitor (e.g. aspirin or ibuprofen) or a selective inhibitor (e.g. celecoxib or valdecoxib); a glucocorticosteroid, e.g. fluticasone, mometasone, dexamethasone, prednisolone, budesonide, ciclesonide or beclamethasone;
  • an anti-inflammatory monoclonal antibody e.g. infliximab, adalimumab, tanezumab, ranibizumab, bevacizumab or mepolizumab;
  • a ⁇ 2 agonist e.g. salmeterol, albuterol, salbutamol, fenoterol or formoterol, particularly a long- acting ⁇ 2 agonist;
  • an intigrin antagonist e.g. natalizumab
  • an adhesion molecule inhibitor such as a VLA-4 antagonist
  • kinin B -i or B 2 receptor antagonist a kinin B -i or B 2 receptor antagonist
  • an immunosuppressive agent such as an inhibitor of the IgE pathway (e.g. omalizumab) or cyclosporine;
  • MMP matrix metalloprotease
  • a tachykinin NK-i , NK 2 or NK 3 receptor antagonist a tachykinin NK-i , NK 2 or NK 3 receptor antagonist
  • protease inhibitor such as an inhibitor of elastase, chymase or catheopsin G;
  • a dopamine receptor agonist e.g. ropinirole
  • a dopamine D2 receptor agonist e.g. bromocriptine
  • a modulator of the N FKB pathway such as an IKK inhibitor
  • a further modulator of a cytokine signalling pathway such as an inhibitor of JAK kinase, syk kinase, p38 kinase, SPHK-1 kinase, Rho kinase, EGF-R or MK-2;
  • an epithelial sodium channel (ENaC) blocker or Epithelial sodium channel (ENaC) inhibitor an epithelial sodium channel (ENaC) blocker or Epithelial sodium channel (ENaC) inhibitor
  • a nucleotide receptor agonist such as a P2Y2 agonist
  • a 5-lipoxygenase (5-LO) inhibitor e.g. Zileuton;
  • an adhesion factor such as VLAM, ICAM or ELAM
  • a CRTH2 receptor (DP 2 ) antagonist a CRTH2 receptor (DP 2 ) antagonist
  • DP ⁇ antagonist a prostaglandin D 2 receptor (DP ⁇ antagonist
  • HPGDS haematopoietic prostaglandin D2 synthase
  • interferon- ⁇ a soluble human TNF receptor, e.g. Etanercept;
  • TLR-4 or TLR-9 inhibitor including the pharmaceutically acceptable salts of the specifically named compounds and the pharmaceutically acceptable solvates of said specifically named compounds and salts.
  • compounds of formula (I) are also useful for veterinary treatment of companion animals, exotic animals and farm animals.
  • APCI in relation to mass spectrometry is atmospheric pressure chemical ionization
  • BOP is (benzotriazol-1 -yloxy)tris(dimethylamino)phosphonium hexafluorophosphate
  • CDCI 3 is deuterochloroform
  • DCC is N,N'-dicyclohexylcarbodiimide
  • DCM is dichloromethane
  • DEA diethylamine
  • DIAD is diisopropyl azodicarboxylate
  • DIEA is N,N-diisopropylethylamine
  • DIPEA is N,N-diisopropylethylamine
  • DMA is N,N-dimethylacetamide
  • DMF is dimethylformamide
  • DMSO-d 6 is fully deuterated dimethyl sulphoxide
  • EDC/EDCI is N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride
  • Et is ethyl
  • h hour(s); HATU is N,N,N',N'-tetramethyl-0-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate; HBTU is N,N,N',N'-tetramethyl-0-(1 H-benzotriazol-1-yl)uronium hexafluorophosphate; HCI is hydrochloric acid;
  • 1 H NMR or 1 H NMR is proton nuclear magnetic resonance
  • HOAt is 1-hydroxy-7-azabenzotriazole
  • HOBt is 1-hydroxybenzotriazole
  • HPLC high performance liquid chromatography
  • H 2 S0 4 is sulphuric acid
  • PA is isopropyl alcohol
  • iPr is isopropyl
  • K 2 C0 3 is potassium carbonate
  • KMn0 4 is potassium permanganate
  • KOH potassium hydroxide
  • KOAc is potassium acetate
  • LCMS is liquid chromatography mass spectrometry
  • LRMS low resolution mass spectrometry
  • NMM is 4-methylmorpholine
  • Me is methyl
  • MeCN is acetonitrile
  • MeOD-d 4 is fully deuterated methanol
  • MgS0 4 is magnesium sulphate
  • 2-MeTHF is 2-methyltetrahydrofuran
  • MS is mass spectroscopy
  • NaCI sodium chloride
  • NaH sodium hydride
  • NBS is N-bromosuccinimide
  • NIS is N-iodosuccinimide
  • MP is N-methylpyrrolidine
  • Pd(OAc) 2 is palladium(ll)acetate
  • RT retention time
  • SEM-CI is (2-chloromethoxy-ethyl)-trimethyl-silane
  • SPhos is 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl
  • STAB is sodium (tri-acetoxy) borohydride
  • TBTU is 0-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate;
  • TEA is triethylamine
  • TFA is trifluoroacetic acid
  • THF is tetrahydrofuran
  • tBME is 2-mMethoxy-2-methyl-propane
  • p-TsOH is para-toluene sulfonic acid.
  • terapéuticaally effective is intended to qualify the amount of compound or pharmaceutical composition, or the combined amount of active ingredients in the case of combination therapy. This amount or combined amount will achieve the goal of treating the relevant condition.
  • treatment means administration of the compound, pharmaceutical composition or combination to effect preventative, palliative, supportive, restorative or curative treatment.
  • treatment encompasses any objective or subjective improvement in a subject with respect to a relevant condition or disease.
  • preventive treatment means that the compound, pharmaceutical composition or combination is administered to a subject to inhibit or stop the relevant condition from occurring in a subject, particularly in a subject or member of a population that is significantly predisposed to the relevant condition.
  • palliative treatment means that the compound, pharmaceutical composition or combination is administered to a subject to remedy signs and/or symptoms of a condition, without necessarily modifying the progression of, or underlying etiology of, the relevant condition.
  • supportive treatment means that the compound, pharmaceutical composition or combination is administered to a subject as a part of a regimen of therapy, but that such therapy is not limited to administration of the compound, pharmaceutical composition or combination.
  • supportive treatment may embrace preventive, palliative, restorative or curative treatment, particularly when the compounds or pharmaceutical compositions are combined with another component of supportive therapy.
  • restorative treatment means that the compound, pharmaceutical composition or combination is administered to a subject to modify the underlying progression or etiology of a condition.
  • Non-limiting examples include an increase in forced expiratory volume in one second (FEV 1 ) for lung disorders, decreased rate of a decline in lung function over time, inhibition of progressive nerve destruction, reduction of biomarkers associated and correlated with diseases or disorders, a reduction in relapses, improvement in quality of life, reduced time spent in hospital during an acute exacerbation event and the like.
  • FEV 1 forced expiratory volume in one second
  • curative treatment means that compound, pharmaceutical composition or combination is administered to a subject for the purpose of bringing the disease or disorder into complete remission, or that the disease or disorder is undetectable after such treatment.
  • selective when used to describe a functionally-defined receptor ligand or enzyme inhibitor means selective for the defined receptor or enzyme subtype as compared with other receptor or enzyme subtypes in the same family.
  • a selective PDE5 inhibitor is a compound which inhibits the PDE5 enzyme subtype more potently than any other PDE enzyme subtype.
  • selectivity is preferably at least 2 fold (as measured using conventional binding assays), more preferably at least 10 fold, most preferably at least 100 fold.
  • alkyl alone or in combination, means an acyclic, saturated hydrocarbon group of the formula C n H 2n+ i which may be linear or branched. Examples of such groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl and hexyl. Unless otherwise specified, an alkyl group comprises from 1 to 6 carbon atoms.
  • -C 6 alkyl refers to alkyl of one to six carbon atoms, inclusive.
  • hydroxy means an OH radical
  • Het 3 is a saturated or partially saturated (i.e. non aromatic) heterocycle and may be attached via a ring nitrogen atom (when the heterocycle is attached to a carbon atom) or a ring carbon atom (in all cases). Equally, when substituted, the substituent may be located on a ring nitrogen atom (if the substituent is joined through a carbon atom) or a ring carbon atom (in all cases).
  • oxiranyl aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, 1 ,4-dioxanyl, morpholinyl, piperazinyl, azepanyl, oxepanyl, oxazepanyl and diazepinyl.
  • Het 3 may be fully saturated or partially unsaturated, i.e. may have one or more degrees of unsaturation but may not be fully aromatic.
  • Het 1 is an aromatic heterocycle and may be attached via a ring carbon atom (in all cases) or a ring nitrogen atom with an appropriate valency (when the heterocycle is attached to a carbon atom). Equally, when substituted, the substituent may be located on a ring carbon atom (in all cases) or a ring nitrogen atom with an appropriate valency (if the substituent is joined through a carbon atom).
  • Specific examples include thienyl, furanyl, pyrrolyl, pyrazolyl, imidazoyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl.
  • Het 2 is an aromatic heterocycle and may be attached via a ring carbon atom (in all cases) or a ring nitrogen atom with an appropriate valency (when the heterocycle is attached to a carbon atom). Equally, when substituted, the substituent may be located on a ring carbon atom (in all cases) or a ring nitrogen atom with an appropriate valency (if the substituent is joined through a carbon atom). Het 2 is aromatic and is therefore necessarily a fused bicycle.
  • imidazo[2,1-b][1 ,3]thiazolyl benzofuranyl, benzothienyl, indolyl, benzimidazolyl, indazolyl, benzotriazolyl, pyrrolo[2,3-b]pyridyl, pyrrolo[2,3-c]pyridyl, pyrrolo[3,2-c]pyridyl, pyrrolo[3,2-b]pyridyl, imidazo[4,5-b]pyridyl, imidazo[4,5-c]pyridyl, pyrazolo[4,3-d]pyridyl, pyrazolo[4,3-c]pyridyl, pyrazolo[3,4-c]pyridyl, pyrazolo[3,4-b]pyridyl, isoindolyl, indazolyl, purinyl, indolizinyl, imidazo[1 ,2-
  • cycloalkyl means a means a monocyclic, saturated hydrocarbon group of the formula C n H 2n -i - Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. Unless otherwise specified, a cycloalkyl group comprises from 3 to 8 carbon atoms.
  • oxo means a doubly bonded oxygen.
  • alkoxy means a radical comprising an alkyl radical that is bonded to an oxygen atom, such as a methoxy radical.
  • examples of such radicals include methoxy, ethoxy, propoxy, isopropoxy, butoxy and tert-butoxy.
  • halo means, fluoro, chloro, bromo or iodo.
  • co-administration As used herein, the terms “co-administration”, “co-administered” and “in combination with”, referring to a combination of a compound of formula (I) and one or more other therapeutic agents, includes the following:
  • excipient is used herein to describe any ingredient other than a compound of formula (I).
  • excipient encompasses diluent, carrier or adjuvant.
  • One way of carrying out the invention is to administer a compound of formula (I) in the form of a prodrug.
  • certain derivatives of a compound of formula (I) which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into a compound of formula (I) having the desired activity, for example by hydrolytic cleavage, particularly hydrolytic cleavage promoted by an esterase or peptidase enzyme.
  • Such derivatives are referred to as 'prodrugs'. Further information on the use of prodrugs may be found in 'Prodrugs as Novel Delivery Systems', Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella) and 'Bioreversible Carriers in Drug Design', Pergamon Press, 1987 (Ed. E. B. Roche, American Pharmaceutical Association). Reference can also be made to Nature Reviews/Drug Discovery, 2008, 7, 355 and Current Opinion in Drug Discovery and Development, 2007, 10, 550.
  • Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as 'pro-moieties' as described, for example, in 'Design of Prodrugs' by H. Bundgaard (Elsevier, 1985).
  • a prodrug in accordance with the invention is (a) an ester or amide derivative of a carboxylic acid in a compound of formula (I); (b) an ester, carbonate, carbamate, phosphate or ether derivative of a hydroxyl group in a compound of formula (I); (c) an amide, imine, carbamate or amine derivative of an amino group in a compound form formula (I); (d) a thioester, thiocarbonate, thiocarbamate or sulphide derivatives of a thiol group in a compound of formula (I); or (e) an oxime or imine derivative of a carbonyl group in a compound of formula (I).
  • prodrugs in accordance with the invention include:
  • the compound of formula (I) contains a primary or secondary amino functionality (-NH 2 or -NHR where R ⁇ H), an amide thereof, for example, a compound wherein, as the case may be, one or both hydrogens of the amino functionality of the compound of formula (I) is/are replaced by (C 1 -C 10 )alkanoyl, -COCH 2 NH 2 or the amino group is derivatised with an amino acid;
  • Certain compounds of formula (I) may themselves act as prodrugs of other compounds of formula (I). It is also possible for two compounds of formula (I) to be joined together in the form of a prodrug. In certain circumstances, a prodrug of a compound of formula (I) may be created by internally linking two functional groups in a compound of formula (I), for instance by forming a lactone.
  • references below to compounds of formula (I) are taken to include the compounds themselves and prodrugs thereof.
  • the invention includes such compounds of formula (I) as well as pharmaceutically acceptable salts of such compounds and pharmaceutically acceptable solvates of said compounds and salts.
  • Pharmaceutically acceptable salts of the compounds of formula (I) include acid addition and base salts.
  • Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, ste
  • Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
  • Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
  • suitable salts see Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth (Wiley-VCH, 2002).
  • compositions of formula (I) may be prepared by one or more of three methods:
  • the resulting salt may precipitate out and be collected by filtration or may be recovered by evaporation of the solvent.
  • the degree of ionisation in the resulting salt may vary from completely ionised to almost non-ionised.
  • the compounds of formula (I), and pharmaceutically acceptable salts thereof may exist in unsolvated and solvated forms.
  • the term 'solvate' is used herein to describe a molecular complex comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
  • the term 'hydrate' may be employed when said solvent is water.
  • Isolated site hydrates are ones in which the water molecules are isolated from direct contact with each other by intervening organic molecules.
  • channel hydrates the water molecules lie in lattice channels where they are next to other water molecules.
  • metal-ion coordinated hydrates the water molecules are bonded to the metal ion.
  • the complex When the solvent or water is tightly bound, the complex will have a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvates and hygroscopic compounds, the water/solvent content will be dependent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm.
  • multi-component complexes other than salts and solvates
  • complexes of this type include clathrates (drug-host inclusion complexes) and co-crystals.
  • the latter are typically defined as crystalline complexes of neutral molecular constituents which are bound together through non-covalent interactions, but could also be a complex of a neutral molecule with a salt.
  • Co-crystals may be prepared by melt crystallisation, by recrystallisation from solvents, or by physically grinding the components together - see Chem Commun, 17, 1889-1896, by O. Almarsson and M. J. Zaworotko (2004).
  • the compounds of the invention may exist in a continuum of solid states ranging from fully amorphous to fully crystalline.
  • the term 'amorphous' refers to a state in which the material lacks long range order at the molecular level and, depending upon temperature, may exhibit the physical properties of a solid or a liquid. Typically such materials do not give distinctive X-ray diffraction patterns and, while exhibiting the properties of a solid, are more formally described as a liquid.
  • a change from solid to liquid properties occurs which is characterised by a change of state, typically second order ('glass transition').
  • 'crystalline' refers to a solid phase in which the material has a regular ordered internal structure at the molecular level and gives a distinctive X-ray diffraction pattern with defined peaks. Such materials when heated sufficiently will also exhibit the properties of a liquid, but the change from solid to liquid is characterised by a phase change, typically first order ('melting point').
  • the compounds of formula (I) may also exist in a mesomorphic state (mesophase or liquid crystal) when subjected to suitable conditions.
  • the mesomorphic state is intermediate between the true crystalline state and the true liquid state (either melt or solution).
  • Mesomorphism arising as the result of a change in temperature is described as 'thermotropic' and that resulting from the addition of a second component, such as water or another solvent, is described as 'lyotropic'.
  • references to compounds of formula (I) include references to pharmaceutically acceptable salts, solvates, multi-component complexes and liquid crystals thereof and to solvates, multi-component complexes and liquid crystals of pharmaceutically acceptable salts thereof.
  • the compounds of formula (I) may exhibit polymorphism and/or one or more kinds of isomerism (e.g. optical, geometric or tautomeric isomerism).
  • the compounds of formula (I) may also be isotopically labelled. Such variation is implicit to the compounds of formula (I) defined as they are by reference to their structural features and therefore within the scope of the invention.
  • Compounds of formula (I) containing one or more asymmetric carbon atoms can exist as two or more stereoisomers. Where a compound of formula (I) contains an alkenyl or alkenylene group, geometric cis/trans (or Z/E) isomers are possible. Where structural isomers are interconvertible via a low energy barrier, tautomeric isomerism ('tautomerism') can occur. This can take the form of proton tautomerism in compounds of formula (I) containing, for example, an imino, keto, or oxime group, or so-called valence tautomerism in compounds which contain an aromatic moiety. It follows that a single compound may exhibit more than one type of isomerism.
  • the pharmaceutically acceptable salts of compounds of formula (I) may also contain a counterion which is optically active (e.g. d-lactate or l-lysine) or racemic (e.g. dl-tartrate or dl- arginine).
  • a counterion which is optically active (e.g. d-lactate or l-lysine) or racemic (e.g. dl-tartrate or dl- arginine).
  • Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation.
  • racemate or the racemate of a salt or derivative
  • HPLC high pressure liquid chromatography
  • the racemate or a racemic precursor
  • a suitable optically active compound for example, an alcohol, or, in the case where the compound of formula (I) contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartaric acid.
  • the resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.
  • Chiral compounds of formula (I) (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of isopropanol, typically from 2% to 20%, and from 0 to 5% by volume of an alkylamine, typically 0.1 % diethylamine.
  • racemic compounds such as the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts.
  • the second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer. While both of the crystal forms present in a racemic mixture have identical physical properties, they may have different physical properties compared to the true racemate. Racemic mixtures may be separated by conventional techniques known to those skilled in the art - see, for example, Stereochemistry of Organic Compounds by E. L. Eliel and S. H. Wilen (Wiley, 1994).
  • the present invention includes all pharmaceutically acceptable isotopically-labelled compounds of formula (I) wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature.
  • Isotopically-labelled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labelled reagent in place of the non-labelled reagent previously employed.
  • hydrogen atoms may be replaced by deuterium atoms since such deuterated compounds are sometimes more resistant to metabolism.
  • active metabolites of compounds of formula (I) that is, compounds formed in vivo upon administration of the drug, often by oxidatation or dealkylation.
  • the total daily dose of a compound of formula (I) is typically in the range of 0.01 mg to 500mg depending, of course, on the mode of administration. In another embodiment of the present invention, the total daily dose of a compound of formula (I) is typically in the range of 0.1 mg to 300mg. In yet another embodiment of the present invention, the total daily dose of a compound of formula (I) is typically in the range of 1 mg to 30mg.
  • the total daily dose may be administered in single or divided doses and may, at the physician's discretion, fall outside of the typical range given herein. These dosages are based on an average human subject having a weight of about 65kg to 70kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.
  • the dosage unit is determined by means of a prefilled capsule, blister or pocket or by a system that utilises a gravimetrically fed dosing chamber.
  • Units in accordance with the invention are typically arranged to administer a metered dose or "puff" containing from 1 to 5000 ⁇ g of drug.
  • the overall daily dose will typically be in the range ⁇ g to 20mg which may be administered in a single dose or, more usually, as divided doses throughout the day.
  • a compound of formula (I) can be administered per se, or in the form of a pharmaceutical composition, which, as active constituent contains an efficacious dose of at least one compound of the invention, in addition to customary pharmaceutically innocuous excipients and/or additives.
  • compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company, 1995).
  • Compounds of formula (I) may be administered orally.
  • Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.
  • Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films, ovules, sprays and liquid formulations.
  • Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
  • Compounds of formula (I) may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 1 1 (6), 981-986, by Liang and Chen (2001 ).
  • the drug may make up from 1 weight % to 80 weight % of the dosage form, more typically from 5 weight % to 60 weight % of the dosage form.
  • tablets generally contain a disintegrant.
  • disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate.
  • the disintegrant will comprise from 1 weight % to 25 weight %.
  • the disintegrant will comprise from 5 weight % to 20 weight % of the dosage form.
  • Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.
  • Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc.
  • surface active agents may comprise from 0.2 weight % to 5 weight % of the tablet, and glidants may comprise from 0.2 weight % to 1 weight % of the tablet.
  • Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate.
  • Lubricants generally comprise from 0.25 weight % to 10 weight %. In one embodiment of the present invention, lubricants comprise from 0.5 weight % to 3 weight % of the tablet.
  • Other possible ingredients include anti-oxidants, colourants, flavouring agents, preservatives and taste-masking agents.
  • Exemplary tablets contain up to about 80% drug, from about 10 weight % to about 90 weight % binder, from about 0 weight % to about 85 weight % diluent, from about 2 weight % to about 10 weight % disintegrant, and from about 0.25 weight % to about 10 weight % lubricant.
  • Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tabletting.
  • the final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated. Formulations of tablets are discussed in Pharmaceutical Dosage Forms: Tablets, Vol. 1 , by H. Lieberman and L. Lachman (Marcel Dekker, New York, 1980).
  • Consumable oral films for human or veterinary use are typically pliable water-soluble or water- swellable thin film dosage forms which may be rapidly dissolving or mucoadhesive and typically comprise a compound of formula (I), a film-forming polymer, a binder, a solvent, a humectant, a plasticiser, a stabiliser or emulsifier, a viscosity-modifying agent and a solvent. Some components of the formulation may perform more than one function.
  • the film-forming polymer may be selected from natural polysaccharides, proteins, or synthetic hydrocolloids and is typically present in the range 0.01 to 99 weight %, more typically in the range 30 to 80 weight %.
  • Films in accordance with the invention are typically prepared by evaporative drying of thin aqueous films coated onto a peelable backing support or paper. This may be done in a drying oven or tunnel, typically a combined coater dryer, or by freeze-drying or vacuuming.
  • Solid formulations for oral administration may be formulated to be immediate and/or modified release.
  • Modified release includes delayed, sustained, pulsed, controlled, targeted and programmed release.
  • Suitable modified release formulations for the purposes of the invention are described in US Patent No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in Pharmaceutical Technology On-line, 25(2), 1-14, by Verma et al (2001 ). The use of chewing gum to achieve controlled release is described in WO-A-00/35298.
  • Compounds of formula (I) may also be administered directly into the blood stream, into muscle, or into an internal organ.
  • parenteral administration includes intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous administration.
  • Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
  • Compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally.
  • the compounds of formula (I) can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler, as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1 ,1 ,1 ,2-tetrafluoroethane or 1 ,1 ,1 ,2,3,3,3-heptafluoropropane, or as nasal drops.
  • the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin. Delivery by inhalation is the preferred route of administration for the
  • the pressurised container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the compound of formula (I) comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the compound, a propellant as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
  • a solution or suspension of the compound of formula (I) comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the compound, a propellant as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
  • the drug product Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
  • comminuting method such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
  • Capsules made, for example, from gelatin or hydroxypropylmethylcellulose
  • blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as l-leucine, mannitol, or magnesium stearate.
  • the lactose may be anhydrous or in the form of the monohydrate, preferably the latter.
  • Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
  • a suitable solution formulation for use in an atomiser using electrohydrodynamics to produce a fine mist may contain from 1 ⁇ g to 20mg of the compound of the invention per actuation and the actuation volume may vary from 1 ⁇ to 10 ⁇ .
  • a typical formulation may comprise a compound of formula (I), propylene glycol, sterile water, ethanol and sodium chloride.
  • Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.
  • Suitable flavours such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for intranasal administration.
  • Formulations for intranasal administration may be formulated to be immediate and/or modified release using, for example, PGLA. Modified release includes delayed, sustained, pulsed, controlled, targeted and programmed release.
  • Compounds of formula (I) may also be administered directly to the eye or ear, typically in the form of drops of a micronised suspension or solution in isotonic, pH-adjusted, sterile saline.
  • Compounds of formula (I) may be combined with soluble macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste, bioavailability and/or stability when using any of the aforementioned modes of administration.
  • Drug-cyclodextrin complexes for example, are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used.
  • the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubiliser.
  • kits of the invention comprises two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I), and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
  • a kit is the familiar blister pack used for the packaging of tablets, capsules and the like.
  • kit is particularly suitable for administering different dosage forms, for example, oral and parenteral, for administering separate compositions at different dosage intervals, or for titrating the separate compositions against one another.
  • the kit typically comprises directions for administration and may be provided with a so-called memory aid.
  • LG 1 is a suitable leaving group such as a halogen atom.
  • the reaction will typically be carried out in a suitable inert solvent in the presence of a base such as diisopropylethylamine.
  • a solution of the compound of formula (II) in DMF is treated with one equivalent of the sulphonyl chloride and 1 equivalent of diisopropylethylamine and stirred at room temperature.
  • a solution of the compound of formula (II) in DMF is treated with 1 .1 equivalents of the alkyl bromide and 1 .1 equivalents of diisopropylethylamine and stirred at 50°C.
  • a solution of the compound of formula (II) in DMF is treated with 1.1 equivalents of the acid chloride and 1 .1 equivalents of diisopropylethylamine and stirred at room temperature.
  • the leaving group LG 1 may be created in situ from the corresponding carboxylic acid of formula
  • a solution of the compound of formula (II) in DMF is treated with the 1 .5 equivalents of the aldehyde of formula (V), 2 equivalents of diisopropylethylamine and 1 .5 equivalents of acetic acid and stirred at room temperature for one hour. Sodium triacetoxyborohydride (1.5 equivalents) is then added and stirring continued at room temperature.
  • the reaction will usually be performed in a suitable inert solvent with heating.
  • the title compound was prepared from 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, ⁇ ) and isothiazole-3-carboxylic acid (1 1 mg, ⁇ ) using the same method as described in Example 1 .
  • the crude material was purified by HPLC Method A to afford 7.7mg of the title compound.
  • LCMS Method A RT 2.39 min (100% area), ES m/z 469.143 [M+H] + .
  • the reaction mixture was heated at 65°C for a further 4 hours. Water (20mL) was added to the reaction mixture at 65°C and then the reaction was allowed to cool slowly to room temperature. The solvents were removed in vacuo and the residue was partitioned between 2-MeTHF (200mL) and saturated sodium hydrogen carbonate aqueous solution (100mL). The organic layer was washed with further saturated sodium hydrogen carbonate aqueous solution (100mL). The combined aqueous layers were re-extracted with 2- MeTHF (250mL). The combined organic layers were dried over MgS0 4 and concentrated in vacuo to yield a brown foam. The crude material was dissolved in MeCN (150mL) and ethanol (30mL) and heated at 50°C for 2 days. The product crystallised from this solution and was collected by filtration and dried in vacuo to give the title compound as a crystalline white solid (3.53g) in an 80% yield.
  • reaction mixture was then stirred at room temperature for 18 hours.
  • a further portion of 5-piperidin-1-yl-pyrazine-2- carboxylic acid (1.07g, 5.18mmol) in DMF (40ml_) was treated with DIPEA (2.46ml_, 14.1 mmol) and activated with HATU (2.15g, 5.65mmol) and the resulting mixture was stirred at room temperature for 10 minutes before being added to the original reaction mixture which was then stirred for a further 4 hours at room temperature.
  • the reaction mixture was poured onto water (1.2L) and the pH was adjusted to 7 with sodium hydroxide solution. The resulting suspension was stirred at room temperature for 30 minutes.
  • the precipitate was collected by filtration, washed with water (400ml_) and then dried under vacuum.
  • the crude material was dissolved in ethanol (1 13ml_) and treated with a 1 M aqueous solution of sodium hydroxide. The reaction mixture was stirred at room temperature for 18 hours.
  • the precipitate was collected by filtration, washed with a cold solution of 1 :3 1 M sodium hydroxide:ethanol (100ml_) and dried under vacuum to give the sodium salt of the title compound, 16.14g.
  • This material was dissolved in water (100ml_) and treated with a 10% aqueous solution of citric acid (10ml_) to adjust the pH to 4. A few drops of 1 M sodium hydroxide solution were added to bring the pH to 7.
  • the resulting suspension was stirred at room temperature for 1 hour and the solid was collected by filtration, washed with water and then dried under vacuum to give the title compound as a white solid (13.864g) in an 89% yield.
  • the title compound was prepared from 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, ⁇ ) and 6-phenoxy-nicotinic acid (17mg, 80 ⁇ mol) using the method of Example 1 .
  • the crude material was purified by HPLC Method A to afford 3.1 mg of the title compound.
  • the title compound was prepared from 4-cyano-pyridine-2-carboxylic acid (12.5mg, 85 ⁇ " ⁇ ) and 5-ethyl-2-fluoro-4-[3-(1 ,4,5,6,7,8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1 H-indazol-6-yl]- phenol trihydrobromide salt (Preparation 32, 50mg, ⁇ ) using the method of Example 8. The crude material was purified by HPLC Method B to afford 6.5mg of the title compound.
  • the title compound was prepared from 4-fluoro-benzoic acid (12.5mg, ⁇ ) and 5-ethyl-2- fluoro-4-[3-(1 ,4,5,6,7,8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 32, 50mg, ⁇ ) using the method of Example 8. The crude material was purified by HPLC Method B to afford 14.5mg of the title compound.
  • the title compound was prepared from isothiazole-3-carboxylic acid (1 1 mg, ⁇ ) and 5- ethyl-2-fluoro-4-[3-(1 ,4,5,6,7,8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 32, 50mg, ⁇ ) using the method of Example 8. The crude material was purified by HPLC Method B to afford 10.3mg of the title compound.
  • the title compound was prepared from 3-hydroxy-benzaldehyde (24.2mg, 198 ⁇ " ⁇ ) and 5- ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, 132 ⁇ " ⁇ ) using the method of Example 18. The crude material was purified by HPLC Method A to afford 39.6mg of the title compound.
  • the title compound was prepared from 4-formyl-pyridine-2-carbonitrile (26mg, 198 ⁇ " ⁇ ) and 5- ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, 132 ⁇ " ⁇ ) using the method of Example 18. The crude material was purified by HPLC Method B to afford 16mg of the title compound.
  • the title compound was prepared from 6-phenoxy-pyridine-3-carbaldehyde (39mg, 198 ⁇ " ⁇ ) and 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]- phenol trihydrobromide salt (Preparation 25, 50mg, 132 ⁇ " ⁇ ) using the method of Example 22.
  • the crude material was purified by HPLC Method A to afford 24.7mg of the title compound.
  • the title compound was prepared from 3,4,5,6-tetrahydro-2H-[1 ,2']bipyridinyl-5'-carbaldehyde (38mg, 198 ⁇ ) and 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)- 1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, 132 ⁇ " ⁇ ) using the method of Example 22. The crude material was purified by HPLC Method A to afford 22.1 mg of the title compound.
  • the title compound was prepared from [1 ,8]naphthyridine-2-carbaldehyde (31 mg, 198 ⁇ " ⁇ ) and 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]- phenol trihydrobromide salt (Preparation 25, 50mg, 132 ⁇ " ⁇ ) using the method of Example 22.
  • the crude material was purified by HPLC Method B to afford 22.5mg of the title compound.
  • the title compound was prepared from 5-piperidin-1-yl-pyrazine-2-carboxylic acid (Preparation 44, 35mg, 168 ⁇ ) and 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H- indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (Preparation 39, 100mg, 168 ⁇ " ⁇ ) using the method of Example 8.
  • the crude material was purified by HPLC Method A to afford 29.0mg of the title compound as the diethylamine salt.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (50 mg, 96 ⁇ mol) and (2-(pyrrolidin-1 -yl)ethanamine, 50mg, 132 ⁇ mol) using the method of Example 32.
  • the crude material was purified by HPLC Method E to afford (30 mg, 52%) of the title compound.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (100 mg, 193 ⁇ mol) and N,N-dimethylethylendiamine, (34 mg, 386 ⁇ ) using the method of Example 32.
  • the crude material was purified by HPLC Method E to afford (50 mg, 46%) of the title compound as white solid.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 ⁇ ) and 4-N,N-dimethylaminopiperidine, (40 mg, 308 ⁇ ) using the method of Example 32.
  • the crude material was purified by HPLC Method C to afford (60mg , 64%) of the title compound as off-white solid.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (120 mg, 231 ⁇ mol) and N-ethylaminoethanol, (41 mg, 463 ⁇ mol) using the method of Example 32.
  • the crude material was purified by HPLC Method D to afford (60mg, 64%) of the title compound as off-white solid.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 ⁇ ) and (R)-3-dimethylaminopyrrolidine, (35 mg, 308 ⁇ mol) using the method of Example 32.
  • the crude material was purified by HPLC Method C to afford (35 mg, 38%) of the title compound as white solid.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 ⁇ ) and (S)-3-dimethylaminopyrrolidine, (35 mg, 308 ⁇ ) using the method of Example 32.
  • the crude material was purified by HPLC Method C to afford (38 mg, 40%) of the title compound as off-white solid.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (120 mg, 231 ⁇ ) and(2-(piperidine-1 -yl)ethanamine, (59 mg, 463 ⁇ ) using the method of Example 32.
  • the crude material was purified by HPLC Method G to afford (38 mg, 27%) of the title compound as off-white solid.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 ⁇ ) and (2-(piperazinyl-1-yl)ethanamine, (40 mg, 309 ⁇ ) using the method of Example 32.
  • the crude material was purified by HPLC Method D to afford (26 mg, 28%) of the title compound as off-white solid.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 ⁇ ) and 1 -methyl-piperazine, (31 mg, 309 ⁇ ) using the method of Example 32.
  • the crude material was purified by HPLC Method D to afford (21 mg, 23%) of the title compound as off-white solid.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (100 mg, 154 ⁇ ) and morpholine, (34 mg, 386 ⁇ ) using the method of Example 32.
  • the crude material was purified by HPLC Method F to afford (42 mg, 38%) of the title compound as off- white solid.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (100 mg, 154 ⁇ ) and 4-methyl-piperidine, (38 mg, 386 ⁇ ) using the method of Example 32.
  • the crude material was purified by HPLC Method F to afford (34 mg, 30%) of the title compound as off-white solid.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (90mg, 173 ⁇ mol) and cylopenylamine, (30mg, 347 ⁇ mol) using the method of Example 32.
  • the crude material was purified by HPLC Method G to afford (28 mg, 28%) of the title compound as off-white solid.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (100mg, 193 ⁇ ) and 2-morpholin-4-yl-ethylamine, (30mg, 347 ⁇ ) using the method of Example 32.
  • the crude material was purified by HPLC Method F to afford (28 mg, 28%) of the title compound as off-white solid.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 ⁇ ) andl-isopropyl-piperazine, (40mg, 308 ⁇ " ⁇ ) using the method of Example 32.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 ⁇ ) and pyrrolidine (22 mg, 308 ⁇ " ⁇ ) using the method of Example 32.
  • the crude material was purified by HPLC Method D to afford (18 mg, 19%) of the title compound as off- white solid.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 ⁇ ) and ethyl-methylamine (18 mg, 308 ⁇ mol) using the method of Example 32.
  • the crude material was purified by HPLC Method E to afford (38 mg, 46%) of the title compound as off-white solid.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (126 mg, 243 ⁇ ) and cyclohexylamine (48 mg,487 ⁇ mol) using the method of Example 32.
  • the crude material was purified by HPLC Method D to afford (29 mg, 20%) of the title compound as off-white solid.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80mg, 154 ⁇ ) and dimethylamine HCI (25 mg, 308 ⁇ ) using the method of Example 32.
  • the crude material was purified by HPLC Method D to afford (17 mg, 21 %) of the title compound as off-white solid.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80mg, 154 ⁇ ) and azetdine HCI (29 mg, 308 ⁇ ) using the method of Example 32.
  • the crude material was purified by HPLC Method D to afford (19 mg, 23%) of the title compound as off-white solid.
  • the title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 3,4,5,6- tetrahydro-2H-[1 ,2']bipyridinyl-5'-carbaldehyde (88.2 mg, 0.46 mmol) using the method of Example 51 .
  • the crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH-DCM) to afford the title compound as an off white solid in 16.99 % yield, 22 mg.
  • the title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 6- phenoxy-pyridine-3-carbaldehyde (92.3 mg, 0.46 mmol) using the method of Example 51.
  • the crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH-DCM) to afford the title compound as an off white solid in 23.6 % yield, 31 mg.
  • the title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 4- methoxybenzaldehyde (63.1 mg, 0.46 mmol) using the method of Example 51.
  • the crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH- DCM) to afford the title compound as an off white solid in 22.1 % yield, 26 mg.
  • the title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 4- hydroxybenzaldehyde (56.6 mg, 0.46 mmol) using the method of Example 51 .
  • the crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH- DCM) to afford the title compound as an off white solid in 24.4 % yield, 28 mg.
  • the title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 3- methoxybenzaldehyde (63.1 mg, 0.46 mmol) using the method of Example 51.
  • the crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH-
  • the title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 3- hydroxybenzaldehyde (56.6 mg, 0.46 mmol) using the method of Example 51 .
  • the crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH- DCM) to afford the title compound as an off white solid in 26.1 % yield, 30 mg.
  • the title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and quinoline-6-carbaldehyde (72.9 mg, 0.46 mmol) using the method of Example 51 .
  • the crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH- DCM) to afford the title compound as an off white solid in 22.9 % yield, 28 mg.
  • the title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and [1 ,8]naphthyridine-3-carbaldehyde (146.1 mg, 0.92 mmol) using the method of Example 51.
  • the crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH-DCM) to afford the title compound as an off white solid in 9.0 % yield, 22 mg.
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (200 mg, 386 ⁇ " ⁇ ) and (S)-2-methyl-piperazine-1 -carboxylic acid tert-butyl ester (155mg, 773 ⁇ ) using the method from Example 61. After purification by HPLC Method E and deprotection using HCI/dioxan, the title compound (58 mg, 25% yield over two steps) was obtained as off- white solid (HCI-salt).
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (100 mg, 193 ⁇ " ⁇ ) and (2S,5R)-2,5-Dimethyl-piperazine-1-carboxylic acid tert-butyl ester (84mg, 386 ⁇ ) using the method from Example 61 . After purification by HPLC Method E and deprotection using HCI/dioxan, the title compound (43 mg, 37% yield over two steps) was obtained as off-white solid (HCI-salt).
  • the title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (200 mg, 386 ⁇ " ⁇ ) and piperazine-1 -carboxylic acid tert-butyl ester (144mg, 773 ⁇ ) using the method from Example 61. After purification by HPLC Method E and deprotection using HCI/dioxan, the title compound (64 mg, 29% yield over two steps) was obtained as off-white solid (HCI-salt).
  • the aqueous layer was re- extracted with DCM (500ml_) and the combined organic layers were washed with brine (2 x 1 L), dried over MgS0 4 and concentrated in vacuo to yield a black oil.
  • the crude material was refluxed in cyclohexane (20ml_) and filtered while hot. The filtrate was concentrated in vacuo and the residue was stirred in heptane for 48 hours. The resulting solid was collected by filtration to give the title compound (13.87g) in a 73% yield.
  • 6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)-phenyl]-1-(tetrahydro- pyran-2-yl)-1 H-indazole-3-carbonitrile (Preparation 6, 37.42g, 75.6mmol) in methanol (700ml_) was added sodium methoxide (12.21 g, 226.8mmol) and the reaction mixture was then stirred at room temperature for 18 hours.
  • reaction mixture was cooled to 0°C and neutralised by dropwise addition of a saturated aqueous solution of sodium hydrogen carbonate (150ml_).
  • the mixture was extracted with EtOAc (2 x 200ml_).
  • the combined organic layers were washed with further saturated aqueous sodium hydrogen carbonate solution (100ml_), dried over MgS0 4 and concentrated in vacuo to give the title compound as a foam (6.06g).
  • the reaction mixture was concentrated in vacuo and azeotroped with toluene (100ml_) and DCM (2 x 100ml_). The resulting gum was dried under vacuum for 3 hours.
  • the crude material was triturated in MeCN (300ml_) and the resulting solid was collected by filtration.
  • the solid was dissolved in ethanol (250ml_) and treated with concentrated hydrochloric acid (12M, 77.2ml_, 927mmol).
  • the resulting solution was heated at 40°C for 18 hours, then at 50°C for 2 hours.
  • the solvents were removed in vacuo and the resulting gum was triturated in MeCN (200ml_).
  • the solid which formed was collected by filtration, washed with further MeCN (200ml_) and dried under vacuum to give the title compound as a beige solid (23.5g, 88% yield, dihydrochloride salt).
  • the reaction mixture was then heated at 1 10°C for 18 hours, cooled to room temperature and filtered through a pad of Celite, washing with EtOAc. The solvent was removed in vacuo and the residue was redissolved in EtOAc (30ml_) and washed with water (30ml_). The organic layer was dried over sodium sulfate and concentrated in vacuo. The crude material was triturated with methanol and the resulting solid was collected by filtration to give the title compound as a beige solid (13.8g) in a 64% yield.
  • the reaction mixture was degassed with nitrogen and treated with tetrakis (triphenylphosphine) palladium(O) (1.85g, 1 .6mmol).
  • the reaction mixture was heated at 1 10°C for 18 hours, cooled to room temperature and filtered through a pad of Arbocel ® , washing with EtOAc (2 x 100ml_).
  • the filtrate was washed with water (100ml_), dried over MgS0 4 and concentrated in vacuo.
  • the crude material was purified by column chromatography on silica gel eluting with 10% EtOAc in heptane to give the title compound as a white solid (2.024g) in a 71 % yield.
  • reaction mixture was degassed with nitrogen, heated at 100°C for 18 hours, cooled to room temperature and concentrated in vacuo.
  • the residue was purified by column chromatography on silica gel eluting with 20% EtOAc in toluene to give the title compound as a foam (801 mg) in a 74% yield.
  • reaction mixture was degassed with nitrogen, heated at 100°C for 18 hours, cooled to room temperature and concentrated in vacuo.
  • the residue was purified by column chromatography on silica gel eluting with 20% EtOAc in toluene to give the title compound as a foam (633mg) in a 57% yield.
  • Phosphorus tribromide (1 1 .56ml_, 122.5mmol) was added to a solution of (2-bromo-4-fluoro-5- methoxy-phenyl)-methanol (Preparation 33, 14.4g, 61 .26mmol) in DCM (235ml_) at 0°C.
  • the reaction was allowed to warm to room temperature and stirred at that temperature for 18 hours.
  • the reaction mixture was cooled to 0°C and quenched by slow addition of saturated sodium hydrogen carbonate aqueous solution until effervescence had ceased.
  • the layers were separated and the aqueous layer was extracted with DCM (2 x 100ml_).
  • the combined organic layers were dried over MgS0 4 and concentrated in vacuo to give the title compound as a white solid (17.48g) in a 96% yield.
  • the mixture was degassed with nitrogen, treated with tetrakis (triphenylphosphine) palladium(O) (3.01 g, 2.6mmol) and heated at 1 10°C for 18 hours.
  • the reaction mixture was concentrated in vacuo and the residue was redissolved in EtOAc (500ml_) and filtered through Arbocel ® , washing with EtOAc (2 x 500ml_).
  • the combined organic phases were washed with water (300ml_), dried over MgS0 4 and concentrated in vacuo to give a brown oil.
  • the residue was purified by column chromatography on silica gel, eluting with 25% EtOAc in heptanes, to give the title compound (1.737g) in a 31 % yield.
  • Acetic acid (430 ⁇ _, 7.56mmol) was added and the reaction mixture was heated at 50°C for 18 hours and then concentrated in vacuo to give a brown oil.
  • the oil was dissolved in ethanol (15ml_) and the resulting solution was treated with concentrated hydrochloric acid (12M, 4.75ml_, 56.7mmol) and then heated at 80°C for 18 hours. The solvent was removed in vacuo to yield the title compound (2.03g) in a 97% yield.
  • the aqueous mixture was extracted with ether (3 ⁇ 300ml_), and the combined organic layers were washed with 2% sodium hydroxide aqueous solution (400ml_) and filtered through a layer of silica gel (40/60 ⁇ ). The filtrate was concentrated in vacuo to yield the title compound which was used without further purification.
  • 6-Cyano-nicotinic acid 120mg, 810 ⁇ " ⁇ was suspended in toluene (1 ml_) and thionyl chloride (1 19 ⁇ _, 1 .62mmol) was added dropwise followed by one drop of DMF.
  • the reaction mixture was refluxed for 2.5 hours and then allowed to cool to room temperature for 18 hours.
  • the solvents were removed in vacuo and the residue was azeotroped with toluene to furnish the title compound as a brown oil (134mg) which was used in further experiments without purification.
  • LCMS m/z 167.02 M+H + .
  • the activity of the compounds of formula (I) may be assessed in the following assays.
  • HPE High percentage effect
  • ZPE 0% effect
  • Greiner 384 well plates are prepared containing 400nl of serially diluted compound, standard and HPE/ZPE. Final top assay concentration is 80 ⁇ as the assay dilution factor is fifty.
  • JAK3 enzyme (Invitrogen) stock solution is made up at 4.1 ⁇ in sterile water.
  • JAK3 enzyme stock is diluted to 2nM in assay buffer (10mM HEPES free acid pH 7.5, 10mM HEPES free base pH 7.5, 10mM MgCL 2 , 0.0005% Tween-20, 0.01 % BSA) containing 2mM DTT ( all supplied by Sigma).
  • ATP is made up at 10mM stock in sterile water and diluted to 800 ⁇ in assay buffer.
  • Peptide (American peptide company) is made up at 30mM in 100% DMSO and diluted to 3 ⁇ in assay buffer.
  • Stop buffer comprises 140mM HEPES, 22.5mM EDTA (Sigma) and 0.15% coating reagent (Caliper Life Sciences).
  • Assays are performed in Greiner polypropylene 384 well plates. Following compound preparation within the plate 10 ⁇ of enzyme in assay buffer containing DTT is added using a Multidrop Micro. Final assay concentration of enzyme is 1 nM. Compound and enzyme are pre- incubated for 60 minutes at room temperature using low evaporation lids before addition of 10 ⁇ ATP/peptide mixture in assay buffer using a Multidrop Micro. Final assay concentrations are 400 ⁇ ATP and 1 .5 ⁇ peptide. Plates are foil sealed and incubated for a further 60 minutes at room temperature. Stop solution is added to the plates (20 ⁇ / ⁇ ) using a Multidrop Micro and plates are loaded onto the Caliper EZReader II.
  • Data is generated by the shift in mobility of non- phosphorylated peptide substrates and phosphorylated products by electrophoresis within a chip and detected via LED induced fluorescence. Data is analysed using LabChip EZReader software which calculates the relative heights of the substrate and product peaks and reports product/product plus substrate peak ratio. Test compound data are subsequently expressed as percentage inhibition defined by HPE and ZPE values for each plate. Percentage inhibition in the presence of test compound is plotted against compound concentration on a log scale to determine an IC 50 from the resultant sigmoid curve.
  • JAK1 isolated enzyme high ATP Caliper endpoint assay
  • HPE High percentage effect
  • ZPE 0% effect
  • Greiner 384 well plates are prepared containing 400nl of serially diluted compound, standard and HPE/ZPE. Final top assay concentration is 80 ⁇ as the assay dilution factor is fifty.
  • JAK1 enzyme (Invitrogen) stock solution is made up at 5.2 ⁇ in sterile water. JAK1 enzyme stock is diluted to 20nM in assay buffer (10mM HEPES free acid pH 7.5, 10mM HEPES free base pH 7.5, 10mM MgCL 2 , 0.0005% Tween-20, 0.01 % BSA) containing 2mM DTT ( all supplied by Sigma) with the addition of one protease tablet per 25mls buffer (Roche). ATP is made up at 10mM stock in sterile water and diluted to 5mM in assay buffer. Peptide H236 (Caliper Life Sciences) is made up at 1.5mM in 100% DMSO and diluted to 3 ⁇ in assay buffer. Stop buffer comprises 140mM HEPES, 22.5mM EDTA (Sigma) and 0.15% coating reagent (Caliper Life Sciences).
  • Assays are performed in Greiner polypropylene 384 well plates. Following compound preparation within the plate 10 ⁇ of enzyme in assay buffer containing DTT is added using a Multidrop Micro. Final assay concentration of enzyme is 10nM. Compound and enzyme are pre- incubated for 30 minutes at room temperature using low evaporation lids before addition of 10 ⁇ ATP/peptide mixture in assay buffer using a Multidrop Micro. Final assay concentrations are 2.5mM ATP and 1 .5 ⁇ peptide. Plates are foil sealed and incubated for a further 120 minutes at room temperature. Stop solution is added to the plates (20 ⁇ / ⁇ ) using a Multidrop Micro and plates are loaded onto the Caliper EZReader II.
  • Data is generated by the shift in mobility of non-phosphorylated peptide substrates and phosphorylated products by electrophoresis within a chip and detected via LED induced fluorescence. Data is analysed using LabChip EZReader software which calculates the relative heights of the substrate and product peaks and reports product/product plus substrate peak ratio. Test compound data are subsequently expressed as percentage inhibition defined by HPE and ZPE values for each plate. Percentage inhibition in the presence of test compound is plotted against compound concentration on a log scale to determine an IC 50 from the resultant sigmoid curve.
  • Example 24(c) of WO-2001/002369 was tested. It gave an IC 50 of 1 19 nM in the JAK-3 assay and an IC 50 of 120 nM in the JAK-1 assay.
  • HPE High percentage effect
  • ZPE 0% effect
  • 100% DMSO 100% DMSO. Plates containing 1 ⁇ of serially diluted compound, standard and HPE/ZPE are diluted by addition of 39 ⁇ assay media (Optimem with 100uM NEAA, 10uM sodium pyruvate and 100U penicillin/1 OOug streptomycin (Invitrogen)) using a Multidrop Combi. This dilutes test compounds to a top concentration of 100 ⁇ . Final top assay concentration is 10 ⁇ as the assay dilution factor is ten. Final DMSO concentration is 0.25%.
  • CD40 ligand is a member of the TNF superfamily and activates B cells.
  • CD40 (Invitrogen) is prepared at 0.1 mg/ml in PBS minus Ca 2+ , minus Mg 2+ . The concentration of CD40 required for activation is predetermined by CD40 titration with the cell line, lnterleukin-4 (IL-4, Invitrogen) is used as the co-activator and functions by binding to the IL-4 receptor complex leading to recruitment and activation of JAK1 and JAK3 tyrosine kinases.
  • IL-4 is prepared at 1 mg/ml in sterile water to generate a stock solution. This is further diluted to 100ng/ml in assay media. Inhibition of the STAT6-beta-lactamase reporter response is measured in the presence of IL-4 at an approximate EC 50 concentration.
  • Beta lactamase dye reagent comprises three components and is made up by adding 1 part CCF4 dye, 5 parts solution B and 77 parts Live Blazer- substrate mixture.
  • Assays are performed in Greiner 384 well black polypropylene clear bottomed plates.
  • the Invitrogen Cellsensor STAT6-b/a-RA-1 cell line is thawed, counted and resuspended at 1 .88x10 6 cells/ml.
  • Cells are stimulated with CD40 ligand by addition of 5.56 ⁇ of 0.1 mg/ml stock per 1 ml of cell suspension.
  • Cells are plated out at 60000 cells/well, 32 ⁇ / ⁇ and incubated at 37°C, 5% C0 2 . After 18 hours 4 ⁇ test compound is added to the plate using a Platemate Plus.
  • Plates are incubated at 37°C, 5% C0 2 for 60 minutes using low evaporation lids before addition of 4 ⁇ IL-4 at a concentration of 100ng/ml. Plates are incubated at 37°C, 5% C0 2 for a further five hours before addition of 10 ⁇ beta lactamase dye. After reagent addition plates are incubated at 37°C, 5% C0 2 for 18 hours. Beta lactamase fluorescence signal is read at 460nm (blue) and 530nm (green) and a ratio calculated using an Envision. Test compound data are expressed as percentage inhibition defined by HPE and ZPE values for each plate. Percentage inhibition in the presence of test compound is plotted against compound concentration on a log scale to determine an IC 50 from the resultant sigmoid curve.
  • Example 4 gave an IC 50 of 140 nM in this assay.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

The present invention relates to compounds of formula (I) to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma and COPD.

Description

INDAZOLES
The present invention relates to indazoles, pharmaceutical compositions comprising such compounds and their use as medicaments. More particularly, the present invention provides 6- phenyl-1 H-indazole derivatives which are Janus Kinase (JAK) inhibitors and useful for the treatment of allergic and respiratory conditions, particularly chronic obstructive pulmonary disease.
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the US and is characterized by airflow obstruction that is not fully reversible with bronchodilators. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily cigarette smoke. Symptoms are typically breathing-related (e.g. chronic cough, exertional dyspnea, expectoration and wheeze). Patients experience periods of stable disease interspersed with inflammatory exacerbations resulting in acute decline in lung function and often hospitalization.
Current treatment guidelines recommend bronchodilators as the mainstay of COPD drug treatment. However, anti-inflammatory inhaled corticosteroids (ICS) and bronchodilator/inhaled corticosteroid combination products, are extensively used. Whilst inhaled corticosteroids do provide some benefits with respect to short term lung function improvements and exacerbation frequency, they do not address the corticosteroid-refractory inflammation which is characteristic of this disease and thought to play a key role in disease progression. There is a clear medical need for anti-inflammatory therapies in COPD that will address the chronic inflammatory component of the disease and ultimately provide symptomatic relief, a reduction in exacerbation frequency and an amelioration of exacerbation severity.
The Janus kinase (JAK) family of receptor associated tyrosine kinases, JAK 1 , JAK 2, JAK 3 and tyrosine kinase 2 (TYK2), are involved in signal transduction associated with a variety of inflammatory cytokines. JAK kinases can function as either hetero or homo-dimers, phosphorylating STAT transcription factors which regulate inflammatory gene transcription. Oral JAK 1/JAK 3 inhibitors such as CP-690550 have shown impressive anti-inflammatory activity in inflammatory diseases such as rheumatoid arthritis and psoriasis.
Many JAK dependent cytokines are thought to play key roles in the pathology of COPD which involves the interplay of multiple inflammatory cells such as T lymphocytes, neutrophils, macrophages and lung epithelium. For example the JAK 1/JAK 3 heterodimer plays a key role in T lymphocyte survival and activation whereas JAK 2 is thought to be critical for regulation of neutrophil activation and apoptosis. JAK 1 and JAK 2 play an important role in IL-13 mediated inflammatory signaling in macrophages, which is thought to link acute inflammatory events to chronic progressive disease. Importantly JAK 1 , JAK 2 and TYK 2 also play an important role in signaling mediated by IFNy, a cytokine associated with the chronic inflammation observed in COPD, which modulates the activity of T cells, epithelium and macrophages whilst not being modulated by corticosteroids.
Macrophage phagocytosis of bacteria is impaired in the lungs of COPD patients, potentially in part due to high local IFNy levels. In vitro studies with isolated patient cells have shown that JAK inhibitors increase phagocytotic rate in the presence of IFNy. Consequently, as well as exerting a direct anti-inflammatory effect, JAK inhibitors may also increase the ability of the lung to maintain a sterile environment.
JAK inhibitors are therefore likely to have utility in the treatment of a range of inflammatory diseases, including lung diseases such as COPD, asthma and pulmonary vascular disease. Compounds which have a broad inhibitory activity across the range of Janus kinases, in particular, are likely to have a potent anti-inflammatory effect. However, such a selectivity profile can also lead to undesirable side-effects in systemically circulating compounds, particularly anemia and neutropenia associated with JAK 2 inhibition. For the treatment of lung diseases, it is therefore particularly favourable to provide JAK inhibitors which can be administered by inhalation and which inhibit Janus kinases locally in the lung without having a significant systemic exposure.
There is thus a need to provide new JAK inhibitors that are potent, selective inhibitors of Janus kinases with appropriate metabolic stability and pharmacokinetic properties, particularly compounds which can be administered by inhalation and are active in lung tissue whilst having poor systemic penetration or high systemic lability.
The invention therefore provides, as embodiment E1 , a compound of formula (I):
Figure imgf000005_0001
(I) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein:
R1 is halo;
R2 is C-|-C6 alkyl optionally substituted by one or more fluorine atoms; X is a bond, -CO-, -S02- or -CH2-;
R3 is Aryl1, Het1 or Het2, each of which is optionally substituted by 1 substituent -Y-R4 and/or 1-4 substituents each independently selected from R5; n is 1 or 2;
Aryl1 is phenyl or naphthyl;
Het1 is (i) a 6-membered aromatic heterocycle containing 1 -3 N atoms or (ii) a 5-membered aromatic heterocycle containing either (a) 1-4 N atoms or (b) 1 O or S atom and 0-3 N atoms;
Het2 is (i) a 10-membered bicyclic aromatic heterocycle containing 1-4 N atoms or (ii) a 9- membered bicyclic aromatic heterocycle containing either (a) 1-4 N atoms or (b) 1 O or S atom and 0-3 N atoms or (iii) an 8-membered bicyclic aromatic heterocycle containing (a) 1-4 N atoms or (b) 1 O or S atom and 1 -3 N atoms or (c) 2 O or S atoms and 0-2 N atoms; Y is a bond or -0-;
R4 is Aryl2 or Het3;
R5 is Ci-C6 alkyl, C3-C8 cycloalkyl, halo, -CN, -OR6, -NR7R8, -SR6, -SOR9, -S02R9, -COR6, - OCOR6, -COOR6, -NR6COR6, -CONR7R8, -NR6S02R9, -S02NR7R8, -NR6CONR7R8, - NR6COOR9 or -NR6S02NR7R8;
R6 is H, d-C6 alkyl or C3-C8 cycloalkyl, said d-C6 alkyl;
R7 and R8 are each independently H, C-|-C6 alkyl or C3-C8 cycloalkyl or are taken together with the nitrogen atom to which they are attached to form a 4-, 5- or 6-membered saturated heterocyclic ring containing 1-2 nitrogen atoms or 1 nitrogen and 1 oxygen atom, said heterocyclic ring being optionally substituted by one or more Ci-C6 alkyl or C3-C8 cycloalkyl groups;
R9 is Ci-C6 alkyl or C3-C8 cycloalkyl;
Aryl2 is phenyl or naphthyl, said phenyl and naphthyl being optionally substituted with 1-5 substituents selected from d-C6 alkyl, C3-C8 cycloalkyl, halo, -CN, -OR6, -NR7R8, -SR6, -SOR9, -S02R9, -COR6, -OCOR6, -COOR6, -NR6COR6, -CONR7R8, -NR6S02R9, -S02NR7R8, - NR6CONR7R8, -NR6COOR9 and -NR6S02NR7R8; and
Het3 is a 3 to 8-membered saturated or partially unsaturated monocyclic heterocycle, containing 1 or 2 heteroatoms selected from O and N, said heterocycle being optionally substituted by 1-5 substituents selected from Ci-C6 alkyl, C3-C8 cycloalkyl, halo, oxo, -OR6, -NR7R8, -SR6, -SOR9, -S02R9, -COR6, -OCOR6, -COOR6, -NR6COR6, -CONR7R8, -NR6S02R9, -S02NR7R8, - NR6CONR7R8, -NR6COOR9 and -NR6S02NR7R8.
The invention also provides, as embodiment E2, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R2, n, X and R3 are as defined in embodiment E1 and R1 is fluoro.
The invention also provides, as embodiment E3, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R1 is as defined in either of embodiments E1 or E2, n, X and R3 are as defined in embodiment E1 and R2 is -CH2CH3 or -
The invention also provides, as embodiment E4, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R1 is as defined in either of embodiments E1 or E2, R2 is as defined in either of embodiments E1 or E3, X and R3 are as defined in embodiment E1 and n is 1.
The invention also provides, as embodiment E5, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R1 is as defined in either of embodiments E1 or E2, R2 is as defined in either of embodiments E1 or E3, X and R3 are as defined in embodiment E1 and n is 2.
The invention also provides, as embodiment E6, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R1 is as defined in either of embodiments E1 or E2, R2 is as defined in either of embodiments E1 or E3, n is defined in any one of embodiments E1 , E4 or E5, R3 is as defined in embodiment E1 and X is a bond.
The invention also provides, as embodiment E7, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R1 is as defined in either of embodiments E1 or E2, R2 is as defined in either of embodiments E1 or E3, n is defined in any one of embodiments E1 , E4 or E5, R3 is as defined in embodiment E1 and X is -CO-.
The invention also provides, as embodiment E8, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R1 is as defined in either of embodiments E1 or E2, R2 is as defined in either of embodiments E1 or E3, n is defined in any one of embodiments E1 , E4 or E5, R3 is as defined in embodiment E1 and X is -CH2-.
The invention also provides, as embodiment E9, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R1 is as defined in either of embodiments E1 or E2, R2 is as defined in either of embodiments E1 or E3, n is defined in any one of embodiments E1 , E4 or E5, R3 is as defined in embodiment E1 and X is -S02-.
The invention also provides, as embodiment E10, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R1 is as defined in either of embodiments E1 or E2, R2 is as defined in either of embodiments E1 or E3, n is as defined in any one of embodiments E1 , E4 or E5, X is as defined in any one of embodiments E1 , E6, E7, E8 or E9 and R3 is is phenyl, thiazolyl, quinolinyl, pyrimidinyl, [1 ,8]naphthyridinyl or pyridyl, each of which is optionally substituted by 1 substituent -Y-R4 and 1-4 substituents each independently selected from R5.
The invention also provides, as embodiment E1 1 , a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R1 is as defined in either of embodiments E1 or E2, R2 is as defined in either of embodiments E1 or E3, n is as defined in any one of embodiments E1 , E4 or E5, X is as defined in any one of embodiments E1 , E6, E7, E8 or E9 and R3 is phenyl, thiazolyl, quinolinyl, pyrimidinyl, [1 ,8]naphthyridinyl or pyridyl, each of which is optionally substituted by 1 substituent selected from piperdininyl, (fluorophenyl)oxy, phenyloxy and morpholinyl and 1-2 substituents each independently selected from fluoro, chloro, cyano, methoxy and hydroxy.
The invention also provides, as embodiment E12, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R1 is as defined in either of embodiments E1 or E2, R2 is as defined in either of embodiments E1 or E3, n is as defined in any one of embodiments E1 , E4 or E5, X is as defined in any one of embodiments E1 , E6, E7, E8 or E9 and R3 is fluorophenyl, methoxyphenyl, thiazolyl, hydroxyphenyl, phenyl, quinolinyl, [1 ,8]naphthyridinyl, (piperidinyl)pyridyl, (piperidinyl)pyrimidinyl, ((fluorophenyl)oxy)pyrimidinyl, (phenyloxy)pyridyl, (morpholinyl)pyridyl, chloropyridyl or cyanopyridyl.
The invention also provides, as embodiment E13, a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein R1 is as defined in either of embodiments E1 or E2, R2 is as defined in either of embodiments E1 or E3, n is defined in any one of embodiments E1 , E4 or E5, and -X-R3 is (fluorophenyl)carbonyl, (thiazolyl)carbonyl, benzyl, ((piperidinyl)pyrimidinyl)carbonyl, ((phenoxy)pyridyl)carbonyl, ((morpholinyl)pyridyl)sulphonyl, ((phenoxy)pyridyl)sulphonyl, (chloropyridyl)carbonyl, (cyanopyridyl)carbonyl, (fluorophenyl)carbonyl, (thiazolyl)carbonyl, (fluorophenyl)sulphonyl, ((fluorophenoxy)pyrimidinyl)carbonyl, (quinolinyl)methyl, (hydroxyphenyl)methyl,
(cyanopyridyl)methyl, (methoxyphenyl)methyl, ((phenoxy)pyridyl)methyl,
((piperidinyl)pyridyl)methyl, ((cyanopyridyl)methyl, (fluorophenyl)methyl or
([1 ,8]naphthyridinyl)methyl.
The invention also provides, rmula:
Figure imgf000009_0001
(la)
or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein X is as defined in any one of embodiments E1 , E6, E7, E8 or E9 and R3 is as defined in any one of embodiments E1 , E10, E1 1 or E12 or -X-R3 is as defined in embodiment E13.
Particularly preferred compounds of formula (I) include:
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo
[4,5-c]pyridin-5-yl}-(4-fluoro-phenyl)-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo
[4,5-c]pyridin-5-yl}-isothiazol-3-yl-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo
[4,5-c]pyridin-5-yl}-isothiazol-3-yl-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo
[4,5-c]pyridin-5-yl}-(5-piperidin-1 -yl-pyrazin-2-yl)-methanone; {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6J-tetrahydro-imidazo
[4,5-c]pyridin-5-yl}-(6-phenoxy-pyridin-3-yl)-methanone;
5-Ethyl-2-fluoro-4-{3-[5-(6-morpholin-4-yl-pyridine-3-sulfonyl)-4,5,6J-tetrahydro-1 H-imidazo[4 c] pyridin-2-yl]-1 H-indazol-6-yl}-phenol;
5-Ethyl-2-fluoro-4-{3-[5-(6-phenoxy-pyridine-3-sulfonyl)-4,5,6,7-tetrahydro-1 H-imidazo
[4,5-c]pyridin-2-yl]-1 H-indazol-6-yl}-phenol;
(5-Chloro-pyridin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-4!5!7,8- tetrahydro-1 H-imidazo[4,5-d]azepin-6-yl}-methanone;
2-{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-4,5J!8-tetrahydro-1 H-imidazo[4,5- d] azepine-6-carbonyl}-isonicotinonitrile;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-4,5,7,8-tetrahydro-1 H-imidazo
[4,5-d]azepin-6-yl}-(4-fluoro-phenyl)-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-4,5,7,8-tetrahydro-1 H-imidazo
[4,5-d]azepin-6-yl}-isothiazol-3-yl-methanone;
5-Ethyl-2-fluoro-4-{3-[5-(4-fluoro-benzenesulfonyl)-4,5,6,7-tetrahydro-1 H-imidazo
[4,5-c]pyridin-2-yl]-1 H-indazol-6-yl}-phenol;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo
[4,5-c]pyridin-5-yl}-[5-(2-fluoro-phenoxy)-pyrazin-2-yl]-methanone;
4- [3-(6-Benzyl-1 ,4!5!6!7!8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1 H-indazol-6-yl]-5-ethyl-2- fluoro-phenol;
(5-Chloro-pyridin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7- tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
5- {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo
[4,5-c]pyridine-5-carbonyl}-pyridine-2-carbonitrile;
5-{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-4,5,7,8-tetrahydro-1 H-imidazo[4,5- d]azepine-6-carbonyl}-pyridine-2-carbonitrile;
5-Ethyl-2-fluoro-4-[3-(5-quinolin-6-ylmethyl-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H- indazol-6-yl]-phenol;
5-Ethyl-2-fluoro-4-{3-[5-(4-hydroxy-benzyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl]-1 H- indazol-6-yl}-phenol;
5-Ethyl-2-fluoro-4-{3-[5-(3-hydroxy-benzyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl]-1 H- indazol-6-yl}-phenol;
4- {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5- c]pyridin-5-ylmethyl}-pyridine-2-carbonitrile;
5- Ethyl-2-fluoro-4-{3-[5-(3-methoxy-benzyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl]-1 H- indazol-6-yl}-phenol; 5-Ethyl-2-fluoro-4-[3-(5-quinolin-3-ylmethyl-4,5,6J-tetrahydro-1 H-imidazo[4,5-c] indazol-6-yl]-phenol;
5-Ethyl-2-fluoro-4-{3-[5-(6-phenoxy-pyridin-3-ylmethyl)-4,5,6J-tetrahydro-1 H-imidazo[4 c]pyridin-2-yl]-1 H-indazol-6-yl}-phenol;
5-Ethyl-2-fluoro-4-{3-[5-(3A5,6-tetrahydro-2H-[1 ^^
1 H-imidazo[4,5-c]pyridin-2-yl]-1 H-indazol-6-yl}-phenol;
3- {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 !4,6J-tetrahydro-imidazo[4,5- c]pyridin-5-ylmethyl}-pyridine-2-carbonitrile;
5-Ethyl-2-fluoro-4-{3-[5-(4-fluoro-benzy
indazol-6-yl}-phenol;
5-Ethyl-2-fluoro-4-[3-(5-[1 ,8]naphthyridin-2-ylmethyl-4!5,6J-tetrahydro-1 H-imidazo[
4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]-phenol;
(2-{6-[5-Fluoro-4-hydroxy-2-(2,2,2-trifluoro-ethyl)-ph
imidazo[4,5-c]pyridin-5-yl)-(5-piperidin-1 -yl-pyrazin-2-yl)-methanone;
(2-{6-[5-Fluoro-4-hydroxy-2-(2,2,2-trifluoro-ethyl)-ph
imidazo[4,5-c]pyridin-5-yl)-(4-fluoro-phenyl)-methanone;
4- [3-(5-Benzyl-4!5!6J-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]-2-fluoro-5- (2,2,2-trifluoro-ethyl)-phenol; or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.
Other preferred compounds of formula (I) include:
{5-[(2-Dimethylamino-ethyl)-methyl-amino]-pyrazin-2-yl}-{2-[6-(2-ethyl-5-fluoro-4-hydroxy- phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5- c]pyridin-5-yl}-[5-(2-pyrrolidin-1-yl-ethylamino)-pyrazin-2-yl]-methanone;
[5-(2-Dimethylamino-ethylamino)-pyrazin-2-yl]-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1 H- indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
[5-(4-Dimethylamino-piperidin-1-yl)-pyrazin-2-yl]-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1 H- indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5- c]pyridin-5-yl}-{5-[ethyl-(2-hydroxy-ethyl)-amino]-pyrazin-2-yl}-methanone;
[5-((R)-3-Dimethylamino-pyrrolidin-1 -yl)-pyrazin-2-yl]-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-
1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone; [5-((S)-3-Dimethylamino-pyrrolidin-1-yl)-pyrazin-2-yl]-{2-[6-(2-ethyl-5-fluoro-4-hy 1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6J-etrahydroimidazo[4,5c]pyridin- 5-yl}-[5-(2-piperidin-1-yl-ethylamino)-pyrazin-2-yl]-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5- c]pyridin-5-yl}-[5-(2-piperazin-1-yl-ethylamino)-pyrazin-2-yl]-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5-
]pyridin-5-yl}-(4-methyl-3,4,5,6-tetrahydro-2H-[1 ,2']bipyrazinyl-5'-yl)-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5- c]pyridin-5-yl}-(5-morpholin-4-yl-pyrazin-2-yl)-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-idazo[4,5c]pyridin- 5-yl}-[5-(4-methyl-piperidin-1-yl)-pyrazin-2-yl]-methanone;
(5-Cyclopentylamino-pyrazin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]- 1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5- c]pyridin-5-yl}-[5-(2-morpholin-4-yl-ethylamino)-pyrazin-2-yl]-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5- c]pyridin-5-yl}-(4-isopropyl-3,4,5,6-tetrahydro-2H-[1 ,2']bipyrazinyl-5'-yl)-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5- c]pyridin-5-yl}-(5-pyrrolidin-1-yl-pyrazin-2-yl)-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5- ]pyridin-5-yl}-[5-(ethyl-methyl-amino)-pyrazin-2-yl]-methanon;
(5-Cyclohexylamino-pyrazin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]- 1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
(5-Dimethylamino-pyrazin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-, 4,6,7- tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
(5-Azetidin-1-yl-pyrazin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4 tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
2-Fluoro-4-{3-[5-(4-fluoro-benzyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl]-1 H-indazol-6- yl}-5-(2,2,2-trifluoro-ethyl)-phenol;
2-Fluoro-4-{3-[5-(3,4,5,6-tetrahydro-2H-[1 ,2']bipyridinyl-5'-ylmethyl)-4,5,6,7-tetrahydro-1 H- imidazo[4,5-c]pyridin-2-yl]-1 H-indazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;
2-Fluoro-4-{3-[5-(6-phenoxy-pyridin-3-ylmethyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2- yl]-H-indazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;
2-Fluoro-4-{3-[5-(4-methoxy-benzyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl]-1 H indazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol; 2-Fluoro-4-{3-[5-(4-hydroxy-benzyl)-4,5,6,7-tetrahydro-1 H-im^
indazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;
2-Fluoro-4-{3-[5-(3-methoxy-benzyl)-4,5,6J-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl]-1 H^ indazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;
2-Fluoro-4-{3-[5-(3-hydroxy-benzyl)-4!5!6J-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl]-1 H- indazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;
2-Fluoro-4-[3-(5-quinolin-6-ylmethyl-4,5,6J-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-y
indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol;
2-Fluoro-4-[3-(5-quinolin-3-ylmethyl-4,5,6J-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-y
indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol;
2-Fluoro-4-[3-(5-[1 ,8]naphthyridin-3-ylmethyl-4,5,6J-tetrahydro-1 H-imidazo[4,5-c]pyri
1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol;
((3R,5S)-3,5-Dimethyl-3,4,5,6-tetrahydro-2H-[1 ,2']b^
hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 !4,6J-tetrahydro-imidazo[4,5- c]pyridin-5-yl}-((S)-3-methyl-3,4,5,6-tetrahydro-2H-n^
((2S!5R)-2!5-Dimethyl-3!4!5!6-tetrahydro-2H-[1 ,2']bipyrazinyl-5'-yl)-{2-[6-(2-ethyl-5-flu hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone; {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 !4,6J-tetrahydro-imidazo[4,5- ]pyridin-5-yl}-(3,4,5,6-tetrahydro-2H-[1 ,2']bipyrazinyl-5'-yl)-methanone; or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.
Most preferred is {2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro- imidazo[4,5-c]pyridin-5-yl}-(5-piperidin-1-yl-pyrazin-2-yl)-methanone or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.
The present invention also provides: a method of treating a disease for which a JAK inhibitor is indicated, in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt; the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, for the manufacture of a medicament for treating a disease or condition for which a JAK inhibitor is indicated; a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use as a medicament; a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, for use in the treatment of a disease or condition for which a JAK inhibitor is indicated; a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, and a pharmaceutically acceptable excipient; a pharmaceutical composition for the treatment of a disease or condition for which a JAK inhibitor is indicated, comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.
The disease or condition for which a JAK inhibitor is indicated is preferably an allergic or respiratory condition such as allergic rhinitis, nasal congestion, rhinorrhea, perennial rhinitis, nasal inflammation, asthma of all types, chronic obstructive pulmonary disease (COPD), chronic or acute bronchoconstriction, chronic bronchitis, small airways obstruction, emphysema, chronic eosinophilic pneumonia, adult respiratory distress syndrome, exacerbation of airways hyperreactivity consequent to other drug therapy, pulmonary vasulcar disease (including pulmonary arterial hypertension), acute lung injury, bronchiectasis, sinusitis, allergic conjunctivitis, idiopathic pulmonary fibrosis or atopic dermatitis, particularly asthma or chronic obstructive pulmonary disease, most particularly chronic obstructive pulmonary disease.
Other diseases and conditions of interest are inflammation (including neuroinflammation), arthritis (including rheumatoid arthritis, spondyloarthropathies, systemic lupus erythematous arthritis, osteoarthritis and gouty arthritis), pain, fever, pulmonary sarcoisosis, silicosis, cardiovascular disease (including atherosclerosis, myocardial infarction, thrombosis, congestive heart failure and cardiac reperfusion injury), cardiomyopathy, stroke, ischaemia, reperfusion injury, brain edema, brain trauma, neurodegeneration, liver disease, inflammatory bowel disease (including Crohn's disease and ulcerative colitis), nephritis, retinitis, retinopathy, macular degeneration, glaucoma, diabetes (including type 1 and type 2 diabetes), diabetic neurorpathy, viral and bacterial infection, myalgia, endotoxic shock, toxic shock syndrome, autoimmune disease, osteoporosis, multiple sclerosis, endometriosis, menstrual cramps, vaginitis, candidiasis, cancer, fibrosis, obesity, muscular dystrophy, polymyositis, Alzheimer's disease, skin flushing, eczema, psoriasis, atopic dermatitis and sunburn.
Types of asthma include atopic asthma, non-atopic asthma, allergic asthma, atopic bronchial IgE-mediated asthma, bronchial asthma, essential asthma, true asthma, intrinsic asthma caused by pathophysiologic disturbances, extrinsic asthma caused by environmental factors, essential asthma of unknown or inapparent cause, bronchitic asthma, emphysematous asthma, exercise- induced asthma, allergen induced asthma, cold air induced asthma, occupational asthma, infective asthma caused by bacterial, fungal, protozoal, or viral infection, non-allergic asthma, incipient asthma, wheezy infant syndrome and bronchiolytis.
The treatment of asthma includes palliative treatment for the symptoms and conditions of asthma such as wheezing, coughing, shortness of breath, tightness in the chest, shallow or fast breathing, nasal flaring (nostril size increases with breathing), retractions (neck area and between or below the ribs moves inward with breathing), cyanosis (gray or bluish tint to skin, beginning around the mouth), runny or stuffy nose, and headache.
The present invention also provides any of the uses, methods or compositions as defined above wherein the compound of formula (I), or pharmaceutically acceptable salt thereof, or pharmaceutically acceptable solvate of said compound or salt, is used in combination with another pharmacologically active compound, particularly one of the functionally-defined classes or specific compounds listed below. Generally, the compounds of the combination will be administered together as a formulation in association with one or more pharmaceutically acceptable excipients.
Suitable agents for use in combination therapy with a compound of formula (I), or pharmaceutically acceptable salt thereof, or pharmaceutically acceptable solvate of said compound or salt, particularly in the treatment of respiratory disease, include: a 5-lipoxygenase activating protein (FLAP) antagonist;
a leukotriene antagonist (LTRA) such as an antagonist of LTB4, LTC4, LTD4, LTE4, CysLT-ι or CysLT2, e.g. montelukast or zafirlukast;
a histamine receptor antagonist, such as a histamine type 1 receptor antagonist or a histamine type 2 receptor antagonist, e.g. loratidine, fexofenadine, desloratidine, levocetirizine, methapyrilene or cetirizine;
an a1 -adrenoceptor agonist or an a2-adrenoceptor agonist, e.g. phenylephrine, methoxamine, oxymetazoline or methylnorephrine;
a muscarinic M3 receptor antagonist, e.g. tiotropium or ipratropium;
a dual muscarinic M3 receptor antagononist/p2 agonist;
a PDE inhibitor, such as a PDE3 inhibitor, a PDE4 inhibitor or a PDE5 inhibitor, e.g. theophylline, sildenafil, vardenafil, tadalafil, ibudilast, cilomilast or roflumilast;
sodium cromoglycate or sodium nedocromil;
a cyclooxygenase (COX) inhibitor, such as a non-selective inhibitor (e.g. aspirin or ibuprofen) or a selective inhibitor (e.g. celecoxib or valdecoxib); a glucocorticosteroid, e.g. fluticasone, mometasone, dexamethasone, prednisolone, budesonide, ciclesonide or beclamethasone;
an anti-inflammatory monoclonal antibody, e.g. infliximab, adalimumab, tanezumab, ranibizumab, bevacizumab or mepolizumab;
a β2 agonist, e.g. salmeterol, albuterol, salbutamol, fenoterol or formoterol, particularly a long- acting β2 agonist;
an intigrin antagonist, e.g. natalizumab;
an adhesion molecule inhibitor, such as a VLA-4 antagonist;
a kinin B -i or B2 receptor antagonist;
an immunosuppressive agent, such as an inhibitor of the IgE pathway (e.g. omalizumab) or cyclosporine;
a matrix metalloprotease (MMP) inhibitor, such as an inhibitor of MMP-9 or MMP-12;
a tachykinin NK-i , NK2 or NK3 receptor antagonist;
a protease inhibitor, such as an inhibitor of elastase, chymase or catheopsin G;
an adenosine A2a receptor agonist;
an adenosine A2b receptor antagonist;
a urokinase inhibitor;
a dopamine receptor agonist (e.g. ropinirole), particularly a dopamine D2 receptor agonist (e.g. bromocriptine);
a modulator of the N FKB pathway, such as an IKK inhibitor;
a further modulator of a cytokine signalling pathway such as an inhibitor of JAK kinase, syk kinase, p38 kinase, SPHK-1 kinase, Rho kinase, EGF-R or MK-2;
a mucolytic, mucokinetic or anti-tussive agent
an antibiotic;
an antiviral agent;
a vaccine;
a chemokine;
an epithelial sodium channel (ENaC) blocker or Epithelial sodium channel (ENaC) inhibitor; a nucleotide receptor agonist, such as a P2Y2 agonist;
a thromboxane inhibitor;
niacin;
a 5-lipoxygenase (5-LO) inhibitor, e.g. Zileuton;
an adhesion factor, such as VLAM, ICAM or ELAM;
a CRTH2 receptor (DP2) antagonist;
a prostaglandin D2 receptor (DP^ antagonist;
a haematopoietic prostaglandin D2 synthase (HPGDS) inhibitor;
interferon-β; a soluble human TNF receptor, e.g. Etanercept;
a HDAC inhibitor;
a phosphoinositotide 3-kinase gamma (ΡΙ3Κγ) inhibitor;
a phosphoinositide 3-kinase delta (ΡΙ3Κδ) inhibitor;
a CXCR-1 or a CXCR-2 receptor antagonist;
an IRAK-4 inhibitor; and
a TLR-4 or TLR-9 inhibitor; including the pharmaceutically acceptable salts of the specifically named compounds and the pharmaceutically acceptable solvates of said specifically named compounds and salts.
Besides being useful for human treatment, compounds of formula (I) are also useful for veterinary treatment of companion animals, exotic animals and farm animals.
When used in the present application, the following abbreviations have the meanings set out below:
AcOH is acetic acid;
APCI (in relation to mass spectrometry) is atmospheric pressure chemical ionization;
BOP is (benzotriazol-1 -yloxy)tris(dimethylamino)phosphonium hexafluorophosphate;
Calc is calculated;
CDCI3 is deuterochloroform;
C02Et is ethyl carboxylate;
DCC is N,N'-dicyclohexylcarbodiimide;
DCM is dichloromethane;
DEA is diethylamine;
DIAD is diisopropyl azodicarboxylate;
DIEA is N,N-diisopropylethylamine;
DIPEA is N,N-diisopropylethylamine;
DMA is N,N-dimethylacetamide;
DMF is dimethylformamide;
DMSO-d6 is fully deuterated dimethyl sulphoxide;
EDC/EDCI is N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride;
ES (in relation to mass spectrometry) is electrospray;
Et is ethyl;
EtOAc is ethyl acetate
Ex is Example;
h is hour(s); HATU is N,N,N',N'-tetramethyl-0-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate; HBTU is N,N,N',N'-tetramethyl-0-(1 H-benzotriazol-1-yl)uronium hexafluorophosphate; HCI is hydrochloric acid;
1 H NMR or 1H NMR is proton nuclear magnetic resonance;
HOAt is 1-hydroxy-7-azabenzotriazole;
HOBt is 1-hydroxybenzotriazole;
HPLC is high performance liquid chromatography;
H2S04 is sulphuric acid;
I PA is isopropyl alcohol;
iPr is isopropyl;
K2C03 is potassium carbonate;
KMn04 is potassium permanganate;
KOH is potassium hydroxide;
KOAc is potassium acetate;
LCMS is liquid chromatography mass spectrometry;
LRMS is low resolution mass spectrometry;
NMM is 4-methylmorpholine;
Me is methyl;
MeCN is acetonitrile;
MeOD-d4 is fully deuterated methanol;
MgS04 is magnesium sulphate;
2-MeTHF is 2-methyltetrahydrofuran;
min is minute(s);
MS is mass spectroscopy;
NaCI is sodium chloride;
NaH is sodium hydride;
NBS is N-bromosuccinimide;
NIS is N-iodosuccinimide;
MP is N-methylpyrrolidine;
Obs is observed;
Pd(OAc)2 is palladium(ll)acetate;
RT is retention time;
SEM-CI is (2-chloromethoxy-ethyl)-trimethyl-silane;
SPhos is 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl;
STAB is sodium (tri-acetoxy) borohydride;
TBTU is 0-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate;
TEA is triethylamine; TFA is trifluoroacetic acid;
THF is tetrahydrofuran;
tBME is 2-mMethoxy-2-methyl-propane;
p-TsOH is para-toluene sulfonic acid.
Unless otherwise defined herein, scientific and technical terms used in connection with the present invention have the meanings that are commonly understood by those of ordinary skill in the art.
The phrase "therapeutically effective" is intended to qualify the amount of compound or pharmaceutical composition, or the combined amount of active ingredients in the case of combination therapy. This amount or combined amount will achieve the goal of treating the relevant condition.
The term "treatment," as used herein to describe the present invention and unless otherwise qualified, means administration of the compound, pharmaceutical composition or combination to effect preventative, palliative, supportive, restorative or curative treatment. The term treatment encompasses any objective or subjective improvement in a subject with respect to a relevant condition or disease.
The term "preventive treatment," as used herein to describe the present invention, means that the compound, pharmaceutical composition or combination is administered to a subject to inhibit or stop the relevant condition from occurring in a subject, particularly in a subject or member of a population that is significantly predisposed to the relevant condition.
The term "palliative treatment," as used herein to describe the present invention, means that the compound, pharmaceutical composition or combination is administered to a subject to remedy signs and/or symptoms of a condition, without necessarily modifying the progression of, or underlying etiology of, the relevant condition.
The term "supportive treatment," as used herein to describe the present invention, means that the compound, pharmaceutical composition or combination is administered to a subject as a part of a regimen of therapy, but that such therapy is not limited to administration of the compound, pharmaceutical composition or combination. Unless otherwise expressly stated, supportive treatment may embrace preventive, palliative, restorative or curative treatment, particularly when the compounds or pharmaceutical compositions are combined with another component of supportive therapy. The term "restorative treatment," as used herein to describe the present invention, means that the compound, pharmaceutical composition or combination is administered to a subject to modify the underlying progression or etiology of a condition. Non-limiting examples include an increase in forced expiratory volume in one second (FEV 1 ) for lung disorders, decreased rate of a decline in lung function over time, inhibition of progressive nerve destruction, reduction of biomarkers associated and correlated with diseases or disorders, a reduction in relapses, improvement in quality of life, reduced time spent in hospital during an acute exacerbation event and the like.
The term "curative treatment," as used herein to describe the present invention, means that compound, pharmaceutical composition or combination is administered to a subject for the purpose of bringing the disease or disorder into complete remission, or that the disease or disorder is undetectable after such treatment.
The term "selective", when used to describe a functionally-defined receptor ligand or enzyme inhibitor means selective for the defined receptor or enzyme subtype as compared with other receptor or enzyme subtypes in the same family. For instance, a selective PDE5 inhibitor is a compound which inhibits the PDE5 enzyme subtype more potently than any other PDE enzyme subtype. Such selectivity is preferably at least 2 fold (as measured using conventional binding assays), more preferably at least 10 fold, most preferably at least 100 fold.
The term "alkyl", alone or in combination, means an acyclic, saturated hydrocarbon group of the formula CnH2n+i which may be linear or branched. Examples of such groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl and hexyl. Unless otherwise specified, an alkyl group comprises from 1 to 6 carbon atoms.
The carbon atom content of alkyl and various other hydrocarbon-containing moieties is indicated by a prefix designating a lower and upper number of carbon atoms in the moiety, that is, the prefix Cj-Cj indicates a moiety of the integer "i" to the integer "j" carbon atoms, inclusive. Thus, for example, C-|-C6 alkyl refers to alkyl of one to six carbon atoms, inclusive.
The term "hydroxy," as used herein, means an OH radical.
Het3 is a saturated or partially saturated (i.e. non aromatic) heterocycle and may be attached via a ring nitrogen atom (when the heterocycle is attached to a carbon atom) or a ring carbon atom (in all cases). Equally, when substituted, the substituent may be located on a ring nitrogen atom (if the substituent is joined through a carbon atom) or a ring carbon atom (in all cases). Specific examples include oxiranyl, aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, 1 ,4-dioxanyl, morpholinyl, piperazinyl, azepanyl, oxepanyl, oxazepanyl and diazepinyl.
Het3 may be fully saturated or partially unsaturated, i.e. may have one or more degrees of unsaturation but may not be fully aromatic.
Het1 is an aromatic heterocycle and may be attached via a ring carbon atom (in all cases) or a ring nitrogen atom with an appropriate valency (when the heterocycle is attached to a carbon atom). Equally, when substituted, the substituent may be located on a ring carbon atom (in all cases) or a ring nitrogen atom with an appropriate valency (if the substituent is joined through a carbon atom). Specific examples include thienyl, furanyl, pyrrolyl, pyrazolyl, imidazoyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl.
Het2 is an aromatic heterocycle and may be attached via a ring carbon atom (in all cases) or a ring nitrogen atom with an appropriate valency (when the heterocycle is attached to a carbon atom). Equally, when substituted, the substituent may be located on a ring carbon atom (in all cases) or a ring nitrogen atom with an appropriate valency (if the substituent is joined through a carbon atom). Het2 is aromatic and is therefore necessarily a fused bicycle. Specific examples include imidazo[2,1-b][1 ,3]thiazolyl, benzofuranyl, benzothienyl, indolyl, benzimidazolyl, indazolyl, benzotriazolyl, pyrrolo[2,3-b]pyridyl, pyrrolo[2,3-c]pyridyl, pyrrolo[3,2-c]pyridyl, pyrrolo[3,2-b]pyridyl, imidazo[4,5-b]pyridyl, imidazo[4,5-c]pyridyl, pyrazolo[4,3-d]pyridyl, pyrazolo[4,3-c]pyridyl, pyrazolo[3,4-c]pyridyl, pyrazolo[3,4-b]pyridyl, isoindolyl, indazolyl, purinyl, indolizinyl, imidazo[1 ,2-a]pyridyl, imidazo[1 ,5-a]pyridyl, pyrazolo[1 ,5-a]pyridyl, pyrrolo[1 ,2- bjpyridazinyl, imidazo[1 ,2-c]pyrimidinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, 1 ,6-naphthyridinyl, 1 ,7-naphthyridinyl, 1 ,8-naphthyridinyl, 1 ,5- naphthyridinyl, 2,6-naphthyridinyl, 2,7-naphthyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[4,3- djpyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, pyrido[2,3-d]pyrazinyl, pyrido[3,4-b]pyrazinyl, pyrimido[5,4-d]pyrimidinyl, pyrazino[2,3-b]pyrazinyl and pyrimido[4,5- djpyrimidine.
The term "cycloalkyl" means a means a monocyclic, saturated hydrocarbon group of the formula CnH2n-i - Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. Unless otherwise specified, a cycloalkyl group comprises from 3 to 8 carbon atoms. The term "oxo" means a doubly bonded oxygen.
The term "alkoxy" means a radical comprising an alkyl radical that is bonded to an oxygen atom, such as a methoxy radical. Examples of such radicals include methoxy, ethoxy, propoxy, isopropoxy, butoxy and tert-butoxy.
The term "halo" means, fluoro, chloro, bromo or iodo.
As used herein, the terms "co-administration", "co-administered" and "in combination with", referring to a combination of a compound of formula (I) and one or more other therapeutic agents, includes the following:
• simultaneous administration of such a combination of a compound of formula (I) and a further therapeutic agent to a patient in need of treatment, when such components are formulated together into a single dosage form which releases said components at substantially the same time to said patient,
• substantially simultaneous administration of such a combination of a compound of formula(l) and a further therapeutic agent to a patient in need of treatment, when such components are formulated apart from each other into separate dosage forms which are taken at substantially the same time by said patient, whereupon said components are released at substantially the same time to said patient,
• sequential administration of such a combination of a compound of formula (I) and a further therapeutic agent to a patient in need of treatment, when such components are formulated apart from each other into separate dosage forms which are taken at consecutive times by said patient with a significant time interval between each administration, whereupon said components are released at substantially different times to said patient; and
• sequential administration of such a combination of a compound of formula (I) and a further therapeutic agent to a patient in need of treatment, when such components are formulated together into a single dosage form which releases said components in a controlled manner.
The term 'excipient' is used herein to describe any ingredient other than a compound of formula (I). The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form. The term "excipient" encompasses diluent, carrier or adjuvant. One way of carrying out the invention is to administer a compound of formula (I) in the form of a prodrug. Thus, certain derivatives of a compound of formula (I) which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into a compound of formula (I) having the desired activity, for example by hydrolytic cleavage, particularly hydrolytic cleavage promoted by an esterase or peptidase enzyme. Such derivatives are referred to as 'prodrugs'. Further information on the use of prodrugs may be found in 'Prodrugs as Novel Delivery Systems', Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella) and 'Bioreversible Carriers in Drug Design', Pergamon Press, 1987 (Ed. E. B. Roche, American Pharmaceutical Association). Reference can also be made to Nature Reviews/Drug Discovery, 2008, 7, 355 and Current Opinion in Drug Discovery and Development, 2007, 10, 550.
Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as 'pro-moieties' as described, for example, in 'Design of Prodrugs' by H. Bundgaard (Elsevier, 1985).
Thus, a prodrug in accordance with the invention is (a) an ester or amide derivative of a carboxylic acid in a compound of formula (I); (b) an ester, carbonate, carbamate, phosphate or ether derivative of a hydroxyl group in a compound of formula (I); (c) an amide, imine, carbamate or amine derivative of an amino group in a compound form formula (I); (d) a thioester, thiocarbonate, thiocarbamate or sulphide derivatives of a thiol group in a compound of formula (I); or (e) an oxime or imine derivative of a carbonyl group in a compound of formula (I).
Some specific examples of prodrugs in accordance with the invention include:
(i) where the compound of formula (I) contains a carboxylic acid functionality
(-COOH), an ester thereof, such as a compound wherein the hydrogen of the carboxylic acid functionality of the compound of formula (I) is replaced by C^Ce alkyl (e.g. ethyl) or (Ci-C8 alkyl)C(=0)OCH2- (e.g. lBuC(=0)OCH2-);
(ii) where the compound of formula (I) contains an alcohol functionality (-OH), an ester thereof, such as a compound wherein the hydrogen of the alcohol functionality of the compound of formula (I) is replaced by -CO(C-i-C8 alkyl) (e.g. methylcarbonyl) or the alcohol is esterified with an amino acid; (iii) where the compound of formula (I) contains an alcohol functionality (-OH), an ether thereof, such as a compound wherein the hydrogen of the alcohol functionality of the compound of formula (I) is replaced by (d-C8 alkyl)C(=0)OCH2- or -CH2OP(=0)(OH)2;
(iv) where the compound of formula (I) contains an alcohol functionality (-OH), a phosphate thereof, such as a compound wherein the hydrogen of the alcohol functionality of the compound of formula (I) is replaced by -P(=0)(OH)2 or -P(=0)(ONa)2 or -P(=0)(0")2Ca2+;
(v) where the compound of formula (I) contains a primary or secondary amino functionality (-NH2 or -NHR where R≠ H), an amide thereof, for example, a compound wherein, as the case may be, one or both hydrogens of the amino functionality of the compound of formula (I) is/are replaced by (C1-C10)alkanoyl, -COCH2NH2 or the amino group is derivatised with an amino acid;
(vi) where the compound of formula (I) contains a primary or secondary amino functionality (-NH2 or -NHR where R≠ H), an amine thereof, for example, a compound wherein, as the case may be, one or both hydrogens of the amino functionality of the compound of formula (I) is/are replaced by -CH2OP(=0)(OH)2.
Certain compounds of formula (I) may themselves act as prodrugs of other compounds of formula (I). It is also possible for two compounds of formula (I) to be joined together in the form of a prodrug. In certain circumstances, a prodrug of a compound of formula (I) may be created by internally linking two functional groups in a compound of formula (I), for instance by forming a lactone.
References below to compounds of formula (I) are taken to include the compounds themselves and prodrugs thereof. The invention includes such compounds of formula (I) as well as pharmaceutically acceptable salts of such compounds and pharmaceutically acceptable solvates of said compounds and salts.
Pharmaceutically acceptable salts of the compounds of formula (I) include acid addition and base salts.
Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate, naphatlene-1 ,5- disulfonic acid and xinofoate salts.
Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts. For a review on suitable salts, see Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth (Wiley-VCH, 2002).
Pharmaceutically acceptable salts of compounds of formula (I) may be prepared by one or more of three methods:
(i) by reacting the compound of formula (I) with the desired acid or base;
(ii) by removing an acid- or base-labile protecting group from a suitable precursor of the compound of formula (I) or by ring-opening a suitable cyclic precursor, for example, a lactone or lactam, using the desired acid or base; or
(iii) by converting one salt of the compound of formula (I) to another by reaction with an appropriate acid or base or by means of a suitable ion exchange column.
All three reactions are typically carried out in solution. The resulting salt may precipitate out and be collected by filtration or may be recovered by evaporation of the solvent. The degree of ionisation in the resulting salt may vary from completely ionised to almost non-ionised.
The compounds of formula (I), and pharmaceutically acceptable salts thereof, may exist in unsolvated and solvated forms. The term 'solvate' is used herein to describe a molecular complex comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' may be employed when said solvent is water.
A currently accepted classification system for organic hydrates is one that defines isolated site, channel, or metal-ion coordinated hydrates - see Polymorphism in Pharmaceutical Solids by K. R. Morris (Ed. H. G. Brittain, Marcel Dekker, 1995). Isolated site hydrates are ones in which the water molecules are isolated from direct contact with each other by intervening organic molecules. In channel hydrates, the water molecules lie in lattice channels where they are next to other water molecules. In metal-ion coordinated hydrates, the water molecules are bonded to the metal ion.
When the solvent or water is tightly bound, the complex will have a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvates and hygroscopic compounds, the water/solvent content will be dependent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm.
Also included within the scope of the invention are multi-component complexes (other than salts and solvates) wherein the drug and at least one other component are present in stoichiometric or non-stoichiometric amounts. Complexes of this type include clathrates (drug-host inclusion complexes) and co-crystals. The latter are typically defined as crystalline complexes of neutral molecular constituents which are bound together through non-covalent interactions, but could also be a complex of a neutral molecule with a salt. Co-crystals may be prepared by melt crystallisation, by recrystallisation from solvents, or by physically grinding the components together - see Chem Commun, 17, 1889-1896, by O. Almarsson and M. J. Zaworotko (2004). For a general review of multi-component complexes, see J Pharm Sci, 64 (8), 1269-1288, by Haleblian (August 1975).
The compounds of the invention may exist in a continuum of solid states ranging from fully amorphous to fully crystalline. The term 'amorphous' refers to a state in which the material lacks long range order at the molecular level and, depending upon temperature, may exhibit the physical properties of a solid or a liquid. Typically such materials do not give distinctive X-ray diffraction patterns and, while exhibiting the properties of a solid, are more formally described as a liquid. Upon heating, a change from solid to liquid properties occurs which is characterised by a change of state, typically second order ('glass transition'). The term 'crystalline' refers to a solid phase in which the material has a regular ordered internal structure at the molecular level and gives a distinctive X-ray diffraction pattern with defined peaks. Such materials when heated sufficiently will also exhibit the properties of a liquid, but the change from solid to liquid is characterised by a phase change, typically first order ('melting point').
The compounds of formula (I) may also exist in a mesomorphic state (mesophase or liquid crystal) when subjected to suitable conditions. The mesomorphic state is intermediate between the true crystalline state and the true liquid state (either melt or solution). Mesomorphism arising as the result of a change in temperature is described as 'thermotropic' and that resulting from the addition of a second component, such as water or another solvent, is described as 'lyotropic'. Compounds that have the potential to form lyotropic mesophases are described as 'amphiphilic' and consist of molecules which possess an ionic (such as -COO"Na+, -COO"K+, or - S03 "Na+) or non-ionic (such as -N"N+(CH3)3) polar head group. For more information, see Crystals and the Polarizing Microscope by N. H. Hartshorne and A. Stuart, 4th Edition (Edward Arnold, 1970).
Hereinafter all references to compounds of formula (I) include references to pharmaceutically acceptable salts, solvates, multi-component complexes and liquid crystals thereof and to solvates, multi-component complexes and liquid crystals of pharmaceutically acceptable salts thereof.
The compounds of formula (I) may exhibit polymorphism and/or one or more kinds of isomerism (e.g. optical, geometric or tautomeric isomerism). The compounds of formula (I) may also be isotopically labelled. Such variation is implicit to the compounds of formula (I) defined as they are by reference to their structural features and therefore within the scope of the invention.
Compounds of formula (I) containing one or more asymmetric carbon atoms can exist as two or more stereoisomers. Where a compound of formula (I) contains an alkenyl or alkenylene group, geometric cis/trans (or Z/E) isomers are possible. Where structural isomers are interconvertible via a low energy barrier, tautomeric isomerism ('tautomerism') can occur. This can take the form of proton tautomerism in compounds of formula (I) containing, for example, an imino, keto, or oxime group, or so-called valence tautomerism in compounds which contain an aromatic moiety. It follows that a single compound may exhibit more than one type of isomerism.
The pharmaceutically acceptable salts of compounds of formula (I) may also contain a counterion which is optically active (e.g. d-lactate or l-lysine) or racemic (e.g. dl-tartrate or dl- arginine).
Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation.
Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of formula (I) contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartaric acid. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person. Chiral compounds of formula (I) (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of isopropanol, typically from 2% to 20%, and from 0 to 5% by volume of an alkylamine, typically 0.1 % diethylamine. Concentration of the eluate affords the enriched mixture. Chiral chromatography using sub-and supercritical fluids may be employed. Methods for chiral chromatography useful in some embodiments of the present invention are known in the art (see, for example, Smith, Roger M., Loughborough University, Loughborough, UK; Chromatographic Science Series (1998), 75 (Supercritical Fluid Chromatography with Packed Columns), pp. 223-249 and references cited therein). In some relevant examples herein, columns were obtained from Chiral Technologies, Inc, West Chester, Pennsylvania, USA, a subsidiary of Daicel® Chemical Industries, Ltd., Tokyo, Japan.
When any racemate crystallises, crystals of two different types are possible. The first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts. The second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer. While both of the crystal forms present in a racemic mixture have identical physical properties, they may have different physical properties compared to the true racemate. Racemic mixtures may be separated by conventional techniques known to those skilled in the art - see, for example, Stereochemistry of Organic Compounds by E. L. Eliel and S. H. Wilen (Wiley, 1994).
The present invention includes all pharmaceutically acceptable isotopically-labelled compounds of formula (I) wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature. Isotopically-labelled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labelled reagent in place of the non-labelled reagent previously employed. In particular, hydrogen atoms may be replaced by deuterium atoms since such deuterated compounds are sometimes more resistant to metabolism. Also included within the scope of the invention are active metabolites of compounds of formula (I), that is, compounds formed in vivo upon administration of the drug, often by oxidatation or dealkylation. Some examples of metabolites in accordance with the invention include
(i) where the compound of formula (I) contains a methyl group, an hydroxymethyl derivative thereof (-CH3 -> -CH2OH):
(ii) where the compound of formula (I) contains an alkoxy group, an hydroxy derivative thereof (-OR -> -OH);
(iii) where the compound of formula (I) contains a tertiary amino group, a secondary amino derivative thereof (-NRR -> -NHR or -NHR );
(iv) where the compound of formula (I) contains a secondary amino group, a primary derivative thereof (-NHR -> -NH2);
(v) where the compound of formula (I) contains a phenyl moiety, a phenol derivative thereof (-Ph -> -PhOH); and
(vi) where the compound of formula (I) contains an amide group, a carboxylic acid derivative thereof (-CONH2 -> COOH).
For administration to human patients, the total daily dose of a compound of formula (I) is typically in the range of 0.01 mg to 500mg depending, of course, on the mode of administration. In another embodiment of the present invention, the total daily dose of a compound of formula (I) is typically in the range of 0.1 mg to 300mg. In yet another embodiment of the present invention, the total daily dose of a compound of formula (I) is typically in the range of 1 mg to 30mg. The total daily dose may be administered in single or divided doses and may, at the physician's discretion, fall outside of the typical range given herein. These dosages are based on an average human subject having a weight of about 65kg to 70kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.
In the case of dry powder inhalers and aerosols, the dosage unit is determined by means of a prefilled capsule, blister or pocket or by a system that utilises a gravimetrically fed dosing chamber. Units in accordance with the invention are typically arranged to administer a metered dose or "puff" containing from 1 to 5000 μg of drug. The overall daily dose will typically be in the range ^g to 20mg which may be administered in a single dose or, more usually, as divided doses throughout the day.
A compound of formula (I) can be administered per se, or in the form of a pharmaceutical composition, which, as active constituent contains an efficacious dose of at least one compound of the invention, in addition to customary pharmaceutically innocuous excipients and/or additives.
Pharmaceutical compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company, 1995).
Compounds of formula (I) may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth. Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films, ovules, sprays and liquid formulations.
Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
Compounds of formula (I) may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 1 1 (6), 981-986, by Liang and Chen (2001 ).
For tablet dosage forms, depending on dose, the drug may make up from 1 weight % to 80 weight % of the dosage form, more typically from 5 weight % to 60 weight % of the dosage form. In addition to the drug, tablets generally contain a disintegrant. Examples of disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate. Generally, the disintegrant will comprise from 1 weight % to 25 weight %. In one embodiment of the present invention, the disintegrant will comprise from 5 weight % to 20 weight % of the dosage form. Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate. Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc. When present, surface active agents may comprise from 0.2 weight % to 5 weight % of the tablet, and glidants may comprise from 0.2 weight % to 1 weight % of the tablet. Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate. Lubricants generally comprise from 0.25 weight % to 10 weight %. In one embodiment of the present invention, lubricants comprise from 0.5 weight % to 3 weight % of the tablet. Other possible ingredients include anti-oxidants, colourants, flavouring agents, preservatives and taste-masking agents.
Exemplary tablets contain up to about 80% drug, from about 10 weight % to about 90 weight % binder, from about 0 weight % to about 85 weight % diluent, from about 2 weight % to about 10 weight % disintegrant, and from about 0.25 weight % to about 10 weight % lubricant.
Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tabletting. The final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated. Formulations of tablets are discussed in Pharmaceutical Dosage Forms: Tablets, Vol. 1 , by H. Lieberman and L. Lachman (Marcel Dekker, New York, 1980).
Consumable oral films for human or veterinary use are typically pliable water-soluble or water- swellable thin film dosage forms which may be rapidly dissolving or mucoadhesive and typically comprise a compound of formula (I), a film-forming polymer, a binder, a solvent, a humectant, a plasticiser, a stabiliser or emulsifier, a viscosity-modifying agent and a solvent. Some components of the formulation may perform more than one function. The film-forming polymer may be selected from natural polysaccharides, proteins, or synthetic hydrocolloids and is typically present in the range 0.01 to 99 weight %, more typically in the range 30 to 80 weight %. Other possible ingredients include anti-oxidants, colorants, flavourings and flavour enhancers, preservatives, salivary stimulating agents, cooling agents, co-solvents (including oils), emollients, bulking agents, anti-foaming agents, surfactants and taste-masking agents. Films in accordance with the invention are typically prepared by evaporative drying of thin aqueous films coated onto a peelable backing support or paper. This may be done in a drying oven or tunnel, typically a combined coater dryer, or by freeze-drying or vacuuming.
Solid formulations for oral administration may be formulated to be immediate and/or modified release. Modified release includes delayed, sustained, pulsed, controlled, targeted and programmed release. Suitable modified release formulations for the purposes of the invention are described in US Patent No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in Pharmaceutical Technology On-line, 25(2), 1-14, by Verma et al (2001 ). The use of chewing gum to achieve controlled release is described in WO-A-00/35298.
Compounds of formula (I) may also be administered directly into the blood stream, into muscle, or into an internal organ. Such parenteral administration includes intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous administration. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
Compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally.
The compounds of formula (I) can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler, as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1 ,1 ,1 ,2-tetrafluoroethane or 1 ,1 ,1 ,2,3,3,3-heptafluoropropane, or as nasal drops. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin. Delivery by inhalation is the preferred route of administration for the compounds of the present invention.
The pressurised container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the compound of formula (I) comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the compound, a propellant as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
Capsules (made, for example, from gelatin or hydroxypropylmethylcellulose), blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as l-leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate, preferably the latter. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
A suitable solution formulation for use in an atomiser using electrohydrodynamics to produce a fine mist may contain from 1 μg to 20mg of the compound of the invention per actuation and the actuation volume may vary from 1 μΙ to 10ΟμΙ. A typical formulation may comprise a compound of formula (I), propylene glycol, sterile water, ethanol and sodium chloride. Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.
Suitable flavours, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for intranasal administration. Formulations for intranasal administration may be formulated to be immediate and/or modified release using, for example, PGLA. Modified release includes delayed, sustained, pulsed, controlled, targeted and programmed release.
Compounds of formula (I) may also be administered directly to the eye or ear, typically in the form of drops of a micronised suspension or solution in isotonic, pH-adjusted, sterile saline.
Compounds of formula (I) may be combined with soluble macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste, bioavailability and/or stability when using any of the aforementioned modes of administration. Drug-cyclodextrin complexes, for example, are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used. As an alternative to direct complexation with the drug, the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubiliser. Most commonly used for these purposes are alpha-, beta- and gamma- cyclodextrins, examples of which may be found in international patent publications WO-A- 91/1 1 172, WO-A-94/02518 and WO-A-98/55148.
Inasmuch as it may desirable to administer a combination of active compounds, for example, for the purpose of treating a particular disease or condition, it is within the scope of the present invention that two or more pharmaceutical compositions, at least one of which contains a compound of formula (I), may conveniently be combined in the form of a kit suitable for coadministration of the compositions. Thus, a kit of the invention comprises two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I), and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like. Such a kit is particularly suitable for administering different dosage forms, for example, oral and parenteral, for administering separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit typically comprises directions for administration and may be provided with a so-called memory aid.
All the compounds of formula (I) can be made by the specific and general experimental procedures described below in combination with the common general knowledge of one skilled in the art (see, for example, Comprehensive Organic Chemistry, Ed. Barton and Ollis, Elsevier; Comprehensive Organic Transformations: A Guide to Functional Group Preparations, Larock, John Wiley and Sons). In the general methods that follow, R1, R2, R3, X and n have the meanings given in embodiment E1 described above unless otherwise stated.
Compounds of formula (I) can be made by reacting a compound of formula:
Figure imgf000034_0001
(II)
with a compound of formula: R3-X-LG1
(III)
in which LG1 is a suitable leaving group such as a halogen atom. The reaction will typically be carried out in a suitable inert solvent in the presence of a base such as diisopropylethylamine. When X is -S02-, for example, a sulphonyl chloride (LG1=CI) may be used. In a typical procedure, a solution of the compound of formula (II) in DMF is treated with one equivalent of the sulphonyl chloride and 1 equivalent of diisopropylethylamine and stirred at room temperature. When X is -CH2-, an alkyl bromide (LG1=Br) may be used. In a typical procedure, a solution of the compound of formula (II) in DMF is treated with 1 .1 equivalents of the alkyl bromide and 1 .1 equivalents of diisopropylethylamine and stirred at 50°C. When X is -CO-, an acid chloride (LG1=CI) may be used. In a typical procedure, a solution of the compound of formula (II) in DMF is treated with 1.1 equivalents of the acid chloride and 1 .1 equivalents of diisopropylethylamine and stirred at room temperature.
Where X is a carbonyl group, the leaving group LG1 may be created in situ from the corresponding carboxylic acid of formula
R3-C02H
(IV)
by using a condensation reagent such as HATU. In a typical procedure, a solution of the compound of formula (il) in DMF is treated with 1.1 equivalents of HATU and 1.1 equivalents of diisopropylethylamine and stirred at room temperature for 30 minutes. An equivalent of the acid of formula (IV) is then added. For a general review on amide bond formation, see Chem. Soc. Rev., 2009, 38(2), 606-631
Where X is -CH2-, an aldehyde of formula:
R3-CHO
(V)
may alternatively be condensed with a compound of formula (II) under reducing conditions in order to provide the desired compound of formula (I). In a typical procedure, a solution of the compound of formula (II) in DMF is treated with the 1 .5 equivalents of the aldehyde of formula (V), 2 equivalents of diisopropylethylamine and 1 .5 equivalents of acetic acid and stirred at room temperature for one hour. Sodium triacetoxyborohydride (1.5 equivalents) is then added and stirring continued at room temperature.
Compounds of formula (II) can be assembled by successive aryl-heteroaryl and heteroaryl- heteroaryl organometallic coupling reactions. One example of of a possible reaction sequence is shown in Scheme 1 (PG = protecting group, LG = leaving group, M = metal species; where multiple protecting groups are shown, they may be the same or different). Free NH groups will generally need to be protected during these reactions. Suitable protecting groups, their introduction and their removal are all part of the common general knowledge of the skilled person - see, for instance, 'Protective Groups in Organic Chemistry' by Wuts and Greene (Wiley-Blackwell).
Suitable reaction conditions for the various steps necessary to prepare and react together the compounds in Scheme 1 may be found in the specific Preparations listed below. For a general review on organometallic cross-couping chemistry, see 'Handbook of Organopalladium Chemistry for Organic Synthesis' (Volume 1 ) editied by Ei-ichi Negishi (John Wiley & Sons).
Scheme 1
Figure imgf000036_0001
Compounds of formula (I) can also be prepared by treating a compound of formula:
Figure imgf000037_0001
with an acid (e.g. concentrated hydrochloric acid). PG1 is an acid-labile protecting group and C=Y is a carbonyl group or an acid-labile, protected form of a carbonyl group (e.g. a ketal). The reaction will usually be performed in a suitable inert solvent with heating.
Compounds of formula (X) can be made from precursors of formula:
Figure imgf000037_0002
Figure imgf000037_0003
Compounds of formula (XI) can be assembled using the aryl-heteroaryl bond forming reactions discussed above. The skilled person will appreciate that many compounds of formula (I) may be interconverted by functional group manipulation.
The starting materials necessary for carrying out the methods described above are in many cases commercially available and may otherwise be described in the literature or in the Preparations below or may be made using analgous procedures to those described in the liternature or in the Preparations below.
Supplementing the general methods presented above, the following experimental details illustrate specifically how certain compounds of formula (I) may be prepared. All Examples are compounds of formula (I). Preparations are intermediates useful in the synthesis of compounds of formula (I).
The following HPLC methods have been used in the characterization of the Examples below:
Method A
HPLC
Analytical (QC) Preparative
conditions
Gemini-NX 3μηι C18
Gemini-NX 5μηι C18
Column 1 10A
21.2 x 100mm
Temperature Ambient Ambient
UV 225nm - ELSD -
Detection UV 225nm - ELSD - MS
MS
Injection volume 5μΙ- 1000μΙ_
Flow rate 1.5ml_/min 18 mL/min
A: H20 + 0.1 %
A: H20 + 0.1 % DEA
ammonium acetate
Mobile phase
B: MeCN + 0.1 %
B: MeCN + 0.1 % DEA
ammonium acetate
Time
Gradient %B Time (min) %B
(min)
0 5 0-1.0 5
0-3.0 5-95 1.0-7.0 5-98
3.0-4.0 95 7.0-9.0 98 4.0-4.1 95-5 9.0-9.10 98-5
4.1 -5.0 5 9.10-10 5
Method B
Figure imgf000039_0001
Method C
HPLC
Preparative
conditions
Phenomenex Luna C18
Column 5μην10θΑ
21 .2 x 150mm
Temperature Ambient UV 254nm - ELSD -
Detection
MS
Injection volume "Ι ΟΟΟμΙ.
Flow rate 18 mL/min
A: H20 + 0.05% formic acid
Mobile phase
B: MeCN + 0.05% formic acid
Gradient Time (min) %B
0-2.5 5
2.5-17.5 5-95
17.5-22.5 95
22.5-22.6 95-5
22.6-23.0 5 d D
HPLC
Preparative
conditions
Zorbax SB C18 5μη>
Column 100A
21 .2 x 150mm
Temperature Ambient
UV 254nm - ELSD -
Detection
MS
Injection volume 1000μΙ_
Flow rate 20 mL/min
A: H20 + 0.05% NH40Ac
Mobile phase
B: MeCN + 0.05% NH40Ac
Gradient Time (min) %B
0-2.5 5
2.5-17.5 5-95
17.5-22.5 95
22.5-22.6 95-5 22.6-23.0
Method E
Figure imgf000041_0001
Method F
HPLC
Preparative
conditions
Xterra RP18
Column
19-250mm
Temperature Ambient
UV 254nm - ELSD -
Detection
MS
Injection volume 1000μί
Flow rate 16 mL/min A: H20 + 0.05%
NH40Ac
Mobile phase
B: MeCN + 0.05%
NH40Ac
Gradient Time (min) %B
0-2.5 5
2.5-17.5 5-95
17.5-22.5 95
22.5-22.6 95-5
22.6-25.0 5
Method G
Figure imgf000042_0001
Example 1
{2-[6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahydro-imidazo [4,5-clpyridin-5-yl)-(4-fluoro-phenyl)-methanone To a solution of 5-ethyl-2-fluoro-4-[3-(4,5,6 J-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H- indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, δθμηιοΐ) in DMF (1 ml_), was added HATU (32mg, 84μη"ΐοΙ), and DIPEA (56μΙ_, 320μη"ΐοΙ). The reaction mixture was stirred at room temperature for 30 minutes. 4-Fluoro-benzoic acid (1 1 .2mg, δθμηηοΐ) was added to the reaction mixture and stirring was continued for 18 hours. Saturated aqueous sodium hydrogen carbonate solution (5ml_) was added to the reaction mixture. The resulting solid was collected by filtration, washing with further saturated aqueous sodium hydrogen carbonate solution. The crude material was purified by HPLC Method B to afford 7.7mg of the title compound.
LCMS (Method A): RT 2.52 min (100% area), ES m/z 500.182 [M+H]+.
Example 2
{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahvdro-imidazo
r4,5-clpyridin-5-yl)-isothiazol-3-yl-methanone
The title compound was prepared from 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, δθμηηοΐ) and isothiazole-3-carboxylic acid (1 1 mg, δθμηηοΐ) using the same method as described in Example 1 . The crude material was purified by HPLC Method A to afford 7.7mg of the title compound. LCMS (Method A) RT 2.39 min (100% area), ES m/z 469.143 [M+H]+.
Example 3
{2-[6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahydro-imidazo
[4,5-clpyridin-5-yl)-isothiazol-3-yl-methanone
To a solution of N-(1 -benzyl-4,4-diethoxy-piperidin-3-yl)-6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1- (tetrahydro-pyran-2-yl)-1 H-indazole-3-carboxamidine (Preparation 9, 6.06g, 9.41 mmol) in ethanol (34mL) was added concentrated hydrochloric acid (12M, 15.8mL, 189mmol). The reaction mixture was heated at 65°C for 18 hours. The reaction mixture was concentrated in vacuo and recharged with fresh ethanol (34mL) and concentrated hydrochloric acid (12M, 15.8mL, 189mmol). The reaction mixture was heated at 65°C for a further 4 hours. Water (20mL) was added to the reaction mixture at 65°C and then the reaction was allowed to cool slowly to room temperature. The solvents were removed in vacuo and the residue was partitioned between 2-MeTHF (200mL) and saturated sodium hydrogen carbonate aqueous solution (100mL). The organic layer was washed with further saturated sodium hydrogen carbonate aqueous solution (100mL). The combined aqueous layers were re-extracted with 2- MeTHF (250mL). The combined organic layers were dried over MgS04 and concentrated in vacuo to yield a brown foam. The crude material was dissolved in MeCN (150mL) and ethanol (30mL) and heated at 50°C for 2 days. The product crystallised from this solution and was collected by filtration and dried in vacuo to give the title compound as a crystalline white solid (3.53g) in an 80% yield.
1H NMR (400 MHz, CD3OD) δ ppm 1.04 (t, 3H), 2.52 (q, 2H), 2.81 (t, 2H), 2.91 (t, 2H), 3.62 (s, 2H), 3.80 (s, 2H), 6.87 (d, 1 H), 6.92 (d, 1 H), 7.1 1 (d, 1 H), 7.26-7.43 (m, 6H), 8.22 (d, 1 H).
LCMS: m/z 468 [M+H]+, 466 [M-H]\
Example 4
{2-[6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahydro-imidazo
[4,5-clpyridin-5-yl)-(5-piperidin-1 -yl-pyrazin-2-yl)-methanone
To a solution of 5-piperidin-1 -yl-pyrazine-2-carboxylic acid (Preparation 43, 10.7g, 51 .8mmol) in DMF (200ml_) was added DIPEA (24.6ml_, 141 mmol) and HATU (21.5g, 56.5mmol) and the resulting mixture was stirred at room temperature for 10 minutes before being added dropwise to a suspension of 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H- indazol-6-yl]-phenol dihydrochloric acid salt (Preparation 1 1 , 19.5g, 47.1 mmol) in DMF (200ml_) over 30 minutes, using a further 75ml_ DMF to wash the vessel. The reaction mixture was then stirred at room temperature for 18 hours. A further portion of 5-piperidin-1-yl-pyrazine-2- carboxylic acid (1.07g, 5.18mmol) in DMF (40ml_) was treated with DIPEA (2.46ml_, 14.1 mmol) and activated with HATU (2.15g, 5.65mmol) and the resulting mixture was stirred at room temperature for 10 minutes before being added to the original reaction mixture which was then stirred for a further 4 hours at room temperature. The reaction mixture was poured onto water (1.2L) and the pH was adjusted to 7 with sodium hydroxide solution. The resulting suspension was stirred at room temperature for 30 minutes. The precipitate was collected by filtration, washed with water (400ml_) and then dried under vacuum. The crude material was dissolved in ethanol (1 13ml_) and treated with a 1 M aqueous solution of sodium hydroxide. The reaction mixture was stirred at room temperature for 18 hours. The precipitate was collected by filtration, washed with a cold solution of 1 :3 1 M sodium hydroxide:ethanol (100ml_) and dried under vacuum to give the sodium salt of the title compound, 16.14g. This material was dissolved in water (100ml_) and treated with a 10% aqueous solution of citric acid (10ml_) to adjust the pH to 4. A few drops of 1 M sodium hydroxide solution were added to bring the pH to 7. The resulting suspension was stirred at room temperature for 1 hour and the solid was collected by filtration, washed with water and then dried under vacuum to give the title compound as a white solid (13.864g) in an 89% yield.
1H NMR (400 MHz, DMSO-d6) δ ppm 0.94 (t, 3H), 1.54-1.60 (m, 2H), 1 .60-1.67 (m, 2H), 2.38 (q, 2H), 2.71-2.83 (m, 2H), 3.64-3.71 (m, 4H), 3.85-3.98 (m, 4H), 4.63-4.78 (m, 2H), 6.66 (d, 1 H), 6.73 (d, 1 H), 7.00-7.08 (m, 1 H), 7.16-7.24 (m, 1 H), 816-8.25 (m, 1 H), 8.29 (s, 1 H), 8.37 (s, 1 H).
LCMS: m/z 567 [M+H]+, 565 [M-H]" Example 5
{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6J-tetrahvdro-imidazo
r4,5-clpyridin-5-yl)-(6-phenoxy-pyridin-3-yl)-methanone
The title compound was prepared from 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, δθμηηοΐ) and 6-phenoxy-nicotinic acid (17mg, 80μmol) using the method of Example 1 . The crude material was purified by HPLC Method A to afford 3.1 mg of the title compound.
LCMS (Method A): RT 2.67 min (100% area), ES m/z 575.213 [M+H]+.
Example 6
5-Ethyl-2-fluoro-4-{3-[5-(6-morpholin-4-yl-pyridine-3-sulfonyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5- clpyridin-2-νΠ-Ι H-indazol-6-yl)-phenol
To a solution of 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H- indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, 80μmol) in DMF (1 ml_), was added 6-morpholin-4-yl-pyridine-3-sulfonyl chloride (21 mg, δθμηηοΐ) and DIPEA (56μΙ_, 320μmol). The reaction mixture was stirred at room temperature for 18 hours. Saturated aqueous sodium hydrogen carbonate solution (5ml_) was added and the resulting solid was collected by filtration and washed with further saturated aqueous sodium hydrogen carbonate solution. The crude material was purified by HPLC Method A to afford 18.7mg of the title compound.
LCMS (Method A): RT 2.58 min (100% area), ES m/z 602.206 [M-H]\ Example 7
5- Ethyl-2-fluoro-4-{3-r5-(6-phenoxy-pyridine-3-sulfonyl)-4,5,6,7-tetrahvdro-1 H-imidazo r4,5-clpyridin-2-yll-1 H-indazol-6-yl)-phenol
The title compound was prepared from 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, δθμηηοΐ) and
6- phenoxy-pyridine-3-sulfonyl chloride (22mg, δθμηηοΐ) using the method of Example 6. The crude material was purified by HPLC Method A to afford 8.4mg of the title compound.
LCMS (Method A): RT 2.82 min (100% area),ES m/z 61 1 .18 [M+H]+.
Example 8
(5-Chloro-pyridin-2-ylH2-r6-(2-ethyl-5-fluoro-4-hvdroxy-phenvn-1 H-indazol-3-yll-4, 5,7,8- tetrahydro-1 H-imidazor4,5-dlazepin-6-yl)-methanone
To a solution of 5-chloro-pyridine-2-carboxylic acid (13.2mg, δδμηηοΙ) in DMF (1 mL) was added HATU (32mg, δδμηηοΙ) and the resulting reaction mixture was stirred at room temperature for 30 minutes. 5-Ethyl-2-fluoro-4-[3-(1 ,4,5,6,7,8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1 H-indazol-6- yl]-phenol trihydrobromide salt (Preparation 32, 50mg, 80μmol) and DIPEA (56μΙ_, 320μmol) were added and stirring was continued at room temperature for 18 hours. Saturated aqueous sodium hydrogen carbonate solution (5ml_) was added to the reaction mixture. The resulting solid was collected by filtration and washed with further saturated aqueous sodium hydrogen carbonate solution. The crude material was purified by HPLC Method A to afford 20.5mg of the title compound.
LCMS (Method A): RT 2.76 min (100% area), ES m/z 531 .163 [M-H]\ Example 9
2-{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-4,5,7,8-tetrahvdro-1 H-imidazor4,5- dlazepine-6-carbonyl)-isonicotinonitrile
The title compound was prepared from 4-cyano-pyridine-2-carboxylic acid (12.5mg, 85μη"ΐοΙ) and 5-ethyl-2-fluoro-4-[3-(1 ,4,5,6,7,8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1 H-indazol-6-yl]- phenol trihydrobromide salt (Preparation 32, 50mg, δθμηηοΐ) using the method of Example 8. The crude material was purified by HPLC Method B to afford 6.5mg of the title compound.
LCMS (Method A): RT 2.66 min (100% area), ES m/z 522.198 [M+H]+.
Example 10
{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-4,5,7,8-tetrahvdro-1 H-imidazo
[4,5-dlazepin-6-yl)-(4-fluoro-phenyl)-methanone
The title compound was prepared from 4-fluoro-benzoic acid (12.5mg, δδμηηοΙ) and 5-ethyl-2- fluoro-4-[3-(1 ,4,5,6,7,8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 32, 50mg, δθμηηοΐ) using the method of Example 8. The crude material was purified by HPLC Method B to afford 14.5mg of the title compound.
LCMS (Method A): RT 2.76 min (100% area), ES m/z 514.198 [M+H]+.
Example 11
{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-4,5,7,8-tetrahvdro-1 H-imidazo
[4,5-dlazepin-6-yl)-isothiazol-3-yl-methanone
The title compound was prepared from isothiazole-3-carboxylic acid (1 1 mg, δδμηηοΙ) and 5- ethyl-2-fluoro-4-[3-(1 ,4,5,6,7,8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 32, 50mg, δθμηηοΐ) using the method of Example 8. The crude material was purified by HPLC Method B to afford 10.3mg of the title compound.
LCMS (Method A): RT 2.54 min (100%area), ES m/z 503.159 [M+H]+.
Example 12 5-Ethyl-2-fluoro-4-{3-r5-(4-fluoro-benzenesulfonyl)-4,5,6,7-tetrahvdro-1 H-imidazo r4,5-clpyridin-2-yll-1 H-indazol-6-yl)-phenol
To a solution of 5-ethyl-2-fluoro-4-[3-(4,5,6 J-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H- indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, δθμηηοΐ) in DMF (1 ml_), was added 4-fluoro-benzenesulfonyl chloride (16mg, δθμηηοΐ), and DIPEA (56μΙ_, 320μη"ΐοΙ). The reaction mixture was stirred at room temperature for 4 hours. Saturated aqueous sodium hydrogen carbonate solution (5ml_) was added to the reaction mixture. The resulting solid was collected by filtration and washed with further saturated aqueous sodium hydrogen carbonate solution. The crude material was purified by reverse phase chromatography (Method C) to afford 7mg of the title compound.
1H NMR (400 MHz, CD3OD) δ ppm 1 .02 (t, 3H), 2.52 (q, 2H), 3.78-3.81 (m, 2H), 4.37-4.29 (m, 2H), 6.88-6.96 (m, 2H), 7.15 (d, 1 H), 7.32-7.36 (m, 2H), 7.40 (s, 1 H), 7.89-7.95 (m, 2H), 8.21 (d, 1 H).
LCMS: m/z 536 [M+H]+. Example 13
{2-[6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahydro-imidazo
[4,5-clpyridin-5-yl)-[5-(2-fluoro-phenoxy)-pyrazin-2-yll-methanone
To a solution of 5-(2-fluoro-phenoxy)-pyrazine-2-carboxylic acid (Preparation 45, 19mg, δθμηηοΐ) in DMF (1 ml_) was added HBTU (32mg, δδμηηοΙ) and the resulting reaction mixture was stirred at room temperature for 30 minutes. 5-Ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, δθμηηοΐ) and DIPEA (56μΙ_, 320μη"ΐοΙ) were added and stirring was continued at room temperature for 16 hours. Saturated aqueous sodium hydrogen carbonate solution (5ml_) was added to the reaction mixture. The resulting solid was collected by filtration and washed with further saturated aqueous sodium hydrogen carbonate solution. The crude material was purified by HPLC Method B to afford 8.3mg of the title compound.
LCMS (Method A): RT 2.97 min (100% area), ES m/z 594.199 [M-H]\
Example 14
4-r3-(6-Benzyl-1 ,4,5,6,7,8-hexahvdro-imidazor4,5-dlazepin-2-vn-1 H-indazol-6-yll-5-ethyl-2- fluoro-phenol
To a solution of 5-ethyl-2-fluoro-4-[3-(1 ,4,5,6,7,8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1 H- indazol-6-yl]-phenol trihydrobromide salt (Preparation 32, 50mg, δθμηηοΐ) in DMF (1 ml_), was added benzyl bromide (14.4mg, 10μΙ_, δδμηηοΙ), and DIPEA (56μΙ_, 320μη"ΐοΙ). The reaction mixture was heated at 50°C for 1 δ hours. The reaction mixture was then cooled to room temperature and partitioned between EtOAc (50ml_) and water (50ml_). The organic layer was washed with brine (50ml_), dried over sodium sulfate and concentrated in vacuo to furnish a brown oil. The crude material was purified by reverse phase chromatography (Method C) to afford 4mg of the title compound.
1H NMR (400 MHz, CD3OD) δ ppm 1 .02 (t, 3H), 2.55 (q, 2H), 3.08-3.1 1 (m, 4H), 3.34-3.38 (m, 4H), 4.23 (s, 2H), 6.88-6.94 (m, 2H), 7.18 (d, 1 H), 7.41-7.4 (m, 3H), 7.52-7.55 (m, 2H), 8.20 (d, 1 H), 8.39 (br s, 1 H).
LCMS: m/z 482 [M+H]+, 480 [M-H]\
Example 15
(5-Chloro-pyridin-2-ylH2-r6-(2-ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 , 4,6,7- tetrahydro-imidazo[4,5-clpyridin-5-yl)-methanone
To a solution of 5-chloro-pyridine-2-carboxylic acid (12mg, δθμηηοΐ) in DMF (1 ml_) was added HBTU (32mg, δδμηηοΙ) and the resulting reaction mixture was stirred at room temperature for 30 minutes. 5-Ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6- yl]-phenol trihydrobromide salt (Preparation 25, 50mg, δθμηηοΐ) and DIPEA (56μΙ_, 320μη"ΐοΙ) were added and stirring was continued at room temperature for 18 hours. Saturated aqueous sodium hydrogen carbonate solution (5ml_) was added to the reaction mixture. The resulting solid was collected by filtration and washed with further saturated aqueous sodium hydrogen carbonate solution. The crude material was purified by reverse phase chromatography (Method C) to afford 3.3mg of the title compound.
1H NMR (400 MHz, CD3OD) δ ppm 1 .02 (t, 3H), 2.52 (q, 2H), 2.88-2.96 (m, 2H), 3.79-3.82 (m, 2H), 4.15-4.19 (m, 2H), 6.82-6.96 (m, 2H), 7.08-7.18 (m, 1 H), 7.39-7.41 (m, 1 H), 7.69-7.71 (m, 1 H), 7.99-8.01 (m, 1 H), 8.19-8.21 (d, 1 H), 8.38-8.42 (m, 1 H).
LCMS: m/z 517 [M+H]+, 515 [M-H]\
Example 16
5-{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahvdro-imidazo
[4,5-clpyridine-5-carbonyl)-pyridine-2-carbonitrile
To a solution of 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H- indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, δθμηηοΐ) in DMF (1 ml_), was added 6-cyano-nicotinoyl chloride (Preparation 46, 17mg, 96μη"ΐοΙ), and DIPEA (56μΙ_, 320μη"ΐοΙ). The reaction mixture was stirred at room temperature for 72 hours and then saturated aqueous sodium hydrogen carbonate solution (5ml_) was added. The resulting solid was collected by filtration and washed with further saturated aqueous sodium hydrogen carbonate solution. The crude material was purified by reverse phase chromatography (Method C) to afford 6.9mg of the title compound. 1H NMR (400 MHz, CD3OD) δ ppm 1 .02 (t, 3H), 2.52 (q, 2H), 2.85-2.98 (m, 2H), 3.75-3.79 (m, 2H), 4.15-4.19 (m, 2H), 6.82-6.96 (m, 2H), 7.08-7.18 (m, 1 H), 7.38-7.40 (m, 1 H), 8.00 (d, 1 H), 8.15-8.20 (m, 2H), 8.22 (d, 1 H).
LCMS: m/z 508 [M+H]+, 506 [M-H]".
Example 17
5-{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-4.5J.8-tetrahvdro-1 H-imi dlazepine-6-carbonyl)-pyridine-2-carbonitrile
To a solution of 5-ethyl-2-fluoro-4-[3-(1 ,4,5,6,7,8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1 H- indazol-6-yl]-phenol trihydrobromide salt (Preparation 32, 28mg, 44μη"ΐοΙ) in DMF (1 mL), was added 6-cyano-nicotinoyl chloride (Preparation 46, 20.9mg, 141 μη"ΐοΙ), and DIPEA (31 μί, 176μη"ΐοΙ). The reaction mixture was stirred at room temperature for 18 hours and then saturated aqueous sodium hydrogen carbonate solution (5ml_) was added. The resulting solid was collected by filtration and washed with further saturated aqueous sodium hydrogen carbonate solution. The crude material was purified by HPLC Method A to afford 10.3mg of the title compound.
LCMS (Method A): RT 2.69 min (100% area), ES m/z 522.198 [M-H]". Example 18
5-Ethyl-2-fluoro-4-[3-(5-quinolin-6-ylmethyl-4,5,6,7-tetrahvdro-1 H-imidazo[4,5-clpyridin-2-yl)-1 H- indazol-6-yll-phenol
To a solution of 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H- indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, 132μη"ΐοΙ) in DMF (1 ml_), was added quinoline-6-carbaldehyde (31 mg, 198μηΊθΙ), DIPEA (34mg, 46μΙ_, 264μηΊθΙ) and AcOH (1 1 .8mg, 1 1 μΙ_, 198μη"ΐοΙ). The reaction mixture was stirred at room temperature for 1 hour. STAB (42mg, 198μη"ΐοΙ) was added and stirring was continued for 18 hours. The reaction mixture was partitioned between EtOAc (10ml_) and saturated aqueous sodium hydrogen carbonate solution (10ml). The organic layer was washed with further saturated aqueous sodium hydrogen carbonate solution (2 x 10ml_), dried over magnesium sulfate and concentrated in vacuo to furnish a brown oil. The crude material was purified by HPLC Method A to afford 20.6mg of the title compound.
LCMS (Method A): RT 2.59 min (100% area), ES m/z 519.223 [M-H]". Example 19
5-Ethyl-2-fluoro-4-f3-r5-(4-hvdroxy-benzvn-4.5,6,7-tetrahvdro-1 H-imidazor4,5-clpyridin-2-yll-1 H- indazol-6-yl)-phenol The title compound was prepared from 4-hydroxy-benzaldehyde (24.2mg, 198μη"ΐοΙ) and 5- ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, 132μmol) using the method of Example 18. The crude material was purified by HPLC Method A to afford 31 .4mg of the title compound.
LCMS (Method A): RT 2.32 min (100% area), ES m/z 482.207 [M-H]\
Example 20
5-Ethyl-2-fluoro-4-{3-r5-(3-hvdroxy-benzyl)-4,5,6,7-tetrahvdro-1 H-imidazor4,5-clpyridin-2-yll-1 H- indazol-6-yl)-phenol
The title compound was prepared from 3-hydroxy-benzaldehyde (24.2mg, 198μη"ΐοΙ) and 5- ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, 132μη"ΐοΙ) using the method of Example 18. The crude material was purified by HPLC Method A to afford 39.6mg of the title compound.
LCMS (Method A): RT 2.39 min (100% area), ES m/z 484.207 [M+H]+.
Example 21
4- {2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahvdro-imidazor4,5- clpyridin-5-ylmethyl)-pyridine-2-carbonitrile
The title compound was prepared from 4-formyl-pyridine-2-carbonitrile (26mg, 198μη"ΐοΙ) and 5- ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, 132μη"ΐοΙ) using the method of Example 18. The crude material was purified by HPLC Method B to afford 16mg of the title compound.
LCMS (Method B): RT 1.75 min (100% area), ES m/z 494.203 [M+H]+.
Example 22
5- Ethyl-2-fluoro-4-f3-r5-(3-methoxy-benzvn-4.5,6,7-tetrahvdro-1 H-imidazor4,5-clpyridin-2-yll-1 H- indazol-6-yl)-phenol formic acid salt
To a solution of 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H- indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, 132μη"ΐοΙ) in DMF (1 mL), was added 3-methoxy-benzaldehyde (27mg, Ι θδμηιοΙ), DIPEA (34mg, 46μί, 264μmol) and AcOH (1 1 .8mg, 1 1 μί, 198μmol). The reaction mixture was stirred at room temperature for 1 hour. STAB (42mg, 198μη"ΐοΙ) was added and stirring was continued for 18 hours. Saturated aqueous sodium hydrogen carbonate solution (5ml) was added to the reaction mixture. The resulting solid was collected by filtration and washed with further saturated aqueous sodium hydrogen carbonate solution. The crude material was purified by HPLC Method B to afford 30.1 mg of the title compound.
LCMS (Method A): RT 2.64 min (100% area), ES m/z 496.223 [M-H]\ Example 23
5-Ethyl-2-fluoro-4-r3-(5-quinolin-3-ylmet^
indazol-6-yll-phenol
The title compound was prepared from quinoline-3-carbaldehyde (31 mg, 198μη"ΐοΙ) and 5-ethyl-
2- fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, 132μη"ΐοΙ) using the method of Example 22. The crude material was purified by HPLC Method B to afford 14.3mg of the title compound.
LCMS (Method A): RT 2.59 min (100% area), ES m/z 519.223 [M+H]+.
Example 24
5-Ethyl-2-fluoro-4-{3-[5-(6-phenoxy-pyridin-3-ylmethyl)-4,5,6,7-tetrahvdro-1 H-imidazo[4,5- clpyridin-2-νΠ-Ι H-indazol-6-yl)-phenol
The title compound was prepared from 6-phenoxy-pyridine-3-carbaldehyde (39mg, 198μη"ΐοΙ) and 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]- phenol trihydrobromide salt (Preparation 25, 50mg, 132μη"ΐοΙ) using the method of Example 22. The crude material was purified by HPLC Method A to afford 24.7mg of the title compound. LCMS (Method B): RT 2.53 min (100% area), ES m/z 561 .234 [M+H]+.
Example 25
5-Ethyl-2-fluoro-4-{3-r5-(3,4,5,6-tetrahvdro-2H-ri ,2'lbipyridinyl-5'-ylmethyl)-4,5,6,7-tetrahvdro- 1 H-imidazo[4,5-clpyridin-2-yll-1 H-indazol-6-yl)-phenol
The title compound was prepared from 3,4,5,6-tetrahydro-2H-[1 ,2']bipyridinyl-5'-carbaldehyde (38mg, 198μηΊθΙ) and 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)- 1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, 132μη"ΐοΙ) using the method of Example 22. The crude material was purified by HPLC Method A to afford 22.1 mg of the title compound.
LCMS (Method B): RT 2.22 min (100% area), ES m/z 552.281 [M+H]+. Example 26
3- {2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahvdro-imidazor4,5- clpyridin-5-ylmethyl)-pyridine-2-carbonitrile
The title compound was prepared from 3-formyl-pyridine-2-carbonitrile (26mg, 198μη"ΐοΙ) and 5- ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]-phenol trihydrobromide salt (Preparation 25, 50mg, 132μη"ΐοΙ) using the method of Example 22. The crude material was purified by HPLC Method A to afford 14.9mg of the title compound. LCMS (Method A): RT 1.46 min (100% area), ES m/z 494.203 [M+H]+. Example 27
5-Ethyl-2-fluoro-4-{3-r5-(4-fluoro-benzyl .5,6,7-tetrahvdro-1 H-imidazor4,5-clDyridin-2-yll-1 H- indazol-6-yl)-phenol
The title compound was prepared from 4-fluoro-benzaldehyde (25mg, 198μη"ΐοΙ) and 5-ethyl-2- fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]-phenol
trihydrobromide salt (Preparation 25, 50mg, 132μmol) using the method of Example 22. The crude material was purified by HPLC Method A to afford 3.4mg of the title compound.
LCMS (Method A): RT 2.77 min (100% area), ES m/z 486.203 [M+H]+.
Example 28
5-Ethyl-2-fluoro-4-r3-(5-ri ,8lnaDhthyridin-2-ylmethyl-4,5,6,7-tetrahvdro-1 H-imidazor
4,5-clpyridin-2-yl)-1 H-indazol-6-yll-phenol
The title compound was prepared from [1 ,8]naphthyridine-2-carbaldehyde (31 mg, 198μη"ΐοΙ) and 5-ethyl-2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]- phenol trihydrobromide salt (Preparation 25, 50mg, 132μη"ΐοΙ) using the method of Example 22. The crude material was purified by HPLC Method B to afford 22.5mg of the title compound. LCMS (Method B): RT 2.28 min (100% area), ES m/z 520.218 [M+H]+.
Example 29
(2-{6-r5-Fluoro-4-hvdroxy-2-(2,2,2-trifluoro-ethyl)-phenyll-1 H-indazol-3-yl)-1 ,4,6,7-tetrahvdro- imidazo[4,5-clpyridin-5-yl)-(5-piperidin-1-yl-pyrazin-2-yl)-methanone diethylamine salt
The title compound was prepared from 5-piperidin-1-yl-pyrazine-2-carboxylic acid (Preparation 44, 35mg, 168μηΊθΙ) and 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H- indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (Preparation 39, 100mg, 168μη"ΐοΙ) using the method of Example 8. The crude material was purified by HPLC Method A to afford 29.0mg of the title compound as the diethylamine salt.
LCMS (Method B): RT 2.66 min (100% area), ES m/z 621 .227 [M+H]+. Example 30
(2-{6-r5-Fluoro-4-hvdroxy-2-(2,2,2-trifluoro-ethyl)-phenyll-1 H-indazol-3-yl)-1 ,4,6,7-tetrahvdro- imidazo[4,5-clpyridin-5-yl)-(4-fluoro-phenyl)-methanone diethylamine salt
The title compound was prepared from 4-fluoro-benzoic acid (24mg, 168μη"ΐοΙ) and 2-fluoro-4-
[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)- phenol (Preparation 39, 100mg, 168μη"ΐοΙ) using the method of Example 8. The crude material was purified by HPLC Method A to afford 33.3mg of the title compound. LCMS (Method B): RT 2.62 min (100% area), ES m/z 554.154 [M+H]+. Example 31
4- r3-(5-Benzyl-4,5,6,7-tetrahvdro-1 H-imidazor4,5-clDyridin-2-vn-1 H-indazol-6-yll-2-fluoro-5- (2,2,2-trifluoro-ethyl)-phenol diethylamine salt
To a solution of 2-fluoro-4-[3-(4,5,6J-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]-
5- (2,2,2-trifluoro-ethyl)-phenol (Preparation 39, 100mg, 168μηΊθΙ) in DMF (1 mL), was added benzyl bromide (28.8mg, 20μΙ_, 168μηΊθΙ), and DIPEA (120μί, 672μηΊθΙ). The reaction mixture was heated at 80°C for 3 hours. The reaction mixture was then cooled to room temperature and saturated aqueous sodium hydrogen carbonate solution (5ml_) was added. The resulting solid was collected by filtration and washed with further saturated aqueous sodium hydrogen carbonate solution. The crude material was purified by HPLC Method A to afford 10.6mg of the title compound.
LCMS (Method A): RT 2.67 min (100% area), ES m/z 522.184 [M+H]+. Example 32
{5-[(2-Dimethylamino-ethyl)-methyl-aminol-pyrazin-2-ylH2-[6-(2-ethyl-5-fluoro-4-hvdroxy- phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahydro-imidazo[4,5-clpyridin-5-yl)-methanone
To a solution of (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1 H-indazol-3-yl)- 6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80mg, 0.154mmol) in DMSO (1 ml_) were added DIPEA (0.08ml_, 0.463mmol) and Ν,Ν,Ν-trimethylethylendiamine (31 .56mg, 0.308mmol) and the mixture stirred at room temperature for 18 hours. The crude reaction mass was purified by prep-HPLC Method C to afford the title compound as an off white solid (25 mg, 28 %).
1 H NMR (400 MHz, DMSO) δ (ppm): 1.01 (t, 3H), 2.18(s, 6H), 2.44(m, 4H), 2.78(bs, 2H), 3.13(s, 3H), 3.70(t, 3H), 3.94(bs, 2H), 4.66-4.76(m, 2H), 6.90(d, 1 H), 7.00(d, 1 H), 7.09(d, 1 H), 7.37(s, 1 H), 8.12(s, 1 H), 8.31 (d, 1 H), 8.38(d, 1 H), 12.51 (s, 1 H), 13.21 (s, 1 H);
LCMS: Rt = 2.59 min; m/z 584[M+H]+
Example 33
{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-Dhenvn-1 H-indazol-3-yll-1 ,4,6,7-tetrahvdro-imidazor4,5- clpyridin-5-yl)-r5-(2-pyrrolidin-1-yl-ethylamino)-pyrazin-2-yll-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (50 mg, 96μmol) and (2-(pyrrolidin-1 -yl)ethanamine, 50mg, 132μmol) using the method of Example 32. The crude material was purified by HPLC Method E to afford (30 mg, 52%) of the title compound.
1 H NMR (400 MHz, DMSO) δ(ρρΓπ): 0.98-1 .01 (t, 3H), 1.13(s, 3H), 1 .22(bs, 2H), 1 .68(bs, 3H), 1 .90(s, 1 H), 2.1 1 (s, 1 H), 2.60(t, 2H), 2.78(bs, 3H), 3.42(m, 2H), 3.91 (bs, 2H), 4.64-4.68(m, 2H), 6.90(d, 1 H), 7.00(d, 1 H), 7.08(d, 1 H), 7.36(s, 1 H), 7.60(bs, 1 H), 7.95(s, 1 H), 8.29-8.33(m, 2H), 9.80(bs, 1 H), 12.52(s, 1 H), 13.22(s, 1 H);
LCMS: Rt = 5.71 min; m/z 596.4[M+H]+.
Example 34
[5-(2-Dimethylamino-ethylamino)-pyrazin-2-yll-{2-[6-(2-ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H- indazol-3-yll-1 ,4,6,7-tetrahvdro-imidazo[4,5-clpyridin-5-yl)-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (100 mg, 193μmol) and N,N-dimethylethylendiamine, (34 mg, 386 μηηοΙ) using the method of Example 32. The crude material was purified by HPLC Method E to afford (50 mg, 46%) of the title compound as white solid.
1 H NMR (400 MHz, DMSO) 5(ppm): 1.03(t, 3H), 2.18(s, 6H), 2.40-2.45(m, 4H), 2.77(bs, 2H), 2.93-2.98(m, H), 3.16(s, 3H), 3.38-3.44(m, 2H), 3.78(m, 2H), 4.66(m, 2H), 6.90(d, 1 H), 6.99(d, 1 H), 7.09(d, 1 H), 7.37(s, 1 H), 7.53(bs, 1 H), 7.96(s, 1 H), 8.29(s, 2H):
LCMS: Rt = 2.53 min; m/z 570[M+H]+.
Example 35
r5-(4-Dimethylamino-piperidin-1-yl)-pyrazin-2-ylH2-r6-(2-ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H- indazol-3-yll-1 ,4,6,7-tetrahydro-imidazor4,5-clpyridin-5-yl)-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 μηηοΙ) and 4-N,N-dimethylaminopiperidine, (40 mg, 308 μηηοΙ) using the method of Example 32. The crude material was purified by HPLC Method C to afford (60mg , 64%) of the title compound as off-white solid.
1 H NMR (400 MHz, DMSO) δ (ppm): 1.01 (t, 3H), 1.39-1.41 (m, 2H), 1.83-1 .86(m, 2H), 2.18(s, 6H), 2.32-2.38(m, 2H), 2.78(bs, 2H), 2.95-3.01 (t, 2H), 3.90(s, 2H), 3.92-3.94(m, 2H), 4.42- 4.45(m, 2H), 4.67-4.75(m, 2H), 6.87(d, 1 H), 6.92(d, 1 H), 7.03(bs, 1 H), 7.37(s, 1 H), 8.33-8.39(m, 3H), 12.50(bs, 1 H), 13.22(bs, 1 H);
LCMS: Rt = 5.46 min; m/z 610.4[M+H]+
Example 36 {2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenylV1 H-m^
clpyridin-5-ylH5-rethyl-(2-hvdroxy-ethyl)-aminol-pyrazin-2-yl)-methan
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (120 mg, 231 μmol) and N-ethylaminoethanol, (41 mg, 463μmol) using the method of Example 32. The crude material was purified by HPLC Method D to afford (60mg, 64%) of the title compound as off-white solid.
1 H NMR (400 MHz, DMSO) δ (ppm): 0.99-1.03(t, 3H), 1.13-1 .16(t, 3H), 2.32-2.41 (m, 2H), 2.78(bs, 2H), 2.94-2.97(m„ 1 H), 3.61 (bs, 5H), 3.94(m, 2H), 4.65-4.86(m, 3H), 6.90(d, 1 H), 7.00(d, 1 H), 7.09(bs, 1 H), 7.36(s, 1 H), 8.14(s, 1 H), 8.31 -8.38(m, 2H), 9.82(bs, 1 H), 12.51 (bs, 1 H), 13.20(bs, 1 H);
LCMS: Rt = 2.69 min; m/z 571 .4[M+H]+. Example 37
[5-((R)-3-Dimethylamino-pyrrolidin-1 -yl)-pyrazin-2-yll-{2-[6-(2-ethyl-5-fluoro-4-hvdroxy-phenyl)- 1 H-indazol-3-yll-1 ,4,6,7-tetrahydro-imidazo[4,5-clpyridin-5-yl)-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 μηηοΙ) and (R)-3-dimethylaminopyrrolidine, (35 mg, 308 μmol) using the method of Example 32. The crude material was purified by HPLC Method C to afford (35 mg, 38%) of the title compound as white solid.
1 H NMR (400 MHz, DMSO) δ (ppm): 1.03(t, 3H), 1.75(m, 2H), 2.21 (s, 6H), 2.79-2.81 (m, 3H), 3.20(m, 2H), 3.41-3.47(m, 2H), 3.71 (m, 1 H), 3.77-3.81 (m, 1 H), 3.92(bs, 2H), 4.66-4.74(m, 2H), 6.90(d, 1 H), 7.00(d, 1 H), 7.09(d, 1 H), 7.37(s, 1 H), 7.98(s, 1 H), 8.31 (d, 1 H), 8.39(m, 1 H), 12.50(s, 1 H), 13.21 (s, 1 H);
LCMS: Rt = 2.61 min; m/z 596.4[M+H]+.
Example 38
[5-((S)-3-Dimethylamino-pyrrolidin-1-yl)-pyrazin-2-yll-{2-[6-(2-ethyl-5-fluoro-4-hvdroxy-phenyl)- 1 H-indazol-3-yll-l ,4,6,7-tetrahydro-imidazor4,5-clpyridin-5-yl)-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 μηηοΙ) and (S)-3-dimethylaminopyrrolidine, (35 mg, 308 μηηοΙ) using the method of Example 32. The crude material was purified by HPLC Method C to afford (38 mg, 40%) of the title compound as off-white solid.
1 H NMR (400 MHz, DMSO) δ (ppm): 1.03(t, 3H), 1.75-1 .83(m, 2H), 2.21 (s, 6H), 2.79-2.81 (m, 3H), 3.18-3.23(m, 2H), 3.43-3.45(m, 2H), 3.69-3.77(m, 1 H), 3.79-3.81 (m, 1 H), 3.90(bs, 2H), 4.66(m, 2H), 6.90(d, 1 H), 7.00(d, 1 H), 7.09(d, 1 H), 7.37(s, 1 H), 7.98(s, 1 H), 8.32(m, 1 H), 8.39(m, 1 H), 12.51 (s, 1 H), 13.22(s, 1 H);
LCMS: Rt = 2.61 min; m/z 596.4[M+H]+.
Example 39
{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 ^^
5-yl)-[5-(2-piperidin-1-yl-ethylarriino)-pyrazin-2-yll-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (120 mg, 231 μηηοΙ) and(2-(piperidine-1 -yl)ethanamine, (59 mg, 463 μηηοΙ) using the method of Example 32. The crude material was purified by HPLC Method G to afford (38 mg, 27%) of the title compound as off-white solid.
1 H NMR (400 MHz, DMSO) δ (ppm): 1.09 (t, 3H), 1.39 (Brs, 2H), 1.39-1.50 (m, 3H), 2.32 (m, 3H), 2.43-2.54 (m, 4H), 2.77 (Brs, 2H), 3.33-3.42 (m, 2H), 3.90 (Brs, 2H), 4.68 (m, 2H), 6.90- 6.92 (d, 1 H), 7.00-7.03 (d, 1 H), 7.09 (m, 1 H), 7.37 (s, 1 H), 7.48 (s, 1 H) 7.94 (s, 1 H), 8.29-8.32 (s, 2H),;
LCMS: Rt = 2.64 min; m/z 610.2 [M+H]+. Example 40
{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahvdro-imidazor4,5- clpyridin-5-yl)-[5-(2-piperazin-1-yl-ethylamino)-pyrazin-2-yll-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 μηηοΙ) and (2-(piperazinyl-1-yl)ethanamine, (40 mg, 309 μηηοΙ) using the method of Example 32. The crude material was purified by HPLC Method D to afford (26 mg, 28%) of the title compound as off-white solid.
1 H NMR (400 MHz, DMSO) δ (ppm): 0.97-1.00 (t, 3H), 1.20 (s, 2H), 2.40-2.43 (m, 2H), 2.50 (s, 2H), 2.76 (Brs, 2H), 3.51 -3.54 (d, 2H), 3.64 (Brs, 4H), 3.87-3.93 (d, 2H), 4.41-4.42 (m, 1 H), 4.64-4.68 (d, 2H) 6.87-6.89 (d, 1 H), 6.97-7.08 (m, 2H), 7.34 (s, 1 H), 8.29 (s, 2H), 8.37 (s, 1 H), 9.79 (s, 1 H), 12.48 (s, 1 H), 13.17 (s, 1 H);
LCMS: Rt = 2.59 min; m/z 612.4 [M+H]+.
Example 41
{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenvn-1 H-indazol-3-yll-1 ,4,6,7-tetrahvdro-imidazor4,5- lPyridin-5-yl)-(4-methyl-3,4,5,6-tetrahvdro-2H-ri ,2'lbipyrazinyl-5'-yl)-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 μηηοΙ) and 1 -methyl-piperazine, (31 mg, 309 μηηοΙ) using the method of Example 32. The crude material was purified by HPLC Method D to afford (21 mg, 23%) of the title compound as off-white solid.
1 H NMR (400 MHz, DMSO) δ (ppm): 0.90-1 .03 (m, 6H), 2.22 (s, 3H), 2.40-2.49 (m, 4H), 2.78 (Brs, 2H), 3.67 (s, 3H), 3.88 (m, 2H), 4.66 (m, 2H), 6.90-6.92 (d, 1 H), 7.00-7.03 (d, 2H), 7.37(s, 1 H) 8.32 (s, 3H), 9.82 (s, 1 H), 12.50 (s, 1 H), 13.20 (s, 1 H);
LCMS: Rt = 2.63min; m/z 582.6 [M+H]+.
Example 42
{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahvdro-imidazor4,5- clpyridin-5-yl)-(5-morpholin-4-yl-pyrazin-2-yl)-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (100 mg, 154 μηηοΙ) and morpholine, (34 mg, 386 μηηοΙ) using the method of Example 32. The crude material was purified by HPLC Method F to afford (42 mg, 38%) of the title compound as off- white solid.
1 H NMR (400 MHz, DMSO) δ (ppm): 0.99-1.03(t, 3H), 2.78 (Brs, 2H), 3.65-3.72(q, 8H), 3.88 (d, 2H), 4.67-4.77(m, 2H), 6.90 (d, 1 H), 2H) 7.00-7.1 1 (m, 2H), 7.37 (s, 1 H), 8.26 (s, 2H), 8.42 (s, 1 H), 12.50 (s, 1 H), 13.20 (s, 1 H);
LCMS: Rt = 3.23 min; m/z 569.4 [M+H]+.
Example 43
{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahvdro-idazor4,5clpyridin- 5-yl)-r5-(4-methyl-piperidin-1-yl)-pyrazin-2-yll-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (100 mg, 154 μηηοΙ) and 4-methyl-piperidine, (38 mg, 386 μηηοΙ) using the method of Example 32. The crude material was purified by HPLC Method F to afford (34 mg, 30%) of the title compound as off-white solid.
1 H NMR (400 MHz, DMSO) δ (ppm): 0.92-0.93 (d, 3H), 0.99-1 .03 (t, 3H), 1 .10-1.16 (m, 2H), 1 .69-1.75 (m, 3H), 1.85 (s, 1 H), 2.78 (Brs, 2H), 2.91-2.98 (t, 2H), 3.93 (Brs, 2H), 4.42-4.45 (d, 2H), 4.66-4.75 (m, 2H) 6.90-6.92 (d, 1 H), 7.00-7.03 (d, 2H), 7.37 (s, 1 H), 8.31-8.39 (m, 3H), 12.51 (s, 1 H), 13.21 (s, 1 H);
LCMS: Rt = 3.1 1 min; m/z 581 .4 [M+H]+.
Example 44 (5-Cvclopentylamino-pyrazin-2-ylH2-r6-(2-ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-in 1 ,4,6,7-tetrahvdro-imidazor4,5-clpyridin-5-yl)-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (90mg, 173 μmol) and cylopenylamine, (30mg, 347 μmol) using the method of Example 32. The crude material was purified by HPLC Method G to afford (28 mg, 28%) of the title compound as off-white solid.
1 H NMR (400 MHz, DMSO) δ (ppm): 1.03 (t, 3H), 1.45-1.51 (m, 2H), 1.56-1 .57 (m, 2H), 1 .69 (m, 2H), 1.93-1.95 (m, 2H), 2.53 (m, 1 H), 2.78 (Brs, 2H), 3.16 (s, 1 H), 3.91 (Brs, 2H), 4.14-4.19 (m 1 H), 4.64 (m ,2H), 6.90-6.92 (d, 1 H), 7.00-7.03 (d, 1 H), 7.09 (d, 1 H), 7.37 (s, 1 H), 7.62 (s, 1 H) 7.88(s, 1 H), 8.29 (s, 2H),;
LCMS: Rt = 2.98 min; m/z 567.6 [M+H]+.
Example 45
{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahvdro-imidazor4,5- clpyridin-5-yl)-[5-(2-morpholin-4-yl-ethylamino)-pyrazin-2-yll-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (100mg, 193 μηηοΙ) and 2-morpholin-4-yl-ethylamine, (30mg, 347 μηηοΙ) using the method of Example 32. The crude material was purified by HPLC Method F to afford (28 mg, 28%) of the title compound as off-white solid.
1 H NMR (400 MHz, DMSO) δ (ppm): 0.99-1.03(t, 3H), 2.49-2.57 (m, 2H), 2.77(Brs, 2H), 3.16 (s, 2H), 3.32 (s, 3H), 3.56-3.58 (m, 2H), 2H) 3.90 (m,2H) 4.69 (m,2H) 6.90-6.92 (d, 1 H), 7.00-7.03 (d, 1 H), 7.09 (m, 1 H), 7.37 (s, 1 H), 7.53 (Brs, 1 H), 7.95 (s, 1 H), 8.29 (s,2H);
LCMS: Rt = 5.89 min; m/z 612.4 [M+H]+.
Example 46
{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahvdro-imidazor4,5- clpyridin-5-yl)-(4-isopropyl-3,4,5,6-tetrahvdro-2H-[1 ,2'lbipyrazinyl-5'-yl)-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 μηηοΙ) andl-isopropyl-piperazine, (40mg, 308μη"ΐοΙ) using the method of Example 32.
The crude material was purified by HPLC Method D to afford (18 mg, 19%) of the title compound as off-white solid.
1 H NMR (400 MHz, DMSO) δ (ppm): 0.95-1.03(m, 9H), 2.53(m, 4H), 2.68-2.78(m, 3H), 3.65(s, 4H), 3.89-3.95(m, 2H), 4.70(m, 2H), 6.90(d, 1 H), 7.00(d, 1 H), 7.09(d, 1 H), 7.37(s, 1 H), 8.31 (m, 2H), 8.39(d, 1 H), 9.82(bs, 1 H), 12.51 (s, 1 H), 13.20(s, 1 H); LCMS: Rt = 6.52 min; m/z 610.4[M+H]+. Example 47
{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl^
clpyridin-5-yl)-(5-pyrrolidin-1 -yl-pyrazin-2-yl)-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 μηηοΙ) and pyrrolidine (22 mg, 308μη"ΐοΙ) using the method of Example 32. The crude material was purified by HPLC Method D to afford (18 mg, 19%) of the title compound as off- white solid.
1 H NMR (400 MHz, DMSO) δ (ppm): 1 .01 (t, 3H), 1 .97(bs, 4H), 2.78(bs, 2H), 3.50(s, 4H), 3.93(bs, 2H), 4.65-4.76(m, 2H), 6.90(d, 1 H), 7.00(d, 1 H), 7.08(d, 1 H), 7.36(s, 1 H), 7.96(s, 1 H), 8.31 (d, 1 H), 8.39(s, 1 H), 9.86(bs, 1 H), 12.52(s, 1 H), 13.22(s, 1 H);
LCMS: Rt = 2.85min; m/z 553.4[M+H]+.
Example 48
{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahvdro-imidazor4,5- lPVridin-5-yl)-[5-(ethyl-methyl-amino)-pyrazin-2-yll-methanon
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80 mg, 154 μηηοΙ) and ethyl-methylamine (18 mg, 308μmol) using the method of Example 32. The crude material was purified by HPLC Method E to afford (38 mg, 46%) of the title compound as off-white solid.
1 H NMR (400 MHz, DMSO) δ (ppm): 1.01 (t, 3H), 1.12(t, 3H), 2.78(m, 2H), 3.1 1 (s, 3H), 3.65(m, 2H), 3.93(m, 2H), 4.76(m, 2H), 6.90(d, 1 H), 7.00(d, 1 H), 7.09(d, 1 H), 7.37(s, 1 H), 8.13(s, 1 H), 8.31 (m, 1 H), 8.39(s, 1 H), 9.84(bs, 1 H), 12.51 (s, 1 H), 13.22(s, 1 H);
LCMS: Rt = 2.85 min; m/z 541 .6[M+H]+.
Example 49
(5-Cvclohexylamino-pyrazin-2-ylH2-r6-(2-ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll- 1 ,4,6,7-tetrahvdro-imidazor4,5-clpyridin-5-yl)-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (126 mg, 243 μηηοΙ) and cyclohexylamine (48 mg,487 μmol) using the method of Example 32. The crude material was purified by HPLC Method D to afford (29 mg, 20%) of the title compound as off-white solid. 1 H NMR (400 MHz, DMSO) δ (ppm): 0.99-1.04(m, 3H), 1.18-1.35(m, 6H), 1.62-1.84(m, 6H), 1 .90-1.93(m, 1 H), 2.78(m, 2H), 3.32(m, 1 H), 3.76-3.91 (m, 2H), 4.66-4.72(m, 2H), 6.90(d, 1 H), 7.00(d, 1 H), 7.09(d, 1 H), 7.37(s, 1 H), 7.51 (bs, 1 H), 7.88(s, 1 H), 8.23(s, 1 H), 12.50(bs, 1 H), 13.22(bs, 1 H);
LCMS: Rt = 3.06 min; m/z 581 .6[M+H]+. Example 50
(5-Dimethylamino-pyrazin-2-ylH2-[6-(2-ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-νΠ-, 4,6,7- tetrahydro-imidazo[4,5-clpyridin-5-yl)-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80mg, 154 μηηοΙ) and dimethylamine HCI (25 mg, 308 μηηοΙ) using the method of Example 32. The crude material was purified by HPLC Method D to afford (17 mg, 21 %) of the title compound as off-white solid.
1 H NMR (400 MHz, DMSO) δ (ppm): 1.01 (t, 3H), 2.79(m, 2H), 3.15(s, 6H), 3.93(m, 2H), 4.70(m, 2H), 6.90(d, 1 H), 7.00(d, 1 H), 7.01 (d, 1 H), 7.09(d, 1 H), 7.37(s, 1 H), 8.15(s, 1 H), 8.31 (m, 1 H), 8.40(s, 1 H), 9.84(bs, 1 H), 12.51 (s, 1 H), 13.20(s, 1 H);
LCMS: Rt = 2.81 min; m/z 527.4[M+H]+.
Example 51
(5-Azetidin-1 -yl-Dyrazin-2-ylH2-r6-(2-ethyl-5-fluoro-4-hvdroxy-Dhenvn-1 H-indazol-3-yll-1 ,4,6,7- tetrahvdro-imidazor4,5-clpyridin-5-yl)-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (80mg, 154 μηηοΙ) and azetdine HCI (29 mg, 308 μηηοΙ) using the method of Example 32. The crude material was purified by HPLC Method D to afford (19 mg, 23%) of the title compound as off-white solid.
1 H NMR (400 MHz, DMSO) δ (ppm): 1.03(t, 3H), 2.43-2.49(m, 2H), 2.78(bs, 2H), 3.37(m, 2H), 3.87-3.95(m, 2H), 4.13(t, 4H), 4.65-4.70(m, 2H), 6.90(d, 1 H), 7.00(d, 1 H), 7.09(d, 1 H), 7.37(s, 1 H), 7.83(s, 1 H), 8.33-8.37(m, 2H), 9.84(bs, 1 H), 12.52(s, 1 H), 13.21 (s, 1 H);
LCMS: Rt = 2.78 min; m/z 539.4[M+H]+.
Example 52
2-Fluoro-4-{3-[5-(4-fluoro-benzyl)-4,5,6,7-tetrahvdro-1 H-imidazo[4,5-clpyridin-2-yll-1 H-indazol-6- yl)-5-(2,2,2-trifluoro-ethyl)-phenol
To a solution of 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]- 5-(2,2,2-trifluoro-ethyl)-phenol (Preparation 39, 100 mg, 0.21 mmol) and KOAc (22.75 mg, 0.23 mmol) in MeOH (1 ml_), 4-fluorobenzaldehyde (57.54 mg, 0.46 mmol) was added and the mixture stirred at room temperature for 1 hr followed by portionwise addition of sodium triacetoxy borohydride (162.12 mg, 0.76 mmol) over 2hrs. The mixture was thereafter stirred at room temperature for 18 hrs. The reaction mixture was concentrated and the residue partitioned between saturated sodium bicarbonate solution & ethyl acetate. The organic phase was dried over sodium sulphate, evaporated in vacuo, purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH-DCM) to afford the title compound as a light yellow solid in 30.35 % yield, 35 mg.
1 H NMR (400 MHz, DMSO) δ (ppm): 2.66(m, 2H), 2.76-2.80(m, 2H), 3.44-3.56(m, 4H), 3.71 (s, 2H), 7.07-7.10(m, 2H), 7.13-7.19(m, 2H), 7.36(s, 1 H), 7.41 -7.43(m, 2H), 8.29-8.36(m, 1 H), 10.13(s, 1 H), 12.21-12.34(m, 1 H), 13.19(s, 1 H);
LCMS: Rt = 3.17 min; m/z 540.4 [M+H]+
Example 53
2-Fluoro-4-{3-r5-(3,4,5,6-tetrahvdro-2H-ri ,2'lbipyridinyl-5'-ylmethyl)-4,5,6,7-tetrahvdro-1 H- imidazo[4,5-clpyridin-2-yll-1 H-indazol-6-yl)-5-(2,2,2-trifluoro-ethyl)-phenol
The title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 3,4,5,6- tetrahydro-2H-[1 ,2']bipyridinyl-5'-carbaldehyde (88.2 mg, 0.46 mmol) using the method of Example 51 . The crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH-DCM) to afford the title compound as an off white solid in 16.99 % yield, 22 mg.
1 H NMR (400 MHz, DMSO) δ (ppm): 1.53(m, 6H), 2.64(m, 2H), 2.73-2.77(m, 2H), 3.41-3.57(m, 10H), 6.78(d, 1 H), 7.02-7.10(m, 2H), 7.14-7.17(m, 1 H), 7.36(s, 1 H), 7.48(d, 1 H), 8.03(s, 1 H), 8.30-8.35(m, 1 H), 10.15(s, 1 H), 12.22-12.34(m, 1 H), 13.20(s, 1 H);
LCMS: Rt = 3.17 min; m/z 606.2 [M+H]+
Example 54
2-Fluoro-4-{3-[5-(6-phenoxy-pyridin-3-ylmethyl)-4,5,6,7-tetrahvdro-1 H-imidazo[4,5-clpyridin-2- yll-H-indazol-6-ylV5-(2,2,2-trifluoro-ethylVphenol
The title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 6- phenoxy-pyridine-3-carbaldehyde (92.3 mg, 0.46 mmol) using the method of Example 51. The crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH-DCM) to afford the title compound as an off white solid in 23.6 % yield, 31 mg. 1 H NMR (400 MHz, DMSO) δ (ppm): 2.67(m, 2H), 2.77(m, 2H), 3.45-3.56(m, 4H), 3.70(s, 2H), 6.78(d, 1 H), 7.00-7.22(m, 6H), 7.36(s, 1 H), 7.39-7.43(t, 2H), 7.84(d, 1 H), 8.1 1 (s, 1 H), 8.30- 8.35(m, 1 H), 10.15(s, 1 H), 12.24-12.36(m, 1 H), 13.21 (s, 1 H);
LCMS: Rt = 3.20 min; m/z 615.4 [M+H]+
Example 55
2-Fluoro-4-{3-[5-(4-methoxy-benzyl)-4,5,6,7-tetrahvdro-1 H-imidazo[4,5-clpyridin-2-yll-1 H indazol-6-yl)-5-(2,2,2-trifluoro-ethyl)-phenol
The title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 4- methoxybenzaldehyde (63.1 mg, 0.46 mmol) using the method of Example 51. The crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH- DCM) to afford the title compound as an off white solid in 22.1 % yield, 26 mg.
1 H NMR (400 MHz, DMSO) δ (ppm): 2.65(m, 2H), 2.73-2.79(m, 2H), 3.37-3.47(m, 2H), 3.50- 3.56(m, 2H), 3.64(s, 2H), 3.75(s, 3H), 6.90-6.92(m, 2H), 7.02-7.10(m, 2H), 7.13-7.16(m, 1 H), 7.27-7.29(m, 2H), 7.36(s, 1 H), 8.29-8.36(m, 1 H), 10.13(s, 1 H), 12.20-12.35(m, 1 H), 13.19(s, 1 H);
LCMS: Rt = 3.15 min; m/z 552.2 [M+H]+ Example 56
2-Fluoro-4-{3-r5-(4-hvdroxy-benzyl)-4,5,6,7-tetrahvdro-1 H-imidazor4,5-clpyridin-2-yll-1 H- indazol-6-yl)-5-(2,2,2-trifluoro-ethyl)-phenol
The title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 4- hydroxybenzaldehyde (56.6 mg, 0.46 mmol) using the method of Example 51 . The crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH- DCM) to afford the title compound as an off white solid in 24.4 % yield, 28 mg.
1 H NMR (400 MHz, DMSO) δ (ppm): 2.66(m, 2H), 2.73-2.78(m, 2H), 3.40-3.43(m, 2H), 3.47- 3.56(m, 2H), 3.59(s, 2H), 6.72-6.74(d, 2H), 7.02-7.10(m, 2H), 7.14-7.18(m, 3H), 7.36(s, 1 H), 8.29-8.36(m, 1 H), 9.27(s, 1 H), 10.13(s, 1 H), 12.20-12.32(m, 1 H), 13.19(s, 1 H);
LCMS: Rt = 2.86 min; m/z 538.2 [M+H]+
Example 57
2-Fluoro-4-{3-[5-(3-methoxy-benzyl)-4,5,6,7-tetrahvdro-1 H-imidazo[4,5-clpyridin-2-yll-1 H- indazol-6-yl)-5-(2,2,2-trifluoro-ethyl)-phenol
The title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 3- methoxybenzaldehyde (63.1 mg, 0.46 mmol) using the method of Example 51. The crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH-
DCM) to afford the title compound as an off white solid in 21.2 % yield, 25 mg.
1 H NMR (400 MHz, DMSO) δ (ppm): 2.66(m, 2H), 2.76-2.80(m, 2H), 3.45-3.56(m, 4H), 3.69(s,
2H), 3.75(s, 3H), 6.83-6.85(d, 1 H), 6.94(m, 2H), 7.02-7.10(m, 2H), 7.14(d, 1 H), 7.24-7.28(t, 1 H),
7.36(s, 1 H), 8.29-8.36(m, 1 H), 10.15(s, 1 H), 12.23-12.35(m, 1 H), 13.20(s, 1 H);
LCMS: Rt = 3.14 min; m/z 552 [M+H]+
Example 58
2-Fluoro-4-{3-r5-(3-hvdroxy-benzyl)-4,5,6,7-tetrahvdro-1 H-imidazor4,5-clpyridin-2-yll-1 H- indazol-6-yl)-5-(2,2,2-trifluoro-ethyl)-phenol
The title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and 3- hydroxybenzaldehyde (56.6 mg, 0.46 mmol) using the method of Example 51 . The crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH- DCM) to afford the title compound as an off white solid in 26.1 % yield, 30 mg.
1 H NMR (400 MHz, DMSO) δ (ppm): 2.66(m, 2H), 2.76-2.81 (m, 2H), 3.43-3.53(m, 4H), 3.63(s, 2H), 6.64-6.66(d, 1 H), 6.76-6.81 (m, 2H), 7.02-7.16(m, 4H), 7.36(s, 1 H), 8.30-8.32(m, 1 H), 9.28(d, 1 H), 10.13(s, 1 H), 12.21 -12.33(m, 1 H), 13.19(s, 1 H);
LCMS: Rt = 2.90 min; m/z 538.2 [M+H]+
Example 59
2-Fluoro-4-r3-(5-quinolin-6-ylmethyl-4,5,6,7-tetrahvdro-1 H-imidazor4,5-clpyridin-2-yl)-1 H- indazol-6-yll-5-(2,2,2-trifluoro-ethyl)-phenol
The title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and quinoline-6-carbaldehyde (72.9 mg, 0.46 mmol) using the method of Example 51 . The crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH- DCM) to afford the title compound as an off white solid in 22.9 % yield, 28 mg.
1 H NMR (400 MHz, DMSO) δ (ppm): 2.67(m, 2H), 2.83.2.89(m, 2H), 3.49-3.55(m, 4H), 3.93(s, 2H), 7.01-7.17(m, 3H), 7.36(s, 1 H), 7.51 (m, 1 H), 7.80(d, 1 H), 7.95(s, 1 H), 7.99(d, 1 H), 8.29- 8.38(m, 2H), 8.87(d, 1 H), 10.13(s, 1 H), 12.21 -12.33(m, 1 H), 13.19(s, 1 H);
LCMS: Rt = 2.90 min; m/z 573.6 [M+H]+
Example 60
2-Fluoro-4-[3-(5-quinolin-3-ylmethyl-4,5,6,7-tetrahvdro-1 H-imidazo[4,5-clpyridin-2-yl)-1 H- indazol-6-yll-5-(2,2,2-trifluoro-ethyl)-phenol The title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2!2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and quinoline-3-carbaldehyde (72.9 mg, 0.46 mmol) using the method of Example 51 . The crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH- DCM) to afford the title compound as an off white solid in 27.8 % yield, 34 mg.
1 H NMR (400 MHz, DMSO) δ (ppm): 2.67-2.70(m, 2H), 2.83.2.90(m, 2H), 3.47-3.58(m, 4H), 3.95(s, 2H), 7.01-7.17(m, 3H), 7.36(s, 1 H), 7.59(t, 1 H), 7.74(t, 1 H), 8.02(t, 2H), 8.29-8.38(m, 2H), 8.93(d, 1 H), 10.14(s, 1 H), 12.23-12.36(m, 1 H), 13.20(s, 1 H);
LCMS: Rt = 2.97 min; m/z 573.6 [M+H]+
Example 61
2-Fluoro-4-[3-(5-[1 ,8lnaphthyridin-3-ylmethyl-4,5,6,7-tetrahvdro-1 H-imidazo[4,5-clpyridin-2-yl)- 1 H-indazol-6-yll-5-(2,2,2-trifluoro-ethyl)-phenol
The title compound was prepared from 2-fluoro-4-[3-(4,5,6,7-tetrahydro-1 H-imidazo[4,5- c]pyridin-2-yl)-1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol (100 mg, 0.21 mmol) and [1 ,8]naphthyridine-3-carbaldehyde (146.1 mg, 0.92 mmol) using the method of Example 51. The crude material was purified initially over silica and finally by Prep TLC (Mobile Phase: 10% MeOH-DCM) to afford the title compound as an off white solid in 9.0 % yield, 22 mg.
1 H NMR (400 MHz, DMSO) δ (ppm): 2.72(m, 2H), 2.89.2.92(m, 2H), 3.50-3.54(m, 2H), 3.60- 3.63(m, 2H), 4.08(s, 2H), 7.02-7.17(m, 3H), 7.36(s, 1 H), 7.61-7.64(m, 1 H), 7.82-7.85(m, 1 H), 8.29-8.38(m, 2H), 8.44-8.47(m, 2H), 9.06(m, 1 H), 10.15(s, 1 H), 12.26-12.39(m, 1 H), 13.21 (s, 1 H);
LCMS: Rt = 2.86 min; m/z 574.2 [M+H]+ Example 62
((3R.5S)-3.5-Dimethyl-3.4.5.6-tetrahvdro-2H-ri .2'lbiDyrazinyl-5'-ylH2-r6-(2-ethyl-5-fluoro-4- hvdroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahydro-imidazor4,5-clpyridin-5-yl)-methanone
To a stirring solution of (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1 H- indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (150mg, 0.154mmol) in DMSO (1.5mL) were added DIPEA (0.143mL, 0.87mmol) and (2R,6S)-2,6-Dimethyl-piperazine- 1 -carboxylic acid tert-butyl ester (124mg, 0.58mmol) and the mixture stirred at room temperature for 18 hours. The crude reaction mass was purified by prep-HPLC Method F to afford (3R,5S)-5'-{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro- imidazo[4,5-c]pyridine-5-carbonyl}-3,5-dimethyl-2,3,5,6-tetrahydro-[1 ,2']bipyrazinyl-4-carboxylic acid tert-butyl ester as an off white solid (80 mg, 40 %).
LCMS: Rt = 3.18 min; m/z 696.6 [M+H]+. To a stirring solution of (3R,5S)-5'-{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]- 1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-carbonyl}-3,5-dimethyl-2,3,5,6-tetrahydro- [1 ,2']bipyrazinyl-4-carboxylic acid tert-butyl ester (80mg, 0.1 14mmol) in dioxane (3ml_), 10% dioxane-HCI (2mL) was added and the mixture stirred at RT for 18 hours. The reaction mass was evaporated in vacuo and the resulting solid triturated with ether to afford the title compound (HCI salt) as an off white solid (62mg 91 %).
1 H NMR (400 MHz, DMSO) : 1 .06 (t, 3H), 1.22-1 .34 (s, 6H), 2.94 (Brs, 2H), 3.01-3.07 (t, 2H), 3.32 (Brs, 2H), 3.97 (m, 2H), 4.61-4.64 (d, 2H), 4.84 (s, 2H), 6.94 (d, 1 H), 7.03 (d, 1 H), 7.32 (s, 1 H), 7.58 (s, 1 H), 8.41-8.48 (m, 3H), 9.27 (m, 1 H), 9.64 (m, 1 H), 9.79 (s, 1 H), 14.33 (s, 1 H); LCMS: Rt = 2.65 min; m/z 596.4 [M+H]+.
Example 63
{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-Dhenvn-1 H-indazol-3-yll-1 ,4,6,7-tetrahvdro-imidazor4,5- clpyridin-5-yl)-((S)-3-methyl-3,4,5,6-tetrahvdro-2H-ri ,2'lbipyrazinyl-5'-yl)-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (200 mg, 386μη"ΐοΙ) and (S)-2-methyl-piperazine-1 -carboxylic acid tert-butyl ester (155mg, 773 μηηοΙ) using the method from Example 61. After purification by HPLC Method E and deprotection using HCI/dioxan, the title compound (58 mg, 25% yield over two steps) was obtained as off- white solid (HCI-salt).
1 H NMR (400 MHz, DMSO) : 0.82 (t, 3H), 1.23-1.31 (s, 3H), 2.93 (Brs, 2H), 3.07-3.18 (m, 3H), 3.97 (Brs, 2H), 4.50-4.53 (d, 2H), 4.83 (s, 2H), 6.93-6.95 (d, 1 H), 7.03-7.06 (d, 1 H), 7.28- 7.30 (m, 1 H), 7.57 (s, 1 H), 8.37 (m, 1 H), 8.44 (s, 1 H), 8.49 (s, 1 H), 9.24 (s, 1 H), 9.40 (m, 1 H), 9.94 (s, 1 H), 14.25 (s, 1 H);
LCMS: Rt = 2.61 min; m/z 582.4 [M+H]+.
Example 64
((2S,5R)-2,5-Dimethyl-3,4,5,6-tetrahvdro-2H-ri ,2'lbipyrazinyl-5'-ylH2-r6-(2-ethyl-5-fluoro-4- hydroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahvdro-imidazo[4,5-clpyridin-5-yl)-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (100 mg, 193μη"ΐοΙ) and (2S,5R)-2,5-Dimethyl-piperazine-1-carboxylic acid tert-butyl ester (84mg, 386 μηηοΙ) using the method from Example 61 . After purification by HPLC Method E and deprotection using HCI/dioxan, the title compound (43 mg, 37% yield over two steps) was obtained as off-white solid (HCI-salt).
1 H NMR (400 MHz, DMSO) : 0.82 (t, 3H), 1.33-1 .34 (m, 6H), 2.95 (Brs, 3H), 3.1 1-3.14 (d, 1 H), 3.37 (s, 1 H), 3.51-3.62 (m, 5H), 3.83 (Brs, 2H), 4.01 (m, 1 H), 4.84 (m, 3H), 6.94-6.96 (d, 1 H), 7.03-7.06 (d, 1 H), 7.31 (Brs, 1 H), 7.58 (s, 1 H), 8.36 (s, 2H), 8.49 (s, 1 H), 9.33 (m, 1 H), 9.53 (s, 1 H), 14.33 (s, 1 H);
LCMS: Rt = 2.55 min; m/z 596.2 [M+H]+. Example 65
{2-r6-(2-Ethyl-5-fluoro-4-hvdroxy-phenyl)-1 H-indazol-3-yll-1 ,4,6,7-tetrahvdro-imidazor4,5- lPVridin-5-yl)-(3,4,5,6-tetrahvdro-2H-[1 ,2'lbipyrazinyl-5'-yl)-methanone
The title compound was prepared from (5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4- hydroxyphenyl)-1 H-indazol-3-yl)-6,7-dihydro-1 H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (200 mg, 386μη"ΐοΙ) and piperazine-1 -carboxylic acid tert-butyl ester (144mg, 773 μηηοΙ) using the method from Example 61. After purification by HPLC Method E and deprotection using HCI/dioxan, the title compound (64 mg, 29% yield over two steps) was obtained as off-white solid (HCI-salt).
1 H NMR (400 MHz, DMSO) : 1.00-1.03 (t, 3H), 2.94 (Brs, 2H), 3.22 (s, 4H), 3.93-3.95 (m, 6H), 4.84 (s, 2H), 6.94-6.96 (d, 1 H), 7.03-7.06 (d, 1 H), 7.30-7.33 (m, 1 H), 7.58 (s, 1 H), 8.42 (s, 2H), 8.50 (s, 1 H), 9.29 (Brs, 2H), 9.95 (s, 1 H), 14.30 (s, 1 H);
LCMS: Rt = 2.48 min; m/z 568.2 [M+H]+.
Preparation 1
6-Bromo-1-(tetrahvdro-pyran-2-yl)-1 H-indazole-3-carbaldehyde
To a solution of 6-bromo-1 H-indazole-3-carbaldehyde (13.97g, 61.9mmol) in DCM (150ml_) was added p-TsOH (2.36g, 12.4mmol) and the mixture was cooled to 0°C. 3,4-Dihydro-2H-pyran (8.47ml_, 92.8mmol) was added dropwise to the solution and the reaction was stirred at room temperature overnight. The reaction mixture was diluted with DCM (200ml_) and washed with a solution of saturated aqueous sodium hydrogen carbonate (500ml_). The aqueous layer was re- extracted with DCM (500ml_) and the combined organic layers were washed with brine (2 x 1 L), dried over MgS04 and concentrated in vacuo to yield a black oil. The crude material was refluxed in cyclohexane (20ml_) and filtered while hot. The filtrate was concentrated in vacuo and the residue was stirred in heptane for 48 hours. The resulting solid was collected by filtration to give the title compound (13.87g) in a 73% yield.
1H NMR (400 MHz, CDCI3) δ ppm 1 .71 -1.80 (m, 3H), 2.10-2.20 (m, 2H), 2.49-2.57 (m, 1 H), 3.76-3.82 (m, 1 H), 3.98-4.03 (m, 1 H), 5.78 (dd, 1 H), 7.46 (dd, 1 H), 7.87 (d, 1 H), 8.16 (d, 1 H), 10.22 (s, 1 H). Preparation 2
6-Bromo-1-(tetrahvdro-pyran-2-yl)-1 H-indazole-3-carbonitrile
To a solution of 6-bromo-1 -(tetrahydro-pyran-2-yl)-1 H-indazole-3-carbaldehyde (Preparation 1 , 60g, 194mmol) in MeCN (1 .5L) was added triethylamine (68.5ml_, 485mmol) and hydroxylamine hydrochloride (20g, 291 mmol). The reaction was heated at 60°C for 3 hours. The reaction was cooled to 0°C, further triethylamine (220ml_, 1.55mol) was added and TFAA (109ml_, 776mmol) was added dropwise. The reaction was allowed to warm to room temperature and stirred for 2 hours. Water (2L) was added to the reaction mixture and the resulting solid was collected by filtration. The solid was dissolved in DCM (1 L) and the resulting solution was washed with water (2 x 500ml_). The organic layer was dried over MgS04 and concentrated in vacuo to give the title compound as a white solid (58.59g) in a 99% yield.
1H NMR (400 MHz, CDCI3) δ ppm 1 .71 -1.80 (m, 3H), 2.08-2.18 (m, 2H), 2.43-2.50 (m, 1 H), 3.73-3.79 (m, 1 H), 3.92-3.96 (m, 1 H), 5.77 (dd, 1 H), 7.47 (dd, 1 H), 7.69 (d, 1 H), 7.93 (d, 1 H).
Preparation 3
4-Bromo-5-ethyl-2-fluoro-phenol
To a solution of 5-ethyl-2-fluoro-phenol (WO-2007/002313, 76.36g, 545mmol) in MeCN (2.5L) was added copper (II) bromide (361 .5g, 1 .619mol). The resulting suspension was stirred at room temperature overnight. The solvent was removed in vacuo and the residue was suspended in EtOAc (3L) and filtered through a pad of Arbocel®. The filtrate was washed with water (2L) and brine (2L), dried over MgS04 and concentrated in vacuo to furnish the title compound (1 19g) in 100% yield.
1H NMR (400 MHz, CDCI3) δ ppm 1 .19 (t, 3H), 2.86 (q, 2H), 5.20 (s, 1 H), 6.90 (d, 1 H), 7.25 (d, 1 H).
Preparation 4
[2-(4-Bromo-5-ethyl-2-fluoro-phenoxymethoxy)-ethyll-trimethyl-silane
To a solution of 4-bromo-5-ethyl-2-fluoro-phenol (Preparation 3, 80g, 365mmol) in DCM (1 L) was added DIPEA (70ml_, 401 mmol) and SEM-CI (71 mL, 401 mmol). The resulting solution was stirred at room temperature for 18 hours. The reaction mixture was washed with water (1 L), dried over MgS04 and concentrated in vacuo to yield the crude product. This material was purified by silica gel chromatography eluting with 30% DCM in heptane to give the title compound as a pale yellow oil (109.8g, 86%).
1H NMR (400 MHz, CDCI3) δ ppm 0.00 (s, 9H), 0.92-0.97 (m, 2H), 1 .19 (t, 3H), 2.67 (q, 2H), 3.77-3.81 (m, 2H), 5.22 (s, 2H), 7.08 (d, 1 H), 7.25 (d, 1 H). Preparation 5
2-r2-Ethyl-5-fluoro-4-(2-trimethylsilany
H ,3,21dioxaborolane
To a solution of [2-(4-bromo-5-ethyl-2-fluoro-phenoxymethoxy)-ethyl]-trimethyl-silane (Preparation 4, 105g, 300.6mmol) in dioxane (1 L) was added bis(pinacolato)diboron (76.4g, 300.6mmol) and KOAc (88.5g, 902mmol). The resulting suspension was degassed with nitrogen, Pd(dppf)CI2 (24.54g, 30.1 mmol) was added and the reaction was heated at reflux for 18 hours. The reaction was cooled to room temperature and the solvent was removed in vacuo. The resulting black solid was suspended in EtOAc (2L) and filtered through Arbocel®, washing with further EtOAc. The filtrate was washed with water (1.5L) and brine (1.5L), dried over MgS04 and concentrated in vacuo to yield the title compound as a black oil (155.5g, 130%) that was used crude in the next step.
1H NMR (400 MHz, CDCI3) δ ppm 0.00 (s, 9H), 0.93-0.97 (m, 2H), 1 .17 (t, 3H), 1.32 (s, 12H), 2.86 (q, 2H), 3.73-3.82 (m, 2H), 5.25 (s, 2H), 7.01 (d, 1 H), 7.47 (d, 1 H).
Preparation 6
6-[2-Ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)-phenyll-1 -(tetrahvdro-pyran-2-yl)-1 H- indazole-3-carbonitrile
To a solution of 6-bromo-1-(tetrahydro-pyran-2-yl)-1 H-indazole-3-carbonitrile (Preparation 2, 28.5g, 93mmol) and 2-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)-phenyl]-4, 4,5,5- tetramethyl-[1 ,3,2]dioxaborolane (Preparation 5, 73.8g, 1 12mmol) in dioxane (500ml_) was added a solution of potassium phosphate (59.2g, 279mmol) in water (120ml_). The mixture was degassed with nitrogen and then tetrakis (triphenylphosphine) palladium(O) (10.8g, 9.3mmol) was added. The reaction mixture was heated at 1 10°C for 18 hours. The reaction mixture was concentrated in vacuo and the residue was redissolved in EtOAc (1 L) and filtered through Arbocel®, washing with EtOAc (2 x 500ml_). The combined organic phases were concentrated in vacuo to give a brown oil. The residue was purified by column chromatography on silica gel eluting with 10% EtOAc in heptane to give the title compound as a viscous oil (37.4g) in an 81 % yield.
1H NMR (400 MHz, CDCI3) δ ppm 0.00 (s, 9H), 0.97 (t, 2H), 1.06 (t, 3H), 1 .66-1.77 (m, 3H), 2.05-2.17 (m, 2H), 2.44-2.48 (m, 3H), 3.67-3.73 (m, 1 H), 3.82 (t, 2H), 3.90-3.94 (m, 1 H), 5.28 (s, 2H), 5.77 (dd, 1 H), 6.95 (d, 1 H), 7.13 (d, 1 H), 7.25 (d, 1 H), 7.58 (s, 1 H), 7.80 (d, 1 H).
Preparation 7
6-r2-Ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)-phenyll-1 -(tetrahvdro-pyran-2-yl)-1 H- indazole-3-carboximidic acid methyl ester To a solution of 6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)-phenyl]-1-(tetrahydro- pyran-2-yl)-1 H-indazole-3-carbonitrile (Preparation 6, 37.42g, 75.6mmol) in methanol (700ml_) was added sodium methoxide (12.21 g, 226.8mmol) and the reaction mixture was then stirred at room temperature for 18 hours. The solvent was removed in vacuo and the residue was partitioned between EtOAc (1 L) and water (500ml_). The organic layer was washed with water (500ml_), dried over MgS04 and concentrated in vacuo to give the title compound as a gum (37.26g) in a 94% yield.
1H NMR (400 MHz, CDCI3) δ ppm 0.00 (s, 9H), 0.97 (t, 2H), 1.06 (t, 3H), 1 .61-1.76 (m, 3H), 2.03-2.15 (m, 2H), 2.47-2.56 (m, 3H), 3.67-3.72 (m, 1 H), 3.82 (t, 2H), 3.97-4.01 (m, 1 H), 4.03 (s, 3H), 5.28 (s, 2H), 5.71 (dd, 1 H), 6.97 (d, 1 H), 7.12 (d, 1 H), 7.15 (d, 1 H), 7.46 (s, 1 H), 8.03 (d, 1 H), 8.45 (s, 1 H).
LCMS: m/z 528 M+H+.
Preparation 8
N-(1 -Benzyl-4,4-diethoxy-piperidin-3-yl)-6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)- phenyll-1 -(tetrahvdro-pyran-2-yl)-1 H-indazole-3-carboxamidine
To a solution of 6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)-phenyl]-1-(tetrahydro- pyran-2-yl)-1 H-indazole-3-carboximidic acid methyl ester (Preparation 7, 17.15g, 32.49mmol) in ethanol (100mL) was added a solution of 1-benzyl-4,4-diethoxy-piperidin-3-ylamine (Tetrahedron, 1995, 51 , 13447-13454; 9.51 g, 34.2mmol) in ethanol (70ml_). Acetic acid (3.56ml_, 62.1 mmol) was added and the reaction mixture was heated at 50°C for 18 hours. The reaction mixture was concentrated in vacuo and the residue was partitioned between EtOAc (400ml_) and saturated sodium hydrogen carbonate aqueous solution (300ml_). The organic layer was washed with further saturated sodium hydrogen carbonate aqueous solution (300ml_). The combined aqueous layers were re-extracted with EtOAc (400ml_). The combined organic layers were dried over MgS04 and concentrated in vacuo. The crude product was purified by column chromatography on silica gel eluting with DCM:methanol:ammonia (80:20:2) to give the title compound (1 1 .31 g) in a 45% yield.
1H NMR (400MHz, CDCI3,) δ ppm 0.00 (s, 9H), 0.95-0.99 (m, 2H), 1.04-1.07 (m, 3H), 1.1 1-1 .19 (m, 6H), 1.58-1.82 (m, 4H), 1.84-1 .93 (m, 2H), 2.06-2.31 (m, 3H), 2.46-2.55 (m, 2H), 2.55-2.71 (m, 3H), 2.71 -2.85 (m, 1 H), 3.47-3.75 (m, 7H), 3.80-3.84 (m, 2H), 3.95-4.05 (m, 1 H), 5.27 (s, 2H), 5.68-5.76 (m, 1 H), 6.98-7.01 (m, 1 H), 7.1 1 -7.24 (m, 5H), 7.29-7.36 (m, 2H), 7.44-7.49 (m, 1 H), 8.1 1-8.28 (m, 1 H).
LCMS: m/z 774 M+H+.
Preparation 9 N-(1 -Benzyl-4,4-diethoxy-piperidin-3-yl)-6-(2-ethyl-5-fluoro
pyran-2-yl)-1 H-indazole-3-carboxamidine
To a solution of N-(1 -benzyl-4,4-diethoxy-piperidin-3-yl)-6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl- ethoxymethoxy)-phenyl]-1-(tetrahydro-pyran-2-yl)-1 H-indazole-3-carboxamidine (Preparation 8, 7.28g, 9.4mmol) in ethanol (32mL) was added concentrated hydrochloric acid (12M, 3.92ml_, 47mmol) and the resulting solution was allowed to stir at room temperature for 18 hours. The reaction mixture was cooled to 0°C and neutralised by dropwise addition of a saturated aqueous solution of sodium hydrogen carbonate (150ml_). The mixture was extracted with EtOAc (2 x 200ml_). The combined organic layers were washed with further saturated aqueous sodium hydrogen carbonate solution (100ml_), dried over MgS04 and concentrated in vacuo to give the title compound as a foam (6.06g).
1H NMR (400MHz, CDCI3) δ ppm 1.01-1.05 (m, 3H), 1.1 1-1.19 (m, 6H), 1.58-1 .82 (m, 3H), 1.84- 1 .93 (m, 2H), 2.06-2.22 (m, 2H), 2.23-2.35 (m, 1 H), 2.43-2.49 (m, 2H), 2.55-2.71 (m, 3H), 2.79- 2.89 (m, 1 H), 3.44-3.68 (m, 7H), 3.95-4.05 (m, 1 H), 4.17-4.26 (m, 1 H), 5.68-5.76 (m, 1 H), 6.87- 6.95 (m, 2H), 7.1 1-7.24 (m, 4H), 7.29-7.36 (m, 2H), 7.44-7.49 (m, 1 H), 8.13-8.24 (m, 1 H).
LCMS: m/z 644 M+H+.
Preparation 10
4,4-Diethoxy-3-{[6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)-phenyll-1 -(tetrahvdro- pyran-2-yl)-1 H-indazole-3-carboximidoyll-amino)-piperidine-1-carboxylic acid tert-butyl ester To a solution of 6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)-phenyl]-1-(tetrahydro- pyran-2-yl)-1 H-indazole-3-carboximidic acid methyl ester (Preparation 7, 31 .4g, 59.5mmol) in ethanol (140ml_) was added a solution of 3-amino-4,4-diethoxy-piperidine-1-carboxylic acid tert- butyl ester (US-2004/0229862, 18.02g, 62.48mmol) in ethanol (100ml_). Acetic acid (6.81 mL, 1 19mmol) was added and the reaction mixture was heated at 50°C for 18 hours. The reaction mixture was concentrated in vacuo and azeotroped with toluene (100mL) to give the title compound as a foam (54.7g).
1H NMR (400MHz, CDCI3,) δ ppm 0.03 (s, 9H), 0.96-1.00 (m, 2H), 1.05-1.08 (m, 3H), 1.17-1 .31 (m, 6H), 1.46 (s, 9H), 1 .69-1.75 (m, 2H), 1.93-2.19 (m, 4H), 2.52-2.58 (m, 2H), 3.47-3.58 (m, 2H), 3.59-3.70 (m, 4H), 3.70-3.75 (m, 4H), 3.84-3.88 (m, 2H), 3.92-4.07 (m, 3H), 5.32 (s, 2H), 5.94-5.99 (m, 1 H), 7.01 (d, 1 H), 7.21 (d, 1 H), 7.27 (d, 1 H), 7.69 (s, 1 H), 8.10 (s, 1 H).
LCMS: m/z 784 M+H+.
Preparation 11
5-Ethyl-2-fluoro-4-r3-(4,5,6,7-tetrahvdro-1 H-imidazor4,5-clpyridin-2-vn-1 H-indazol-6-yll-phenol dihvdrochloric acid salt To a solution of 4,4-diethoxy-3-{[6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)- phenyl]-1 -(tetrahydro-pyran-2-yl)-1 H-indazole-3-carboximidoyl]-amino}-piperidine-1-carboxylic acid tert-butyl ester (Preparation 10, 46.65g, 55.27mmol) in ethanol (200ml_) was added concentrated hydrochloric acid (12M, 100ml_, 1.2mol) and the resulting solution was stirred at room temperature for 18 hours. The reaction mixture was concentrated in vacuo and azeotroped with toluene (100ml_) and DCM (2 x 100ml_). The resulting gum was dried under vacuum for 3 hours. The crude material was triturated in MeCN (300ml_) and the resulting solid was collected by filtration. The solid was dissolved in ethanol (250ml_) and treated with concentrated hydrochloric acid (12M, 77.2ml_, 927mmol). The resulting solution was heated at 40°C for 18 hours, then at 50°C for 2 hours. The solvents were removed in vacuo and the resulting gum was triturated in MeCN (200ml_). The solid which formed was collected by filtration, washed with further MeCN (200ml_) and dried under vacuum to give the title compound as a beige solid (23.5g, 88% yield, dihydrochloride salt).
1H NMR (400 MHz, CD3OD) δ ppm 1.05 (t, 3H), 2.53 (q, 2H), 3.22 (t, 2H), 3.73 (t, 2H), 4.55 (s, 2H), 6.90-6.96 (m, 2H), 7.35 (d, 1 H), 7.58 (s, 1 H), 8.21 (d, 1 H).
LCMS: m/z 378 M+H+
Preparation 12
1 - Bromo-2-ethyl-5-fluoro-4-methoxy-benzene
To a solution of 4-ethyl-1-fluoro-2-methoxy-benzene (WO-2010/090537, 12.2g, 79.1 mmol) in MeCN (150ml_) was added a solution of NBS (14.4g, 80.7mmol) in MeCN (50ml_). The resulting solution was stirred at room temperature for 18 hours. The solvent was removed in vacuo and the residue was diluted with diethyl ether (150ml_). Precipitated solid was removed by filtration and the filtrate was washed with sodium sulfite aqueous solution (100ml_) and brine (100ml_), dried over MgS04 and concentrated in vacuo to give the title compound as a yellow oil (18g) in a 97% yield.
1H NMR (400 MHz, CDCI3) δ ppm 1 .21 (t, 3H), 2.69 (q, 2H), 3.87 (s, 3H), 6.82 (d, 1 H), 7.24 (d, 1 H).
Preparation 13
2- (2-Ethyl-5-fluoro-4-methoxy-phenyl)-4,4,5,5-tetramethyl-ri,3,21dioxaborolane
To a solution of 1-bromo-2-ethyl-5-fluoro-4-methoxy-benzene (Preparation 12, 18.0g, 77.2mmol) in dioxane (100ml_) were added SPhos (4.12g, l O.Ommol), 4,4,5, 5-tetramethyl-1 ,3,2- dioxaborolane (14.8g, 1 16mmol) and triethylamine (10.7ml_, 77.2mmol). The reaction mixture was degassed with nitrogen prior to the addition of dichlorobis(acetonitrile)palladium (II) (801 mg, 3.09mmol). The reaction mixture was then heated at 1 10°C for 18 hours, cooled to room temperature and filtered through a pad of Celite, washing with EtOAc. The solvent was removed in vacuo and the residue was redissolved in EtOAc (30ml_) and washed with water (30ml_). The organic layer was dried over sodium sulfate and concentrated in vacuo. The crude material was triturated with methanol and the resulting solid was collected by filtration to give the title compound as a beige solid (13.8g) in a 64% yield.
1H NMR (400 MHz, CDCI3) δ ppm 1.18 (t, 3H), 1.32 (s, 12H), 2.87 (q, 2H), 3.89 (s, 3H), 6.76 (d, 1 H), 7.46 (d, 1 H).
LCMS: m/z 281 M+H+.
Preparation 14
6-(2-Ethyl-5-fluoro-4-methoxy-phenyl)-1 -(tetrahydro-pyran-2-yl)-1 H-indazole
To a solution of 6-bromo-1-(tetrahydro-pyran-2-yl)-1 H-indazole (WO-2010/027500, 2.25g, 8.0mmol) and 2-(2-ethyl-5-fluoro-4-methoxy-phenyl)-4,4,5,5-tetramethyl-[1 ,3,2]dioxaborolane (Preparation 13, 2.24g, 8.0mmol) in dioxane (32ml_) was added potassium phosphate (5.1 g, 24mmol) as a solution in water (8ml_). The reaction mixture was degassed with nitrogen and treated with tetrakis (triphenylphosphine) palladium(O) (1.85g, 1 .6mmol). The reaction mixture was heated at 1 10°C for 18 hours, cooled to room temperature and filtered through a pad of Arbocel®, washing with EtOAc (2 x 100ml_). The filtrate was washed with water (100ml_), dried over MgS04 and concentrated in vacuo. The crude material was purified by column chromatography on silica gel eluting with 10% EtOAc in heptane to give the title compound as a white solid (2.024g) in a 71 % yield.
1H NMR (400 MHz, CDCI3) δ ppm 1.12 (t, 3H), 1.62-1 .81 (m, 3H), 2.07-2.17 (m, 2H), 2.54-2.63 (m, 3H), 3.70-3.76 (m, 1 H), 3.95 (s, 3H), 4.01 -4.07 (m, 1 H), 5.71 (dd, 1 H), 6.90 (d, 1 H), 7.01 (d, 1 H), 7.09 (dd, 1 H), 7.46 (s, 1 H), 7.71 (d, 1 H), 8.05 (s, 1 H).
Preparation 15
6-(2-Ethyl-5-fluoro-4-methoxy-phenyl)-1 H-indazole
To a solution of 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1 -(tetrahydro-pyran-2-yl)-1 H-indazole (Preparation 14, 1.8g, 5.07mmol) in methanol (100ml_) was added concentrated hydrochloric acid (12M) and the resulting solution was heated at 60°C overnight, cooled to room temperature and concentrated in vacuo. The residue was redissolved in EtOAc (50ml_) and washed with saturated sodium hydrogen carbonate aqueous solution (50ml_). The organic layer was dried over MgS04 and concentrated in vacuo to yield the title product (1.465g) in 95% yield.
1H NMR (400 MHz, CDCI3) δ ppm 1 .09 (t, 3H), 2.56 (q, 2H), 3.95 (s, 3H), 6.90 (d, 1 H), 6.98 (d, 1 H), 7.10 (dd, 1 H), 7.38 (s, 1 H), 7.76 (d, 1 H), 8.14 (br s, 1 H), 10.69 (br s, 1 H)
LCMS: m/z 271 M+H+. Preparation 16
6-(2-Ethyl-5-fluoro-4-methoxy-phenyl)-3-iodo-1 H-indazole
To a solution of 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1 H-indazole (Preparation 15, 1.46g, 5.4mmol) in DMF (20ml_) was added KOH (1.14g, 20.3mmol) and the mixture was stirred for 5 minutes. A solution of iodine (2.75g, 10.8mmol) in DMF (5ml_) was slowly added and the reaction was stirred at room temperature for 30 minutes. The reaction mixture was diluted with water (100ml_) and extracted with EtOAc (100ml_). The organic layer was washed with water (2 x 100ml_) and saturated sodium metabisulfite aqueous solution (100ml_), dried over MgS04 and concentrated in vacuo to furnish the title compound (1.94g) in a 91 % yield.
1H NMR (400 MHz, CDCI3) δ ppm 1 .08 (t, 3H), 2.55 (q, 2H), 3.95 (s, 3H), 6.90 (d, 1 H), 6.97 (d, 1 H), 7.16 (dd, 1 H), 7.37 (s, 1 H), 7.52 (d, 1 H), 10.64 (br s, 1 H).
LCMS: m/z 397 M+H+.
Preparation 17
6-(2-Ethyl-5-fluoro-4-methoxy-phenyl)-3-iodo-1 -(tetrahydro-pyran-2-yl)-1 H-indazole
To a solution of 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-3-iodo-1 H-indazole (Preparation 16, 1 .94g, 4.9mmol) in DCM (10ml_) was added p-TsOH (187mg, 982μη"ΐοΙ) and the mixture was cooled to 0°C. 3,4-Dihydro-2H-pyran (660μΙ_, 7.4mmol) was added dropwise to the solution and the reaction was stirred at room temperature overnight. The reaction mixture was diluted with DCM (5ml_) and washed with saturated sodium hydrogen carbonate aqueous solution (20ml_). The organic layer was dried over MgS04 and concentrated in vacuo to yield a black oil. The residue was purified by column chromatography (Biotage SNAP 10g) eluting with a gradient of 20% EtOAc in heptane to give the title compound as a colourless oil (2.09g) in an 89% yield. 1H NMR (400 MHz, CDCI3) δ ppm 1.1 1 (t, 3H), 1.60-1 .64 (m, 1 H), 1.72-1.76 (m, 2H), 2.02-2.10 (m, 2H), 2.50-2.58 (m, 3H), 3.69-3.73 (m, 1 H), 3.95 (s, 3H), 4.01-4.05 (m, 1 H), 5.68 (dd, 1 H), 6.90 (d, 1 H), 7.10 (d, 1 H), 7.15 (dd, 1 H), 7.42-7.46 (m, 2H).
LCMS: m/z 481 M+H+.
Preparation 18
6-(2-Ethyl-5-fluoro-4-methoxy-phenyl)-1-(tetrahvdro-pyran-2-yl)-3-trimethylstannanyl-1 H- indazole
To a solution of 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-3-iodo-1-(tetrahydro-pyran-2-yl)-1 H- indazole (Preparation 17, 2.09g, 4.35mmol) in toluene (24ml_) was added 1 ,1 ,1 ,2,2,2- hexamethyl-distannane (1 ml_, 4.79mmol) followed by tetrakis (triphenylphosphine) palladium(O) (100mg, 87μη"ΐοΙ). The reaction mixture was degassed with nitrogen and heated at 100°C for 18 hours. The reaction was then cooled to room temperature and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with 10% EtOAc in heptane to give the title compound as a colourless oil (1.47g) in a 65% yield.
1H NMR (400 MHz, CDCI3) δ ppm 0.47 (t, 9H), 1.12 (t, 3H), 1.60-1 .64 (m, 1 H), 1.73-1 .78 (m, 2H), 2.05-2.18 (m, 2H), 2.57 (q, 2H), 2.59-2.67 (m, 1 H), 3.70-3.76 (m, 1 H), 3.95 (s, 3H), 4.06- 4.09 (m, 1 H), 5.74 (dd, 1 H), 6.91 (d, 1 H), 7.00-7.06 (m, 2H), 7.48 (s, 1 H), 7.68 (s, 1 H).
LCMS: m/z 519 M+H+.
Preparation 19
6,7-Dihydro-4H-imidazo[4,5-clpyridine-1 ,5-dicarboxylic acid di-tert-butyl ester
To a solution of 4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridine (21 .3g, 109mmol) in methanol (250ml_) was added DIPEA (47.3ml_, 272mmol) and a solution of di-tert-butyl dicarbonate (59.3g, 272mmol) in methanol (130ml_). The reaction mixture was stirred at room temperature for 18 hours and concentrated in vacuo to yield an oil. The residue was redissolved in EtOAc (500ml_) and the resulting solution was washed with water (500ml_), dried over MgS04 and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with 30% EtOAc in DCM to yield the title compound as a white solid (26.85g) in 76% yield.
1H NMR (400 MHz, CDCI3) δ ppm 1.48 (s, 9H), 1 .60 (s, 9H), 2.61 -2.92 (m, 2H), 3.62-3.72 (m, 2H), 4.59-4.65 (m, 2H), 7.98 (s, 1 H).
Preparation 20
1 ,4,6,7-Tetrahydro-imidazor4,5-clpyridine-5-carboxylic acid tert-butyl ester
To a solution of 6, 7-dihydro-4H-imidazo[4,5-c]pyridine-1 ,5-dicarboxylic acid di-tert-butyl ester (Preparation 19, 26.8g, 82.9mmol) in methanol (210ml_) was added 1 M sodium hydroxide aqueous solution (170ml_, 170mmol). The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with 10% citric acid aqueous solution (250ml_), basified to pH8 and extracted with DCM (2 x 500ml_). The combined organic layers were dried over MgS04 and concentrated in vacuo to give the title compound as a brown foam (18.5g) in a 97% yield.
1H NMR (400 MHz, CDCI3) δ ppm 1.47 (s, 9H), 2.64-2.72 (m, 2H), 3.68-3.75 (m, 2H), 4.43-4.53 (m, 2H), 7.52 (s, 1 H).
Preparation 21
2-lodo-1 ,4,6,7-tetrahydro-imidazo[4,5-clpyridine-5-carboxylic acid tert-butyl ester
To a solution of 1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester (Preparation 20, 18.g, 80.62mmol) in THF (300ml_) was added NIS (27.2g, 121 mmol). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with EtOAc (800ml_), washed with sodium thiosulfate aqueous solution (3 x 700ml_) and brine (500ml_), dried over MgS04 and concentrated in vacuo to give the title compound as a yellow solid (18.25g) in a 64.8% yield.
1H NMR (400 MHz, CDCI3) δ ppm 1.46 (s, 9H), 2.66-2.74 (m, 2H), 3.64-3.75 (m, 2H), 4.42-4.54 (m, 2H).
Preparation 22
2-lodo-1-(2-trimethylsilanyl-ethoxymethyl)-1 ,4,6,7-tetrahydro-imidazo[4,5-clpyridine-5-carboxylic acid tert-butyl ester
To a solution of 2-iodo-1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester (Preparation 21 , 17.25g, 49.4mmol) in THF (250ml_) was added NaH (60% in paraffin oil, 2.08g, 51.9mmol) and the resulting solution was stirred at room temperature for 1.5 hours. The reaction mixture was cooled to 0°C and SEM-CI (9.18mL, 51.9mmol) was added dropwise. The reaction was stirred at room temperature for 18 hours, cooled to 0°C and quenched carefully with water (500ml_). The resulting solution was extracted with EtOAc (2 x 500ml_) and the combined organics layers were dried over MgS04, filtered through a pad of silica and concentrated in vacuo to give the title compound (23.4g) in a 99% yield.
1H NMR (400 MHz, CDCI3) δ ppm 0.00 (s, 9H), 0.90-0.95 (m, 2H), 1.47 (s, 9H), 2.64-2.76 (m, 2H), 3.54 (t, 2H), 3.63-3.75 (m, 2H), 4.43-4.57 (m, 2H), 5.15 (s, 2H).
Preparation 23
2-r6-(2-Ethyl-5-fluoro-4-methoxy-Dhenvn-1-(tetrahvdro-Dyran-2-vn-1 H-indazol-3-yll-1 -(2- trimethylsilanyl-ethoxymethyl)-1 ,4,6,7-tetrahvdro-imidazor4,5-clpyridine-5-carboxylic acid tert- butyl ester
To a solution of 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1 -(tetrahydro-pyran-2-yl)-3- trimethylstannanyl-1 H-indazole (Preparation 18, 735mg, 1 .53mmol) in toluene (6ml_) was added 2-iodo-1 -(2-trimethylsilanyl-ethoxymethyl)-1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester (Preparation 22, 805mg, 1 .68mmol), copper (I) iodide (60mg, 310μη-ιοΙ) and tetrakis (triphenylphosphine) palladium(O) (173mg, Ι δΟμηηοΙ). The reaction mixture was degassed with nitrogen, heated at 100°C for 18 hours, cooled to room temperature and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with 20% EtOAc in toluene to give the title compound as a foam (801 mg) in a 74% yield. 1H NMR (400 MHz, CDCI3) δ ppm -0.12 (s, 9H), 0.81-0.90 (m, 2H), 1 .10 (t, 3H), 1 .50 (s, 9H), 1 .67-1.83 (m, 3H), 2.12-2.20 (m, 2H), 2.57 (q, 2H), 2.58-2.60 (m, 1 H), 2.81 -2.84 (m, 2H), 3.49- 3.56 (m, 2H), 3.72-3.82 (m, 3H), 3.95 (s, 3H), 4.01-4.04 (m, 1 H), 4.60-4.63 (m, 2H), 5.74-5.76 (m, 1 H), 5.83-5.86 (m, 1 H), 5.98-6.00 (m, 1 H), 6.90 (d, 1 H), 7.03 (d, 1 H), 7.19 (dd, 1 H), 7.46 (s, 1 H), 8.42 (d, 1 H). LCMS: m/z 706 M+H+.
Preparation 24
2-r6-(2-Ethyl-5-fluoro-4-methoxy-DhenylV1 H-indazol-3-yll-4,5,6J-tetrahvdro-1 H-imid
clpyridine trihydrochloride salt
To a solution of 2-[6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1 -(tetrahydro-pyran-2-yl)-1 H-indazol-3- yl]-1 -(2-trimethylsilanyl-ethoxymethyl)-1 ,4,6J-tetrahydro-imidazo[4,5-c]pyridine-5-carboxyli^ acid tert-butyl ester (Preparation 23, 801 mg, 1 .13mmol) in methanol (20mL) was added concentrated hydrochloric acid (12M, 8ml_) and the resulting solution was heated at 60°C for 18 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo to furnish the title compound (739mg).
1H NMR (400 MHz, CD3OD) δ ppm 1 .04 (t, 3H), 2.55 (q, 2H), 3.25-3.26 (m, 2H), 3.62-3.65 (m, 2H), 3.89 (s, 3H), 4.48-4.52 (m, 2H), 6.94 (d, 1 H), 7.02 (d, 1 H), 7.30-7.32 (m, 1 H), 7.56 (s, 1 H), 8.27-8.29 (m, 1 H).
LCMS: m/z 392 M+H+.
Preparation 25
5-Ethyl-2-fluoro-4-r3-(4,5,6,7-tetrahvdro-1 H-imidazor4,5-clpyridin-2-yl)-1 H-indazol-6-yll-phenol trihydrobromide salt
A 1 M solution of boron tribromide in DCM (4.54ml_, 4.54mmol) was added dropwise to a solution of 2-[6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1 H-indazol-3-yl]-4,5,6,7-tetrahydro-1 H- imidazo[4,5-c]pyridine (Preparation 24, 739mg, 1 .13mmol) in DCM (10ml_) at 0°C. The resulting solution was stirred at room temperature for 18 hours. Further boron tribromide (4.54ml_, 4.54mmol) was added dropwise and the reaction was allowed to stir at room temperature for 5 hours. Precipitated solid was collected by filtration, washed with tBME, then triturated with EtOAc to yield the title compound as the trihydrobromide salt (665mg) in a 94% yield.
1H NMR (400 MHz, CD3OD) δ ppm 1 .05 (t, 3H), 2.52 (q, 2H), 3.25-3.26 (m, 2H), 3.75-3.76 (m, 2H), 4.60-4.61 (m, 2H), 6.89-6.96 (m, 2H), 7.32-7.41 (m, 1 H), 7.58-7.59 (m, 1 H), 8.22-8.23 (m, 1 H).
LCMS: m/z 378 M+H+. Preparation 26
4,5,7,8-Tetrahydro-imidazor4,5-dlazepine-1 ,6-dicarboxylic acid di-tert-butyl ester
To a solution of 1 ,4,5,6,7,8-Hexahydro-imidazo[4,5-d]azepine (WO-2000/063208; 5.0g, 23.5mmol) in methanol (60mL) was added DIPEA (5.6mL, 59.6mmol) and a solution of BOC- anhydride (13.07g, 59.6mmol) in methanol (30mL). The reaction mixture was stirred at room temperature for 18 hours and concentrated in vacuo to yield an oil. The residue was redissolved in DCM (250ml_) and the resulting solution was washed with water (100ml_) and saturated aqueous ammonium chloride solution (100ml_), dried over MgS04 and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with 50% EtOAc in heptane to yield the title compound as a brown oil (6.87g) in 85% yield.
1H NMR (400 MHz, CDCI3) δ ppm 1.40 (s, 9H), 1 .53 (s, 9H), 2.84-2.87 (m, 2H), 3.10-3.12 (m, 2H), 3.50-3.62 (m, 4H), 7.87 (s, 1 H).
Preparation 27
4,5,7,8-Tetrahydro-1 H-imidazo[4,5-dlazepine-6-carboxylic acid tert-butyl ester
To a solution of 4,5,7, 8-tetrahydro-imidazo[4,5-d]azepine-1 ,6-dicarboxylic acid di-tert-butyl ester (Preparation 26, 6.87g, 20.37mmol) in methanol (60ml_) was added an aqueous 1 M solution of sodium hydroxide (40.7ml_, 40.7mmol). The resulting mixture was stirred at room temperature for 2 hours and then concentrated in vacuo. The residue was partitioned between DCM (100ml_) and water (100ml_). The organic layer was dried over MgS04 and concentrated in vacuo to give the title compound as a brown foam (4.8g) in a 99% yield.
1H NMR (400 MHz, CDCI3) δ ppm 1.46 (s, 9H), 2.78-2.83 (m, 4H), 3.56-3.62 (m, 4H), 7.40 (s, 1 H).
Preparation 28
2-lodo-4,5,7,8-tetrahvdro-1 H-imidazor4,5-dlazepine-6-carboxylic acid tert-butyl ester
To a solution of 4,5,7,8-tetrahydro-1 H-imidazo[4,5-d]azepine-6-carboxylic acid tert-butyl ester (Preparation 27, 4.8g, 20.23mmol) in THF (60ml_) was added NIS (4.78g, 21.24mmol). The reaction was stirred at room temperature for 18 hours and the solvent was then removed in vacuo. The residue was dissolved in EtOAc (200ml_) and the resulting solution was washed with sodium thiosulfate solution (150ml_). The aqueous layer was re-extracted with EtOAc (150ml_) and the combined organic layers were washed with brine (150ml_), dried over MgS04 and concentrated in vacuo to give the title compound as a tan solid (6.14g) in an 84% yield.
1H NMR (400 MHz, CDCI3) δ ppm 1.46 (s, 9H), 2.79-2.87 (m, 4H), 3.53-3.59 (m, 4H).
LCMS: m/z 364 M+H+.
Preparation 29
2-lodo-1-(2-trimethylsilanyl-ethoxymethyl)-4,5,7,8-tetrahvdro-1 H-imidazor4,5-dlazepine-6- carboxylic acid tert-butyl ester
To a solution of 2-iodo-4,5,7,8-tetrahydro-1 H-imidazo[4,5-d]azepine-6-carboxylic acid tert-butyl ester (Preparation 28, 2.2g, 6.06mmol) in THF (35ml_) was added NaH (60% in paraffin oil, 254mg, 6.36mmol) and the resulting solution was stirred at room temperature for 1.5 hours. The reaction mixture was cooled to 0°C and SEM-CI (1.13mL, 6.36mmol) was added dropwise. The reaction mixture was stirred at room temperature for 18 hours and then cooled to 0°C and quenched carefully with water (100ml_). The resulting solution was extracted with EtOAc (2 x 100ml_) and the combined organic layers were dried over MgS04 and concentrated in vacuo. The residue was purified by column chromatography (Biotage SNAP 100g) eluting with 40% EtOAc in DCM to give the title compound (2.34g) in a 78% yield.
1H NMR (400 MHz, CDCI3) δ ppm -0.01 (s, 9H), 0.89-0.93 (m, 2H), 1 .46 (s, 9H), 2.82-2.92 (m, 4H), 3.54-3.66 (m, 6H), 5.16 (s, 2H).
LCMS: m/z 494 M+H+.
Preparation 30
2-r6-(2-Ethyl-5-fluoro-4-methoxy-phenyl)-1-(tetrahvdro-pyran-2-yl)-1 H-indazol-3-yll-1 -(2- trimethylsilanyl-ethoxymethyl)-4,5,7,8-tetrahydro-1 H-imidazo[4,5-dlazepine-6-carboxylic acid tert-butyl ester
To a solution of 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1 -(tetrahydro-pyran-2-yl)-3- trimethylstannanyl-1 H-indazole (Preparation 18, 735mg, 1 .53mmol) in toluene (6ml_) was added 2-iodo-1 -(2-trimethylsilanyl-ethoxymethyl)-4,5,7,8-tetrahydro-1 H-imidazo[4,5-d]azepine-6- carboxylic acid tert-butyl ester (Preparation 29, 829mg, 1 .68mmol), copper (I) iodide (60mg, 310μmol) and tetrakis (triphenylphosphine) palladium(O) (173mg, Ι δΟμηηοΙ). The reaction mixture was degassed with nitrogen, heated at 100°C for 18 hours, cooled to room temperature and concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with 20% EtOAc in toluene to give the title compound as a foam (633mg) in a 57% yield. 1H NMR (400 MHz, CDCI3) δ ppm -0.13 (s, 9H), 0.80-0.84 (m, 2H), 1 .09 (t, 3H), 1 .50 (s, 9H), 1 .65-1.84 (m, 3H), 2.10-2.18 (m, 2H), 2.56 (q, 2H), 2.58-2.64 (m, 1 H), 2.91 -3.08 (m, 4H), 3.50- 3.54 (m, 2H), 3.63-3.76 (m, 5H), 3.95 (s, 3H), 3.99-4.04 (m, 1 H), 5.74 (dd, 1 H), 5.83-5.88 (m, 1 H), 5.97-6.03 (m, 1 H), 6.90 (d, 1 H), 7.03 (d, 1 H), 7.18 (dd, 1 H), 7.45 (s, 1 H), 8.40-8.43 (m, 1 H). LCMS: m/z 720 M+H+.
Preparation 31
2-r6-(2-Ethyl-5-fluoro-4-methoxy-phenyl)-1 H-indazol-3-yll-1 ,4,5,6,7,8-hexahvdro-imidazor4,5- dlazepine trihvdrochloride salt
To a solution of 2-[6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1 -(tetrahydro-pyran-2-yl)-1 H-indazol-3- yl]-1 -(2-trimethylsilanyl-ethoxymethyl)-4,5,7,8-tetrahydro-1 H-imidazo[4,5-d]azepine-6-carboxylic acid tert-butyl ester (Preparation 30, 633mg, 879μη"ΐοΙ) in methanol (20ml_) was added concentrated hydrochloric acid (12M, 8ml_) and the resulting solution was heated at 60°C for 18 hours. A further amount of concentrated hydrochloric acid (12M, 4ml_) was added and the reaction mixture was heated at 60°C for a further 18 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo to furnish the title compound (410mg).
1H NMR (400 MHz, CD3OD) δ ppm 1 .07 (t, 3H), 2.60 (q, 2H), 3.35-3.37 (m, 4H), 3.62-3.63 (m,
4H), 3.93 (s, 3H), 6.99 (d, 1 H), 7.07 (d, 1 H), 7.35 (d, 1 H), 7.59 (s, 1 H), 8.24 (m, 1 H).
LCMS: m/z 406 M+H+.
Preparation 32
5-Ethyl-2-fluoro-4-[3-(1 ,4,5,6,7,8-hexahvdro-imidazo[4,5-dlazepin-2-yl)-1 H-indazol-6-yll-phenol trihvdrobromide salt
A 1 M solution of boron tribromide in DCM (3.18ml_, 3.18mmol)was added dropwise to a solution of 2-[6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1 H-indazol-3-yl]-1 ,4,5,6,7,8-hexahydro-imidazo[4,5- d]azepine (Preparation 31 , 410mg, 796μη"ΐοΙ) in DCM (10ml_) at 0°C. The resulting solution was stirred at room temperature for 18 hours. The precipitated solid was collected by filtration, washed with tBME, then triturated with EtOAc to yield the title compound (380mg) in a 75% yield.
1H NMR (400 MHz, CD3OD) ppm 1 .05 (t, 3H), 2.52 (q, 2H), 3.36-3.39 (m, 4H), 3.63-3.66 (m, 4H), 6.89-6.96 (m, 2H), 7.34 (d, 1 H), 7.57 (s, 1 H), 8.22 (d, 1 H).
LCMS: m/z 392 M+H+.
Preparation 33
(2-Bromo-4-fluoro-5-methoxy-phenyl)-methanol
To a solution of (4-fluoro-3-methoxy-phenyl)-methanol (10.0g, 64.04mmol) in MeCN (160ml_) was added a solution of NBS (1 1 .4g, 64.04mmol) in MeCN (50ml_) and the resulting mixture was stirred at room temperature for 18 hours. The reaction mixture was concentrated in vacuo and the residue was suspended in diethyl ether (200ml_). Solid material was removed by filtration and washed with further diethyl ether. The filtrate was washed with water (200ml_) and brine (100mL), dried over MgS04 and concentrated in vacuo to give the title compound as a white solid (14.4g) in a 96% yield.
1H NMR (400 MHz, CDCI3) δ ppm 1 .94 (t, 1 H), 3.90 (s, 3H), 4.70 (d, 2H), 7.14 (d, 1 H), 7.27 (d, 1 H).
Preparation 34
1 -Bromo-2-bromomethyl-5-fluoro-4-methoxy-benzene
Phosphorus tribromide (1 1 .56ml_, 122.5mmol)was added to a solution of (2-bromo-4-fluoro-5- methoxy-phenyl)-methanol (Preparation 33, 14.4g, 61 .26mmol) in DCM (235ml_) at 0°C. The reaction was allowed to warm to room temperature and stirred at that temperature for 18 hours. The reaction mixture was cooled to 0°C and quenched by slow addition of saturated sodium hydrogen carbonate aqueous solution until effervescence had ceased. The layers were separated and the aqueous layer was extracted with DCM (2 x 100ml_). The combined organic layers were dried over MgS04 and concentrated in vacuo to give the title compound as a white solid (17.48g) in a 96% yield.
1H NMR (400 MHz, CDCI3) δ ppm 3.89 (s, 3H), 4.55 (s, 2H), 7.04 (d, 1 H), 7.29 (d, 1 H). Preparation 35
1 - Bromo-5-fluoro-4-methoxy-2-(2,2,2-trifluoro-ethyl)-benzene
To a solution of 1-bromo-2-bromomethyl-5-fluoro-4-methoxy-benzene (Preparation 34, 10.84g, 36.4mmol) in DMF (80ml_) was added copper (I) iodide (1 .746g, 9.09mmol) and the solution was degassed with nitrogen. To this solution was added difluoro-fluorosulfonyl-acetic acid methyl ester (1 1.57ml_, 90.9mmol) and the resulting reaction mixture was heated at 120°C for 4 hours. The reaction mixture was cooled to 0°C, diluted with EtOAc (60ml_) and stirred for 10 minutes at 0°C. A solution of ammonium hydroxide (60ml_) was added dropwise and the mixture was stirred as it warmed from 0°C to room temperature over 20 minutes. Ethyl acetate (200ml_) and water (100mL) were added and the layers were separated. The aqueous layer was further extracted with EtOAc (2 x 100mL). The combined organic layers were washed with water (100mL) and brine (100ml_), dried over Na2S04 and concentrated in vacuo. The crude residue was purified by column chromatography on silica gel eluting with 20% EtOAc in heptane to give the title compound as a yellow solid (7.356g) in a 70% yield.
1H NMR (400 MHz, CDCI3) δ ppm 3.56 (q, 2H), 3.89 (s, 3H), 6.94 (d, 1 H), 7.32 (d, 1 H).
LCMS: m/z 288 M+H+.
Preparation 36
2- r5-Fluoro-4-methoxy-2-(2,2,2-trifluoro-ethylVphenyll-4,4,5,5-tetramethyl-1 ,3,2ldioxaborolane To a solution of 1-bromo-5-fluoro-4-methoxy-2-(2,2,2-trifluoro-ethyl)-benzene (Preparation 35, 7.07g, 26.82mmol) in dioxane (100ml_) was added 4,4,5,5,4',4',5',5'-octamethyl- [2,2']bi[[1 ,3,2]dioxaborolanyl] (8.17g, 32.18mmol) and KOAc (7.9g, 80.46mmol). The mixture was degassed with nitrogen prior to the addition of [1 ,1 '-bis(diphenylphosphino)ferrocene]- dichloropalladium(ll) (2.3g, 2.68mmol). The reaction mixture was stirred at 1 10°C for 18 hours, then cooled to room temperature and concentrated in vacuo. The residue was dissolved in methanol and filtered through Arbocel®, washing with methanol. The filtrate was concentrated in vacuo and then partitioned between EtOAc (200ml_) and water (200ml_). The aqueous layer was extracted with further EtOAc (2 x 100mL). The combined organic layers were washed with water (200ml_) and brine (150ml_), dried over Na2S04 and concentrated in vacuo to give the title compound as an oil (8.96g) in a 100% yield. 1H NMR (400 MHz, CDCI3) δ ppm 1 .31 (s, 12H), 3.78 (q, 2H), 3.95 (s, 3H), 6.85 (d, 1 H), 7.53 (d, 1 H).
Preparation 37
6-[5-Fluoro-4-methoxy-2-(2,2,2-trifluoro-ethyl)-phenyll-1 -(tetrahydro-pyran-2-yl)-1 H-indazole-3- carbonitrile
To a solution of 6-bromo-1-(tetrahydro-pyran-2-yl)-1 H-indazole-3-carbonitrile (Preparation 2, 3.99g, 13.03mmol) and 2-[5-fluoro-4-methoxy-2-(2!2!2-trifluoro-ethyl)-phenyl]-4!4!5,5- tetramethyl-[1 ,3,2]dioxaborolane (Preparation 36, 7.46g, 15.63mmol) in dioxane (60ml_) was added a solution of potassium phosphate (18.8g, 39.09mmol) in water (12ml_). The mixture was degassed with nitrogen, treated with tetrakis (triphenylphosphine) palladium(O) (3.01 g, 2.6mmol) and heated at 1 10°C for 18 hours. The reaction mixture was concentrated in vacuo and the residue was redissolved in EtOAc (500ml_) and filtered through Arbocel®, washing with EtOAc (2 x 500ml_). The combined organic phases were washed with water (300ml_), dried over MgS04 and concentrated in vacuo to give a brown oil. The residue was purified by column chromatography on silica gel, eluting with 25% EtOAc in heptanes, to give the title compound (1.737g) in a 31 % yield.
1H NMR (400 MHz, CDCI3) δ ppm 1 .68-1.80 (m, 3H), 2.1 1 -2.17 (m, 2H), 2.45-2.53 (m, 1 H),
3.27- 3.41 (m, 3H), 3.74 (m, 1 H), 3.96 (s, 3H), 5.80 (dd, 1 H), 7.06 (m, 2H), 7.24 (m, 1 H), 7.84 (s, 1 H), 7.87 (d, 1 H).
Preparation 38
6-r5-Fluoro-4-methoxy-2-(2,2,2-trifluoro-ethyl)-phenyll-1 -(tetrahvdro-pyran-2-yl)-1 H-indazole-3- carboximidic acid methyl ester
To a solution of 6-[5-fluoro-4-methoxy-2-(2,2,2-trifluoro-ethyl)-phenyl]-1-(tetrahydro-pyran-2-yl)- 1 H-indazole-3-carbonitrile (Preparation 37, 1 .737g, 4.00mmol) in methanol (40ml_) was added sodium methoxide (648mg, 12.0mmol) and the reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was partitioned between EtOAc (50ml_) and water (50ml_) and the aqueous layer was extracted with further EtOAc (2 x 50ml_). The combined organic layers were dried over MgS04 and concentrated in vacuo to give the title compound as an oily solid (1.64g) in an 88% yield.
1H NMR (400 MHz, CDCI3) δ ppm 1 .63-1.78 (m, 3H), 2.07-2.18 (m, 2H), 2.53-2.61 (m, 1 H),
3.28- 3.42 (m, 3H), 3.96 (s, 3H), 4.00-4.04 (m, 1 H), 4.07 (s, 3H), 5.74 (dd, 1 H), 7.05 (d, 1 H), 7.09 (d, 1 H), 7.14 (dd, 1 H), 7.52 (s, 1 H), 8.10 (d, 1 H).
Preparation 38 2-{6-r5-Fluoro-4-methoxy-2-(2,2,2-trifluoro-ethvn-Dhenyll-1 H-indazol-3-yl .5,6J-tetrahvd imidazor4,5-clpyridine trihydrochloride salt
To a solution of 6-[5-fluoro-4-methoxy-2-(2,2,2-trifluoro-ethyl)-phenyl]-1-(tetrahydro-pyran-2-yl)- 1 H-indazole-3-carboximidic acid methyl ester (Preparation 37, 1.64g, 3.78mmol) in ethanol (5mL) was added a solution of 3-amino-4,4-diethoxy-piperidine-1-carboxylic acid tert-butyl ester (US-2004/0229862, 1.15g, 3.97mmol) in ethanol (7.5mL). Acetic acid (430μΙ_, 7.56mmol) was added and the reaction mixture was heated at 50°C for 18 hours and then concentrated in vacuo to give a brown oil. The oil was dissolved in ethanol (15ml_) and the resulting solution was treated with concentrated hydrochloric acid (12M, 4.75ml_, 56.7mmol) and then heated at 80°C for 18 hours. The solvent was removed in vacuo to yield the title compound (2.03g) in a 97% yield.
1H NMR (400 MHz, CD3OD) δ ppm 3.20-3.26 (m, 2H), 3.40-3.54 (m, 2H), 3.66-3.75 (m, 2H), 3.80 (s, 3H), 4.51-4.55 (m, 2H), 7.15 (d, 1 H), 7.24 (d, 1 H), 7.33 (d, 1 H), 7.62 (s, 1 H), 8.27 (d, 1 H).
LCMS: m/z 446 M+H+. Preparation 39
2-Fluoro-4-r3-(4,5,6,7-tetrahvdro-1 H-imidazor4,5-clpyridin-2-yl)-1 H-indazol-6-yll-5-(2,2,2- trifluoro-ethvD-phenol dihvdrobromide salt
Boron tribromide (750μΙ_, 7.83mmol) was added driowuse to a solution of 2-{6-[5-fluoro-4- methoxy-2-(2,2,2-trifluoro-ethyl)-phenyl]-1 H-indazol-3-yl}-4,5,6,7-tetrahydro-3H-imidazo[4,5- c]pyridine trihydrochloride salt (Preparation 38, 2.03g, 3.66mmol) in DCM (25ml_) at 0°C. The resulting solution was stirred at room temperature for 18 hours. Further boron tribromide (2ml_, 20.7mmol) was added dropwise and the reaction mixture was allowed to stir at room temperature for 18 hours. The precipitated solid was collected by filtration, washed with DCM and triturated with EtOAc to yield the title compound as the dihydrobromide salt (1 .56g) in a 67% yield.
1H NMR (400 MHz, CD3OD) δ ppm 3.24 (dd, 2H), 3.41 (q, 2H), 3.75 (dd, 2H), 4.58 (s, 2H), 7.05-7.09 (m, 2H), 7.34 (d, 1 H), 7.60 (s, 1 H), 8.26 (d, 1 H).
LCMS: m/z 432 M+H+.
Preparation 40
5-Hvdroxy-pyrazine-2-carboxylic acid methyl ester
Thionyl chloride (152ml_, 2.08mol) was added dropwise at -20 °C to methanol (5L). After the addition was completed, the mixture was stirred at this temperature for 30 minutes. Then 5- hydroxy-pyrazine-2-carboxylic acid (100g, 714mmol) was added, and the mixture was heated at reflux for 2 hours. The reaction mixture was concentrated in vacuo, and the residue was recrystallised from methanol (400ml_) to give 71 g (464mmol) of the title compound in 65% yield.
Preparation 41
5-Chloro-pyrazine-2-carboxylic acid methyl ester
A mixture of 5-hydroxy-pyrazine-2-carboxylic acid methyl ester (Preparation 40, 50 g, 324mmol) and POCI3 (500ml_, 5.36mol) was heated under reflux for 1.5 hours and then poured onto ice. The resulting mixture was extracted with ether (4 χ 500ml_). The organic layers were concentrated in vacuo, and the residue was recrystallised from toluene to give the title compound (30.8g) in a 55% yield.
Preparation 42
5-Piperidin-1-yl-pyrazine-2-carboxylic acid methyl ester
To a solution of 5-chloro-pyrazine-2-carboxylic acid methyl ester (Preparation 41 , 85g, 492mmol) in DMF (365ml_) was added DIPEA (129ml_, 738mmol) and piperidine (58.4ml_, 591 mmol) and the resulting solution was stirred at room temperature for 18 hours. The reaction mixture was poured onto water (4L) and the resulting precipitate was collected by filtration to give the title compound as a white solid (85.12g) in a 78% yield.
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .50-1.56 (m, 4H), 1.60-1 .62 (m, 2H), 3.68-3.73 (m, 4H), 3.80 (s, 3H), 8.35 (s, 1 H), 8.60 (s, 1 H).
Preparation 43
5-Piperidin-1-yl-pyrazine-2-carboxylic acid
5-Piperidin-1-yl-pyrazine-2-carboxylic acid methyl ester (Preparation 42, 85.1 g, 384mmol) was added to a solution of sodium hydroxide (61 .5g, 1 .53mol) in water (760ml_). The mixture was stirred mechanically for 1 hour at room temperature. THF (300ml_) was added and stirring was continued for 3 hours. The volatile solvents were removed in vacuo and the remaining aqueous solution was adjusted to pH 4. The mixture was cooled on ice to induce precipitation of the product. The resulting solid was collected by filtration and dried in vacuo to give the title compound as a white solid (56g) in a 70% yield.
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .43-1.61 (m, 6H), 3.60-3.70 (m, 4H), 8.28 (s, 1 H), 8.58 (s, 1 H), 12.59 (br s, 1 H).
LCMS: m/z 208 [M+H]+.
Preparation 44
5-(2-Fluoro-phenoxy)-pyrazine-2-carboxylic acid methyl ester 2-Fluorophenol (21 .6g, 233mmol) was dissolved in DMF (250ml_) under a calcium chloride drying tube. The solution was cooled to 0°C, and then 60% NaH in paraffin oil (9.3 g, 233mmol) was added in small portions. After the main portion of NaH had dissolved, 5-chloro-pyrazine-2- carboxylic acid methyl ester (Preparation 41 , 40.2g, 233mmol) was added. The mixture was refluxed for 1 hour and then poured into water (1 L). The aqueous mixture was extracted with ether (3 χ 300ml_), and the combined organic layers were washed with 2% sodium hydroxide aqueous solution (400ml_) and filtered through a layer of silica gel (40/60 μηη). The filtrate was concentrated in vacuo to yield the title compound which was used without further purification.
Preparation 45
5-(2-Fluoro-phenoxy)-pyrazine-2-carboxylic acid
5- (2-Fluoro-phenoxy)-pyrazine-2-carboxylic acid methyl ester (Preparation 44, 57.9g, 233mmol) was added to a solution of KOH (15g, 267mmol) in 78% ethanol (330ml_). The solution was stirred at room temperature for 18 hours, and the formed precipitate was collected by filtration. The resulting solid was dissolved in water (200ml_), and the solution was acidified with aqueous hydrochloric acid. The formed precipitate was collected by filtration, dried and recrystallised from 41 % ethanol (265ml_) to give the title compound (28.3g, 120.8mmol) in 51 .8% yield.
1H NMR (400 MHz, DMSO-d6) δ ppm 7.29-7.48 (m, 4H), 8.75 (s, 2H), 13.51 (s, 1 H).
LCMS: m/z 235.1 [M+H]+.
Preparation 46
6- Cvano-nicotinoyl chloride
6-Cyano-nicotinic acid (120mg, 810μη"ΐοΙ) was suspended in toluene (1 ml_) and thionyl chloride (1 19μΙ_, 1 .62mmol) was added dropwise followed by one drop of DMF. The reaction mixture was refluxed for 2.5 hours and then allowed to cool to room temperature for 18 hours. The solvents were removed in vacuo and the residue was azeotroped with toluene to furnish the title compound as a brown oil (134mg) which was used in further experiments without purification. LCMS: m/z 167.02 M+H+.
The activity of the compounds of formula (I) may be assessed in the following assays.
Preparation 47
(5-chloropyrazin-2-yl)(2-(6-(2-ethyl-5-fluoro-4-hvdroxyphenyl)-1 H-indazol-3-yl)-6 dihydro-1 H-imidazo[4,5-clpyndin-5(4H)-yl)methanone To a solution of 5-ethyl-2-fluoro-4-[3-(4,5,6 J-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H- indazol-6-yl]-phenol preparation 25 (500mg, 1 .326mmol) and 7 (209.54mg, 1.326mmol) in dry DMF (10ml), DIPEA (0.65ml, 3.978mmol) and T3P (2.38 ml, 3.978mmol) were added and the reaction mixture was stirred at room temperature for 1 h. TLC & LCMS showed product formation. The reaction mixture was evaporated in vacuo, ice water was added to form solid precipitate which was washed with water, saturated sodium bi carbonate and pentane to afford a brown solid (460mg, 67.08%).
1 H NMR (400 MHz, DMSO) δ (ppm): 1.04(t, 3H), 2.66-2.81 (m, 2H), 3.72(m, 1 H), 4.04(t, 1 H), 4.57(s, 1 H), 4.74(s, 1 H), 6.89-6.92(m, 1 H), 6.98-7.13(m, 2H), 7.36(d, 1 H), 8.31 (d, 1 H), 8.75(d, 1 H), 8.86-8.87(m, 1 H), 9.82(s, 1 H), 12.55(s, 1 H), 13.21 (s, 1 H);
LCMS: Rt = 2.89min; m/z 518.4 [M+H]+.
JAK3 isolated enzyme high ATP Caliper endpoint assay
4mM stock solutions of test compounds are prepared and serially diluted in 100% DMSO. A standard curve using PF-00956980-00 at a top concentration of 4mM is also prepared. High percentage effect (HPE) is defined by 500μΜ PF-00956980-00 and 0% effect (ZPE) is defined by 100% DMSO. Greiner 384 well plates are prepared containing 400nl of serially diluted compound, standard and HPE/ZPE. Final top assay concentration is 80μΜ as the assay dilution factor is fifty.
JAK3 enzyme (Invitrogen) stock solution is made up at 4.1 μΜ in sterile water. JAK3 enzyme stock is diluted to 2nM in assay buffer (10mM HEPES free acid pH 7.5, 10mM HEPES free base pH 7.5, 10mM MgCL2, 0.0005% Tween-20, 0.01 % BSA) containing 2mM DTT ( all supplied by Sigma). ATP is made up at 10mM stock in sterile water and diluted to 800μΜ in assay buffer. Peptide (American peptide company) is made up at 30mM in 100% DMSO and diluted to 3μΜ in assay buffer. Stop buffer comprises 140mM HEPES, 22.5mM EDTA (Sigma) and 0.15% coating reagent (Caliper Life Sciences).
Assays are performed in Greiner polypropylene 384 well plates. Following compound preparation within the plate 10μΙ of enzyme in assay buffer containing DTT is added using a Multidrop Micro. Final assay concentration of enzyme is 1 nM. Compound and enzyme are pre- incubated for 60 minutes at room temperature using low evaporation lids before addition of 10μΙ ATP/peptide mixture in assay buffer using a Multidrop Micro. Final assay concentrations are 400μΜ ATP and 1 .5μΜ peptide. Plates are foil sealed and incubated for a further 60 minutes at room temperature. Stop solution is added to the plates (20μΙΛ/νβΙΙ) using a Multidrop Micro and plates are loaded onto the Caliper EZReader II. Data is generated by the shift in mobility of non- phosphorylated peptide substrates and phosphorylated products by electrophoresis within a chip and detected via LED induced fluorescence. Data is analysed using LabChip EZReader software which calculates the relative heights of the substrate and product peaks and reports product/product plus substrate peak ratio. Test compound data are subsequently expressed as percentage inhibition defined by HPE and ZPE values for each plate. Percentage inhibition in the presence of test compound is plotted against compound concentration on a log scale to determine an IC50 from the resultant sigmoid curve.
JAK1 isolated enzyme high ATP Caliper endpoint assay
4mM stock solutions of test compounds are prepared and serially diluted in 100% DMSO. A standard curve using PF-00956980 (commercially available from Sigma Aldrich) at a top concentration of 4mM is also prepared. High percentage effect (HPE) is defined by 500μΜ PF- 00956980 and 0% effect (ZPE) is defined by 100% DMSO. Greiner 384 well plates are prepared containing 400nl of serially diluted compound, standard and HPE/ZPE. Final top assay concentration is 80μΜ as the assay dilution factor is fifty.
JAK1 enzyme (Invitrogen) stock solution is made up at 5.2μΜ in sterile water. JAK1 enzyme stock is diluted to 20nM in assay buffer (10mM HEPES free acid pH 7.5, 10mM HEPES free base pH 7.5, 10mM MgCL2, 0.0005% Tween-20, 0.01 % BSA) containing 2mM DTT ( all supplied by Sigma) with the addition of one protease tablet per 25mls buffer (Roche). ATP is made up at 10mM stock in sterile water and diluted to 5mM in assay buffer. Peptide H236 (Caliper Life Sciences) is made up at 1.5mM in 100% DMSO and diluted to 3μΜ in assay buffer. Stop buffer comprises 140mM HEPES, 22.5mM EDTA (Sigma) and 0.15% coating reagent (Caliper Life Sciences).
Assays are performed in Greiner polypropylene 384 well plates. Following compound preparation within the plate 10μΙ of enzyme in assay buffer containing DTT is added using a Multidrop Micro. Final assay concentration of enzyme is 10nM. Compound and enzyme are pre- incubated for 30 minutes at room temperature using low evaporation lids before addition of 10μΙ ATP/peptide mixture in assay buffer using a Multidrop Micro. Final assay concentrations are 2.5mM ATP and 1 .5μΜ peptide. Plates are foil sealed and incubated for a further 120 minutes at room temperature. Stop solution is added to the plates (20μΙΛ/νβΙΙ) using a Multidrop Micro and plates are loaded onto the Caliper EZReader II. Data is generated by the shift in mobility of non-phosphorylated peptide substrates and phosphorylated products by electrophoresis within a chip and detected via LED induced fluorescence. Data is analysed using LabChip EZReader software which calculates the relative heights of the substrate and product peaks and reports product/product plus substrate peak ratio. Test compound data are subsequently expressed as percentage inhibition defined by HPE and ZPE values for each plate. Percentage inhibition in the presence of test compound is plotted against compound concentration on a log scale to determine an IC50 from the resultant sigmoid curve.
The following Table shows the available IC50 data for Examples 1-31 in the JAK-1 and JAK-3 isolated enzyme high ATP Caliper endpoint assays described above.
Figure imgf000087_0001
Figure imgf000087_0002
As a comparator compound, Example 24(c) of WO-2001/002369 was tested. It gave an IC50 of 1 19 nM in the JAK-3 assay and an IC50 of 120 nM in the JAK-1 assay.
JAK1/3 whole cell reporter gene assay
4mM stock solutions of test compounds are prepared and serially diluted in 100% DMSO. A standard curve using PF-00956980 at a top concentration of 10mM is also prepared. High percentage effect (HPE) is defined by 10mM PF-00956980 and 0% effect (ZPE) is defined by 100% DMSO. Plates containing 1 μΙ of serially diluted compound, standard and HPE/ZPE are diluted by addition of 39μΙ assay media (Optimem with 100uM NEAA, 10uM sodium pyruvate and 100U penicillin/1 OOug streptomycin (Invitrogen)) using a Multidrop Combi. This dilutes test compounds to a top concentration of 100μΜ. Final top assay concentration is 10μΜ as the assay dilution factor is ten. Final DMSO concentration is 0.25%.
CD40 ligand is a member of the TNF superfamily and activates B cells. CD40 (Invitrogen) is prepared at 0.1 mg/ml in PBS minus Ca2+, minus Mg2+. The concentration of CD40 required for activation is predetermined by CD40 titration with the cell line, lnterleukin-4 (IL-4, Invitrogen) is used as the co-activator and functions by binding to the IL-4 receptor complex leading to recruitment and activation of JAK1 and JAK3 tyrosine kinases. IL-4 is prepared at 1 mg/ml in sterile water to generate a stock solution. This is further diluted to 100ng/ml in assay media. Inhibition of the STAT6-beta-lactamase reporter response is measured in the presence of IL-4 at an approximate EC50 concentration.
Beta lactamase dye reagent comprises three components and is made up by adding 1 part CCF4 dye, 5 parts solution B and 77 parts Live Blazer- substrate mixture.
Assays are performed in Greiner 384 well black polypropylene clear bottomed plates. The Invitrogen Cellsensor STAT6-b/a-RA-1 cell line is thawed, counted and resuspended at 1 .88x106 cells/ml. Cells are stimulated with CD40 ligand by addition of 5.56μΙ of 0.1 mg/ml stock per 1 ml of cell suspension. Cells are plated out at 60000 cells/well, 32μΙΛ/νβΙΙ and incubated at 37°C, 5% C02. After 18 hours 4μΙ test compound is added to the plate using a Platemate Plus. Plates are incubated at 37°C, 5% C02 for 60 minutes using low evaporation lids before addition of 4μΙ IL-4 at a concentration of 100ng/ml. Plates are incubated at 37°C, 5% C02 for a further five hours before addition of 10μΙ beta lactamase dye. After reagent addition plates are incubated at 37°C, 5% C02 for 18 hours. Beta lactamase fluorescence signal is read at 460nm (blue) and 530nm (green) and a ratio calculated using an Envision. Test compound data are expressed as percentage inhibition defined by HPE and ZPE values for each plate. Percentage inhibition in the presence of test compound is plotted against compound concentration on a log scale to determine an IC50 from the resultant sigmoid curve.
Example 4 gave an IC50 of 140 nM in this assay.
JAK1 and JAK2 PathHunter assay
4mM stock solutions of test compounds are prepared and serially diluted in 100% DMSO. A standard curve using PF-00956980 at a top concentration of 10mM is also prepared. High percentage effect (HPE) is defined by "l OmM PF-00956980 and 0% effect (ZPE) is defined by 100% DMSO. Plates containing 1 μΙ of serially diluted compound, standard and HPE/ZPE are diluted by addition of 65μΙ compound diluent (PBS minus Ca2+, minus Mg2+ with 0.05% pluronic F127) using a Multidrop Combi. This dilutes test compounds to a top concentration of 60μΜ. Final top assay concentration is 10μΜ as the assay dilution factor is six. Final DMSO concentration is 0.25%.
Prolactin (Peprotech) is used for the agonist challenge. Prolactin is prepared at 40μΜ in compound diluent to generate a stock solution and further diluted to 6μΜ in compound diluent. A standard curve is prepared in compound diluent. Prolactin is also diluted to a concentration of 15nM (2.5nM fac). Antagonism of the JAK1 or JAK2 prolactin response is measured in the presence of prolactin at an approximate EC8o concentration for JAK1 and approximately Edoo for JAK2.
PathHunter detection reagent comprises three components and is made up by adding 1 part Galacton Star, 5 parts Emerald II and 19 parts Cell Assay Buffer.
Assays are performed in Greiner white 384 well plates. The PathHunter U20S cell line expressing the cytosolic tyrosine kinase JAK1 or JAK2 and the membrane bound cytokine receptor prolactin is plated out using OptiMEM (Invitrogen) at 5000 cells/well, 20μΙΛ/νβΙΙ and incubated at 37°C, 5% C02. After 18 hours 5μΙ test compound is added to the plate using a Platemate Plus. Plates are incubated at 37°C, 5% C02 for 60 minutes before addition of 5μΙ prolactin at a concentration of 15nM. Plates are incubated at room temperature for a further 180 minutes before addition of 10μΙ detection reagent. After reagent addition plates are covered and incubated at room temperature for 60 minutes. Luminescence signal is read using an Envision. Test compound data are expressed as percentage inhibition defined by HPE and ZPE values for each plate. Percentage inhibition in the presence of test compound is plotted against compound concentration on a log scale to determine an IC50 from the resultant sigmoid curve.
Example 4 gave a JAK-1 IC50 of 75 nM and a JAK-2 IC50 of 176 nM in this assay.
Functional Assessment of JAK inhibitory Potency using hrlL-2 and haCD3 stimuated IFNy
Production in Human Isolated PBMC.
Isolation of human Peripheral Blood Mononuclear Cells (PBMC)
Peripheral venous blood from healthy volunteers of either sex was collected into 50ml centrifuge tubes (Corning) containing 1 ml of 5mg/ml heparin (Sigma H3400) in distilled water. The heparininsed blood was diluted using an equal volume of sterile Dulbeccos phosphate buffered saline (PBS: Invitrogen 14190) before decanting into 50ml Leucosep tubes (Sigma A0561 ). The Leucosep tubes were centrifuged at 400g for 30min at room temperature and the buffycoat at the FicolhPlamsa interface collected into clean centrifuge tubes and the volum made up to 50ml using PBS and centrifuging at 200g for 10min at room temperature. The supernatent was discarded and the pellet resuspended in assay media (Dulbeccos Modified Essential Medium (DMEM: Invitrogen 1 1971025) containing 5% Foetal Bovine Serum, 100U/ml penicilin/ 100μg ml streptomycin (Sigma P4458) at 2x106 lymphocytes per ml for IFNy experiments and at 1x106 lymphocytes per ml for the pYSTAT5 experiments. hrlL2/haCD3 Stimulated IFNy Production
180μΙ of PBMC cell suspension was added to each well of a sterile 96 well, flat bottomed plate (Corning-Costar 3598). After a 1 h incubation at 37°C, 10μΙ of test compound dilution (final assay concentration range of 0.3nM to 1 μΜ in half log increments) or vehicle (2% DMSO in Hanks Balanced Salt Solution (Sigma H8264)) was added to the appropriate well and the pates incubated at 37°C, in 95%02/5%C02 for 1 h. 10μΙ of 200ng/ml IL-2(R&D systems 202- IL):20μg ml aCD3 (BD Biosciences 555329) (final assay concentrations of 10ng/ml and ^g/ml respectively) in assay buffer was added and the plates incubated at 37°C, in 95%02/5% C02 for 18h. Plates were removed from the incubator and centrifuged at 200g for 5min at room temperature. 100μΙ supernatent was collected, diluted 1 :4 and IFNy content determined using a commercially available IFNy ELISA kit (Invitrogen CHC1233) as per the manufacturer's instructions. Absorbances were measured using a Spectramax 190/250 plate reader (Molecular Devices). The IFNy concentration of test wells was expressed as % of the IFNy concentration produced in wells exposed to IL-2/aCD3 in the absence of test compound, and IC50 values determined using a 4 parameter curve fit.
Example 4 gave an IC50 of 70 nM in this assay. hrlL2/haCD3 Stimulated pYSTAT5 in PBMC lymphocytes
90μΙ of PBMC cell suspension was added to each well of a 96 well plate (Corning-Costar 3598) along with 10μΙ of test compound dilution giving a final assay concentration range of 0.03nM to 1 μΜ in half log increments. The plates were incuated at 37°C, in 95%02/5% C02 for 1 h before 10μΙ rhlL2 ^g/ml final assay concentration) was added to appropriate wells and the plates incubated at the stated conditions for a further 15min. 25μΙ of 20% formaldehyde (Tousimis) was added to all wells and the plates left at room temperature for 10min prior to centrifugation at 400g for 4min at room temperature. 200μΙ PBS was added to each well and centrifugation repeated as just described. The supernatent was removed and 50μΙ of a 1 :50 dilution of Mouse anti-human CD3 (BD Biosciences 555329) in 0.1 % BSA (Sigma A7906)/ PBS added to each well (excluding control wells) and the plates incubated at room temperature in the dark for 30min. 150μΙ of 0.1 % BSA/PBS was added to each well and the plate centrifuged at 400g for 4min before the supernatent was discarded and 10ΟμΙ ice-cold Phosflow Perm Buffer III (BD Biosciences 612599) added. The plates were briefly vortexed and incubated on ice in the dark for 30min before 10ΟμΙ of 0.1 %BSA/PBS was added and the plates centrifuged again as just described. 20μΙ of a 1 :20 dilution of AF647 anti-phospho-STAT5 antibody (in PBS) was added to the wells (excluding controls) and incubated in the dark at room temperature for 30min before adding 180μΙ of 0.1 %BSA PBS and centrifuging as already described. Once the supernatent was discarded the cells were resuspended in 10ΟμΙ of 2% formaldehyde and the plates stored at 4°C overnight. Plates were read the next day on a FACS Canto (Becton Dickinson). Lymphocytes were gated on PE immunofluorescence and the AF647 signal used as a measure of pYSTAT5 expression. IC50 values were generated in Excel using a four parameter curve fit.
Example 4 gave an IC50 of 45 nM in this assay.
For determination of compound duration of action (DoA) cells were incubated with compound at an approximate IC8o concentration for 1 h before being washed by cenrifugation and resuspension in assay media without compound. At set intervals after wash cells were stimulated with IL-2:aCD3 for 15 min and the plates processed as described above. 100% inhibition was defined as reduction of pYSTAT5 levels down to basal. DoA was calculated as the time taken for the inhibition to reverse by 50% (T50%).
Example 4 gave a DoA of >8.8 hours in this assay.

Claims

Claims
Figure imgf000092_0001
(I) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein:
R1 is halo;
R2 is Ci-C6 alkyl optionally substituted by one or more fluorine atoms; X is a bond, -CO-, -S02- or -CH2-;
R3 is Aryl1, Het1 or Het2, each of which is optionally substituted by 1 substituent -Y-R4 and/or 1-4 substituents each independently selected from R5; n is 1 or 2;
Aryl1 is phenyl or naphthyl;
Het1 is (i) a 6-membered aromatic heterocycle containing 1 -3 N atoms or (ii) a 5-membered aromatic heterocycle containing either (a) 1-4 N atoms or (b) 1 O or S atom and 0-3 N atoms; Het2 is (i) a 10-membered bicyclic aromatic heterocycle containing 1-4 N atoms or (ii) a 9- membered bicyclic aromatic heterocycle containing either (a) 1-4 N atoms or (b) 1 O or S atom and 0-3 N atoms or (iii) an 8-membered bicyclic aromatic heterocycle containing (a) 1-4 N atoms or (b) 1 O or S atom and 1 -3 N atoms or (c) 2 O or S atoms and 0-2 N atoms;
Y is a bond or -0-;
R4 is Aryl2 or Het3;
R5 is C Ce alkyi, C3-C8 cycloalkyi, halo, -CN, -OR6, -NR7R8, -SR6, -SOR9, -S02R9, -COR6, - OCOR6, -COOR6, -NR6COR6, -CONR7R8, -NR6S02R9, -S02NR7R8, -NR6CONR7R8, - NR6COOR9 or -NR6S02NR7R8;
R6 is H, Ci-C6 alkyi or C3-C8 cycloalkyi, said Ci-C6 alkyi being optionally substituted by halo or C3-C8 cycloalkyi;
R7 and R8 are (a) each independently H, C^Ce alkyi or C3-C8 cycloalkyi, said C^Ce alkyi being optionally substituted by -NR10R11, wherein R1 and R11 are C-|-C6 alkyi or taken together with the nitrogen atom to which they are attached form a 4-, 5- or 6-membered saturated heterocyclic ring containing 1 -2 nitrogen atoms or 1 nitrogen and 1 oxygen atom, said heterocyclic ring being optionally substituted by one or more C^Ce alkyi or C3-C8 cycloalkyi groups; or, (b) are taken together with the nitrogen atom to which they are attached to form a 4-, 5- or 6-membered saturated heterocyclic ring containing 1-2 nitrogen atoms or 1 nitrogen and 1 oxygen atom, said heterocyclic ring being optionally substituted by one or more C-|-C6 alkyi or C3-C8 cycloalkyi groups;
R9 is Ci-C6 alkyi or C3-C8 cycloalkyi;
Aryl2 is phenyl or naphthyl, said phenyl and naphthyl being optionally substituted with 1-5 substituents selected from d-C6 alkyi, C3-C8 cycloalkyi, halo, -CN, -OR6, -NR7R8, -SR6, -SOR9, -S02R9, -COR6, -OCOR6, -COOR6, -NR6COR6, -CONR7R8, -NR6S02R9, -S02NR7R8, - NR6CONR7R8, -NR6COOR9 and -NR6S02NR7R8; and
Het3 is a 3 to 8-membered saturated or partially unsaturated monocyclic heterocycle, containing 1 or 2 heteroatoms selected from O and N, said heterocycle being optionally substituted by 1-5 substituents selected from Ci-C6 alkyi, C3-C8 cycloalkyi, halo, oxo, -OR6, -NR7R8, -SR6, -SOR9, -S02R9, -COR6, -OCOR6, -COOR6, -NR6COR6, -CONR7R8, -NR6S02R9, -S02NR7R8, - NR6CONR7R8, -NR6COOR9 and -NR6S02NR7R8.
2. A compound of formula (I), as claimed in claim 1 , or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, wherein R1 is fluoro.
3. A compound of formula (I), as claimed in claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, wherein R2 is -CH2CH3 or -CH2CF3..
4. A compound of formula (I), as claimed in any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, wherein n is 1.
5. A compound of formula (I), as claimed in claim any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, wherein n is 2.
6. A compound of formula (I), as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, wherein X is a bond.
7. A compound of formula (I), as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, wherein X is -CO-.
8. A compound of formula (I), as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, wherein X is -S02-.
9. A compound of formula (I), as claimed in any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, wherein X is -CH2-.
10. A compound of formula (I), as claimed in any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, wherein R3 is phenyl, thiazolyl, quinolinyl, pyrimidinyl, [1 ,8]naphthyridinyl or pyridyl, each of which is optionally substituted by 1 substituent selected from piperdininyl, (fluorophenyl)oxy, phenyloxy and morpholinyl and 1-2 substituents each independently selected from fluoro, chloro, cyano, methoxy and hydroxy
1 1. A compound of formula (I), as claimed in claim 1 , which is:
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo
[4,5-c]pyridin-5-yl}-(4-fluoro-phenyl)-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo
[4,5-c]pyridin-5-yl}-isothiazol-3-yl-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo
[4,5-c]pyridin-5-yl}-isothiazol-3-yl-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo
[4,5-c]pyridin-5-yl}-(5-piperidin-1 -yl-pyrazin-2-yl)-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo
[4,5-c]pyridin-5-yl}-(6-phenoxy-pyridin-3-yl)-methanone;
5-Ethyl-2-fluoro-4-{3-[5-(6-morpholin-4-yl-pyridine-3-sulfonyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5- c] pyridin-2-yl]-1 H-indazol-6-yl}-phenol;
5-Ethyl-2-fluoro-4-{3-[5-(6-phenoxy-pyridine-3-sulfonyl)-4,5,6,7-tetrahydro-1 H-imidazo
[4,5-c]pyridin-2-yl]-1 H-indazol-6-yl}-phenol;
(5-Chloro-pyridin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-4, 5,7,8- tetrahydro-1 H-imidazo[4,5-d]azepin-6-yl}-methanone;
2-{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-4,5,7,8-tetrahydro-1 H-imidazo[4,5- d] azepine-6-carbonyl}-isonicotinonitrile;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-4, 5, 7, 8-tetrahydro-1 H-imidazo
[4,5-d]azepin-6-yl}-(4-fluoro-phenyl)-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-4, 5, 7, 8-tetrahydro-1 H-imidazo
[4,5-d]azepin-6-yl}-isothiazol-3-yl-methanone;
5-Ethyl-2-fluoro-4-{3-[5-(4-fluoro-benzenesulfonyl)-4,5,6,7-tetrahydro-1 H-imidazo
[4,5-c]pyridin-2-yl]-1 H-indazol-6-yl}-phenol;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo
[4,5-c]pyridin-5-yl}-[5-(2-fluoro-phenoxy)-pyrazin-2-yl]-methanone;
4- [3-(6-Benzyl-1 , 4,5,6, 7,8-hexahydro-imidazo[4,5-d]azepin-2-yl)-1 H-indazol-6-yl]-5-ethyl-2- fluoro-phenol;
(5-Chloro-pyridin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 , 4,6,7- tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
5- {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo
[4,5-c]pyridine-5-carbonyl}-pyridine-2-carbonitrile; 5-{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-4,5J,8-tetrahydro-1 ^ d]azepine-6-carbonyl}-pyridine-2-carbonitrile;
5-Ethyl-2-fluoro-4-[3-(5-quinolin-6-ylmethyl-4,5,6J-tetrahydro-1 H-imidazo[4,5-c]pyridin indazol-6-yl]-phenol;
5-Ethyl-2-fluoro-4-{3-[5-(4-hydroxy-benzyl)-4!5!6J-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-^ indazol-6-yl}-phenol;
5-Ethyl-2-fluoro-4-{3-[5-(3-hydroxy-benzylH^
indazol-6-yl}-phenol;
4- {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 !4,6J-tetrahydro-imidazo[4,5- c]pyridin-5-ylmethyl}-pyridine-2-carbonitrile;
5- Ethyl-2-fluoro-4-{3-[5-(3-methoxy-benzyl)-4A6J-tetrah
indazol-6-yl}-phenol;
5-Ethyl-2-fluoro-4-[3-(5-quinolin-3-ylmethyl-4,5,6J-tetrahydro-1 H-imidazo[4,5-c]pyridin indazol-6-yl]-phenol;
5-Ethyl-2-fluoro-4-{3-[5-(6-phenoxy-pyridin-3-ylmethyl)-4,5,6J-tetrahydro-1 H-imidazo[4 c]pyridin-2-yl]-1 H-indazol-6-yl}-phenol;
5-Ethyl-2-fluoro-4-{3-[5-(3A5,6-tetrahydro-2H-[1 ^
1 H-imidazo[4,5-c]pyridin-2-yl]-1 H-indazol-6-yl}-phenol;
3- {2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 !4,6J-tetrahydro-imidazo[4,5- c]pyridin-5-ylmethyl}-pyridine-2-carbonitrile;
5-Ethyl-2-fluoro-4-{3-[5-(4-fluoro-benzyl)-4,5!6J-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-y indazol-6-yl}-phenol;
5-Ethyl-2-fluoro-4-[3-(5-[1 ,8]naphthyridin-2-ylmethyl-4!5,6J-tetrahydro-1 H-imidazo[
4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]-phenol;
(2-{6-[5-Fluoro-4-hydroxy-2-(2,2,2-trifluoro-ethyl)-ph
imidazo[4,5-c]pyridin-5-yl)-(5-piperidin-1-yl-pyrazin-2-yl)-methanone;
(2-{6-[5-Fluoro-4-hydroxy-2-(2!2!2-trifluoro-ethyl)-phenyl]-1 H-indazol-3-yl}-1 !4,6J-tetrah imidazo[4,5-c]pyridin-5-yl)-(4-fluoro-phenyl)-methanone; or
4- [3-(5-Benzyl-4,5!6J-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl)-1 H-indazol-6-yl]-2-fluoro-5- (2,2,2-trifluoro-ethyl)-phenol; or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.
12. A compound of formula (I), as claimed in claim 1 , which is: {5-[(2-Dimethylamino-ethyl)-methyl-amino]-pyrazin-2-yl}-{2-[6-(2-ethyl-5-fluoro
phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5- c]pyridin-5-yl}-[5-(2-pyrrolidin-1-yl-ethylamino)-pyrazin-2-yl]-methanone;
[5-(2-Dimethylamino-ethylamino)-pyrazin-2-yl]-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1 H indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
[5-(4-Dimethylamino-piperidin-1-yl)-pyrazin-2-yl]-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-pheny indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5- c]pyridin-5-yl}-{5-[ethyl-(2-hydroxy-ethyl)-amino]-pyrazin-2-yl}-methanone;
[5-((R)-3-Dimethylamino-pyrrolidin-1 -yl)-pyrazin-2-yl]-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phen
1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
[5-((S)-3-Dimethylamino-pyrrolidin-1-yl)-pyrazin-2-yl]-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-pheny
1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6J-etrahydroimidazo[4,5c]pyridin-
5-yl}-[5-(2-piperidin-1-yl-ethylamino)-pyrazin-2-yl]-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5- c]pyridin-5-yl}-[5-(2-piperazin-1-yl-ethylamino)-pyrazin-2-yl]-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5-
]pyridin-5-yl}-(4-methyl-3,4,5,6-tetrahydro-2H-[1 ,2']bipyrazinyl-5'-yl)-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5- c]pyridin-5-yl}-(5-morpholin-4-yl-pyrazin-2-yl)-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-idazo[4,5c]pyridin- 5-yl}-[5-(4-methyl-piperidin-1-yl)-pyrazin-2-yl]-methanone;
(5-Cyclopentylamino-pyrazin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]- 1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5- c]pyridin-5-yl}-[5-(2-morpholin-4-yl-ethylamino)-pyrazin-2-yl]-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5- c]pyridin-5-yl}-(4-isopropyl-3,4,5,6-tetrahydro-2H-[1 ,2']bipyrazinyl-5'-yl)-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5- c]pyridin-5-yl}-(5-pyrrolidin-1-yl-pyrazin-2-yl)-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4!6!7-tetrahydro-imidazo[4,5- ]pyridin-5-yl}-[5-(ethyl-methyl-amino)-pyrazin-2-yl]-methanon;
(5-Cyclohexylamino-pyrazin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]- 1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone; (5-Dimethylamino-pyrazin-2-yl)-{2-[6-(2-ethyl-5-fluoro H-indazol-3-yl]-, 4,6,7- tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
(5-Azetidin-1-yl-pyrazin-2-yl)-{2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3
tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
2-Fluoro-4-{3-[5-(4-fluoro-benzyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl]-1 H-inda yl}-5-(2,2,2-trifluoro-ethyl)-phenol;
2-Fluoro-4-{3-[5-(3,4,5,6-tetrahydro-2H-[1 ,2']bipyridinyl-5'-ylmethyl)-4,5,6,7-tetrahydro-1 H- imidazo[4,5-c]pyridin-2-yl]-1 H-indazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;
2-Fluoro-4-{3-[5-(6-phenoxy-pyridin-3-ylmethyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2- yl]-H-indazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;
2-Fluoro-4-{3-[5-(4-methoxy-benzyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl]-1 H indazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;
2-Fluoro-4-{3-[5-(4-hydroxy-benzyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl]-1 H- indazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;
2-Fluoro-4-{3-[5-(3-methoxy-benzyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl]-1 H- indazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;
2-Fluoro-4-{3-[5-(3-hydroxy-benzyl)-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-yl]-1 H- indazol-6-yl}-5-(2,2,2-trifluoro-ethyl)-phenol;
2-Fluoro-4-[3-(5-quinolin-6-ylmethyl-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-y
indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol;
2-Fluoro-4-[3-(5-quinolin-3-ylmethyl-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyridin-2-y
indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol;
2-Fluoro-4-[3-(5-[1 ,8]naphthyridin-3-ylmethyl-4,5,6,7-tetrahydro-1 H-imidazo[4,5-c]pyri
1 H-indazol-6-yl]-5-(2,2,2-trifluoro-ethyl)-phenol;
((3R,5S)-3,5-Dimethyl-3,4,5,6-tetrahydro
hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5- c]pyridin-5-yl}-((S)-3-methyl-3,4,5,6-tetrahydro-2H-[1 ,2']bipyrazinyl-5'-yl)-methanon
((2S,5R)-2,5-Dimethyl-3,4,5,6-tetrahydro-2H-[1 ,2']bipyrazinyl-5'-yl)-{2-[6-(2-ethyl-5-fluor^^^ hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-methanone;
{2-[6-(2-Ethyl-5-fluoro-4-hydroxy-phenyl)-1 H-indazol-3-yl]-1 ,4,6,7-tetrahydro-imidazo[4,5-
]pyridin-5-yl}-(3,4,5,6-tetrahydro-2H-[1 ,2']bipyrazinyl-5'-yl)-methanone; or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.
13. A pharmaceutical composition comprising a compound of formula (I), as claimed in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt, and a pharmaceutically acceptable excipient.
14. A method of treating a disease or condition for which a JAK inhibitor is indicated, in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.
15. A method of treating a disease or condition selected from allergic rhinitis, nasal congestion, rhinorrhea, perennial rhinitis, nasal inflammation, asthma of all types, chronic obstructive pulmonary disease , chronic or acute bronchoconstriction, chronic bronchitis, small airways obstruction, emphysema, chronic eosinophilic pneumonia, adult respiratory distress syndrome, exacerbation of airways hyper-reactivity consequent to other drug therapy, pulmonary vasulcar disease, pulmonary arterial hypertension, acute lung injury, bronchiectasis, sinusitis, allergic conjunctivitis, idiopathic pulmonary fibrosis or atopic dermatitis, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.
16. A method of treating chronic obstructive pulmonary disease, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.
17. A method of treating a disease or condition selected from inflammation, neuroinflammation, arthritis, rheumatoid arthritis, spondyloarthropathies, systemic lupus erythematous arthritis, osteoarthritis, gouty arthritis, pain, fever, pulmonary sarcoisosis, silicosis, cardiovascular disease, atherosclerosis, myocardial infarction, thrombosis, congestive heart failure and cardiac reperfusion injury, cardiomyopathy, stroke, ischaemia, reperfusion injury, brain edema, brain trauma, neurodegeneration, liver disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, nephritis, retinitis, retinopathy, macular degeneration, glaucoma, diabetes (type 1 and type 2), diabetic neurorpathy, viral and bacterial infection, myalgia, endotoxic shock, toxic shock syndrome, autoimmune disease, osteoporosis, multiple sclerosis, endometriosis, menstrual cramps, vaginitis, candidiasis, cancer, fibrosis, obesity,muscular dystrophy, polymyositis, Alzheimer's disease, skin flushing, eczema, psoriasis, atopic dermatitis and sunburn, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.
18. A method of treating psoriasis, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), as claimed in any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt.
PCT/IB2012/053546 2011-07-27 2012-07-11 Indazoles WO2013014567A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
JP2014522177A JP5579351B1 (en) 2011-07-27 2012-07-11 Indazole
CN201280037293.XA CN103717599B (en) 2011-07-27 2012-07-11 Indazole
MDA20140002A MD20140002A2 (en) 2011-07-27 2012-07-11 Indazoles
AU2012288491A AU2012288491A1 (en) 2011-07-27 2012-07-11 Indazoles
EA201490357A EA201490357A1 (en) 2011-07-27 2012-07-11 INTRODUCTION
BR112014001801A BR112014001801A2 (en) 2011-07-27 2012-07-11 indazoles
CA2841882A CA2841882A1 (en) 2011-07-27 2012-07-11 6-phenyl-1h-indazole derivatives and their use as janus kinase inhibitors
AP2014007372A AP2014007372A0 (en) 2011-07-27 2012-07-11 Indazoles
UAA201400660A UA108442C2 (en) 2011-07-27 2012-07-11 Indazol
KR1020147001773A KR20140026627A (en) 2011-07-27 2012-07-11 Indazoles
EP12756557.0A EP2736907B1 (en) 2011-07-27 2012-07-11 Indazoles
GEAP201213360A GEP20156398B (en) 2011-07-27 2012-07-11 Indazoles
MX2014001004A MX2014001004A (en) 2011-07-27 2012-07-11 Indazoles.
TNP2014000033A TN2014000033A1 (en) 2011-07-27 2014-01-21 INDAZOLES
IL230662A IL230662A0 (en) 2011-07-27 2014-01-26 Indazoles
MA36716A MA35285B1 (en) 2011-07-27 2014-01-27 indazoles
CU2014000009A CU20140009A7 (en) 2011-07-27 2014-01-27 INDAZOLES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512144P 2011-07-27 2011-07-27
US61/512,144 2011-07-27

Publications (1)

Publication Number Publication Date
WO2013014567A1 true WO2013014567A1 (en) 2013-01-31

Family

ID=46826868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/053546 WO2013014567A1 (en) 2011-07-27 2012-07-11 Indazoles

Country Status (29)

Country Link
US (2) US8575336B2 (en)
EP (1) EP2736907B1 (en)
JP (1) JP5579351B1 (en)
KR (1) KR20140026627A (en)
CN (1) CN103717599B (en)
AP (1) AP2014007372A0 (en)
AR (1) AR087348A1 (en)
AU (1) AU2012288491A1 (en)
BR (1) BR112014001801A2 (en)
CA (1) CA2841882A1 (en)
CL (1) CL2014000122A1 (en)
CO (1) CO6862160A2 (en)
CR (1) CR20140042A (en)
CU (1) CU20140009A7 (en)
DO (1) DOP2014000016A (en)
EA (1) EA201490357A1 (en)
EC (1) ECSP14013222A (en)
GT (1) GT201400016A (en)
IL (1) IL230662A0 (en)
MA (1) MA35285B1 (en)
MD (1) MD20140002A2 (en)
MX (1) MX2014001004A (en)
NI (1) NI201400005A (en)
PE (1) PE20141059A1 (en)
TN (1) TN2014000033A1 (en)
TW (1) TWI462922B (en)
UA (1) UA108442C2 (en)
UY (1) UY34220A (en)
WO (1) WO2013014567A1 (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895544B2 (en) 2011-07-27 2014-11-25 Pfizer Limited Indazoles
WO2015173683A1 (en) 2014-05-14 2015-11-19 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
WO2016139212A1 (en) 2015-03-04 2016-09-09 F. Hoffmann-La Roche Ag Triazolopyridine compounds and methods of use thereof
WO2017077288A1 (en) * 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
WO2017077283A1 (en) * 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
WO2017079205A1 (en) * 2015-11-03 2017-05-11 Theravance Biopharma R&D Ip, Llc Jak kinase inhibitor compounds for treatment of respiratory disease
WO2017089390A1 (en) 2015-11-23 2017-06-01 F. Hoffmann-La Roche Ag Janus kinases inhibitors, compositions thereof and use thereof
WO2017140825A1 (en) 2016-02-18 2017-08-24 F. Hoffmann-La Roche Ag Therapeutic compounds, compositions and methods of use thereof
WO2017191098A1 (en) 2016-05-05 2017-11-09 F. Hoffmann-La Roche Ag Pyrazole derivatives, compositions and therapeutic use thereof
WO2018046409A1 (en) 2016-09-06 2018-03-15 F. Hoffmann-La Roche Ag 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
WO2018122212A1 (en) 2016-12-29 2018-07-05 F. Hoffmann-La Roche Ag Pyrazolopyrimidine compounds and methods of use thereof
WO2018165395A1 (en) * 2017-03-09 2018-09-13 Theravance Biopharma R&D Ip, Llc Fused imidazo-piperidine jak inhibitors
WO2018166993A2 (en) 2017-03-14 2018-09-20 F. Hoffmann-La Roche Ag Pyrazolochlorophenyl compounds, compositions and methods of use thereof
WO2018204233A1 (en) * 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
WO2018204236A1 (en) * 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Crystalline forms of a jak inhibitor compound
WO2018204238A1 (en) * 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Fused imidazo-piperidine jak inhibitor compound
WO2018215389A1 (en) 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
WO2018215390A1 (en) 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
WO2019139714A1 (en) 2018-01-15 2019-07-18 Genentech, Inc. Pyrazolopyrimidine compounds as jak inhibitors
WO2020051105A1 (en) * 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Dimethyl amino azetidine amides as jak inhibitors
US10836763B2 (en) 2018-09-04 2020-11-17 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as JAK inhibitors
US10844057B2 (en) 2018-09-04 2020-11-24 Theravance Biopharma R&D Ip, Llc Process for preparing JAK inhibitors and intermediates thereof
WO2020257143A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
WO2020257145A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof
WO2020257142A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
US10968222B2 (en) 2018-10-29 2021-04-06 Theravance Biopharma R&D Ip, Llc 2-azabicyclo hexane JAK inhibitor compound
WO2021136345A1 (en) * 2019-12-30 2021-07-08 路良 Jak inhibitor compound and use thereof
EP3932919A4 (en) * 2019-02-25 2022-12-14 Henan Medinno Pharmaceutical Technology Co., Ltd. Jak inhibitor compound and use thereof
RU2786361C2 (en) * 2018-09-04 2022-12-20 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Method for production of jak inhibitors and their intermediate compounds
WO2022272020A1 (en) * 2021-06-25 2022-12-29 Theravance Biopharma R&D Ip, Llc Imidazolo indazole compounds as jak inhibitors
US11702415B2 (en) 2020-03-02 2023-07-18 Theravance Biopharma R&D Ip, Llc Crystalline hydrate of a JAK inhibitor compound

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3286181B1 (en) 2015-04-22 2021-01-27 Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds
US20170157215A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
JP7004677B2 (en) * 2016-06-01 2022-01-21 バイエル・アニマル・ヘルス・ゲーエムベーハー Substituted indazole useful for the treatment and prevention of allergic and / or inflammatory diseases in animals
CN114075200A (en) * 2020-08-14 2022-02-22 河南迈英诺医药科技有限公司 JAK inhibitor compounds for the treatment of severe pneumonia
CN114075199A (en) * 2020-08-14 2022-02-22 河南迈英诺医药科技有限公司 JAK inhibitor compounds and uses thereof
EP4003990A1 (en) 2019-08-30 2022-06-01 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
TW202144346A (en) * 2020-03-18 2021-12-01 四川海思科製藥有限公司 Indazole derivative and medical use thereof
CN117343063A (en) * 2022-07-04 2024-01-05 河南迈英诺医药科技有限公司 Compounds as TRK inhibitors and/or RET inhibitors and uses thereof

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011172A1 (en) 1990-01-23 1991-08-08 The University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1994002518A1 (en) 1992-07-27 1994-02-03 The University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1998055148A1 (en) 1997-06-05 1998-12-10 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising cyclodextrins
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
US6106864A (en) 1995-09-15 2000-08-22 Pfizer Inc. Pharmaceutical formulations containing darifenacin
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
WO2001002369A2 (en) 1999-07-02 2001-01-11 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
US20040229862A1 (en) 2003-05-13 2004-11-18 Alexander Flohr Imidazo-benzothiazoles
WO2007002313A2 (en) 2005-06-24 2007-01-04 Bristol-Myers Squibb Company Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
US20090203690A1 (en) * 2007-06-08 2009-08-13 Abbott Laboratories 5-substituted indazoles as kinase inhibitors
WO2010027500A1 (en) 2008-09-08 2010-03-11 Signal Pharmaceuticals, Llc Aminotriazolopyridines and their use as kinase inhibitors
WO2010069966A1 (en) * 2008-12-18 2010-06-24 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
WO2010090537A2 (en) 2009-02-05 2010-08-12 Benjamin Bell A continuous flow worm farm
US20110034497A1 (en) * 2009-08-10 2011-02-10 Epitherix, Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
US20110059951A1 (en) * 2009-09-01 2011-03-10 Rodgers James D HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
KR101127161B1 (en) * 2009-07-13 2012-03-20 한국화학연구원 Quinolinone compounds substituted with tetrahydroimidazopyridine group
CN102595899A (en) * 2009-08-10 2012-07-18 埃皮瑟瑞克斯有限公司 Indazoles as WNT/B-catenin signaling pathway inhibitors and therapeutic uses thereof
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011172A1 (en) 1990-01-23 1991-08-08 The University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1994002518A1 (en) 1992-07-27 1994-02-03 The University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6106864A (en) 1995-09-15 2000-08-22 Pfizer Inc. Pharmaceutical formulations containing darifenacin
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
WO1998055148A1 (en) 1997-06-05 1998-12-10 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising cyclodextrins
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
WO2001002369A2 (en) 1999-07-02 2001-01-11 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
US20040229862A1 (en) 2003-05-13 2004-11-18 Alexander Flohr Imidazo-benzothiazoles
WO2007002313A2 (en) 2005-06-24 2007-01-04 Bristol-Myers Squibb Company Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
US20090203690A1 (en) * 2007-06-08 2009-08-13 Abbott Laboratories 5-substituted indazoles as kinase inhibitors
WO2010027500A1 (en) 2008-09-08 2010-03-11 Signal Pharmaceuticals, Llc Aminotriazolopyridines and their use as kinase inhibitors
WO2010069966A1 (en) * 2008-12-18 2010-06-24 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
WO2010090537A2 (en) 2009-02-05 2010-08-12 Benjamin Bell A continuous flow worm farm
US20110034497A1 (en) * 2009-08-10 2011-02-10 Epitherix, Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
US20110059951A1 (en) * 2009-09-01 2011-03-10 Rodgers James D HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
"Bioreversible Carriers in Drug Design", 1987, PERGAMON PRESS
"Comprehensive Organic Chemistry", ELSEVIER
"Handbook of Organopalladium Chemistry for Organic Synthesis", vol. 1, JOHN WILEY & SONS
CHEM. SOC. REV., vol. 38, no. 2, 2009, pages 606 - 631
CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, vol. 10, 2007, pages 550
H. BUNDGAARD: "Design of Prodrugs", 1985, ELSEVIER
H. LIEBERMAN; L. LACHMAN: "Pharmaceutical Dosage Forms: Tablets", vol. 1, 1980, MARCEL DEKKER
HALEBLIAN, J PHARM SCI, vol. 64, no. 8, August 1975 (1975-08-01), pages 1269 - 1288
K. R. MORRIS: "Polymorphism in Pharmaceutical Solids", 1995, MARCEL DEKKER
LAROCK: "Comprehensive Organic Transformations: A Guide to Functional Group Preparations", JOHN WILEY AND SONS
LIANG; CHEN, EXPERT OPINION IN THERAPEUTIC PATENTS, vol. 11, no. 6, 2001, pages 981 - 986
N. H. HARTSHORNE; A. STUART: "Crystals and the Polarizing Microscope", 1970
NATURE REVIEWS/DRUG DISCOVERY, vol. 7, 2008, pages 355
O. ALMARSSON; M. J. ZAWOROTKO, CHEM COMMUN, vol. 17, 2004, pages 1889 - 1896
STAHL; WERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH
T. HIGUCHI; W. STELLA: "Prodrugs as Novel Delivery Systems", vol. 14, ACS SYMPOSIUM SERIES
TETRAHEDRON, vol. 51, 1995, pages 13447 - 13454
VERMA ET AL., PHARMACEUTICAL TECHNOLOGY ON-LINE, vol. 25, no. 2, 2001, pages 1 - 14
WUTS; GREENE: "Protective Groups in Organic Chemistry", WILEY-BLACKWELL

Cited By (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895544B2 (en) 2011-07-27 2014-11-25 Pfizer Limited Indazoles
JP2017515836A (en) * 2014-05-14 2017-06-15 ファイザー・インク Pyrazolopyridine and pyrazolopyrimidine
WO2015173683A1 (en) 2014-05-14 2015-11-19 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
US9518052B2 (en) 2014-05-14 2016-12-13 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
CN106459048A (en) * 2014-05-14 2017-02-22 辉瑞公司 Pyrazolopyridines and pyrazolopyrimidines
US10022376B2 (en) 2014-05-14 2018-07-17 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
WO2016139212A1 (en) 2015-03-04 2016-09-09 F. Hoffmann-La Roche Ag Triazolopyridine compounds and methods of use thereof
CN108349972B (en) * 2015-11-03 2021-06-08 施万生物制药研发Ip有限责任公司 JAK kinase inhibitor compounds for the treatment of respiratory diseases
US11299492B2 (en) 2015-11-03 2022-04-12 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
WO2017079205A1 (en) * 2015-11-03 2017-05-11 Theravance Biopharma R&D Ip, Llc Jak kinase inhibitor compounds for treatment of respiratory disease
US10556901B2 (en) 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
EA034914B1 (en) * 2015-11-03 2020-04-06 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Jak kinase inhibitor compounds for treatment of respiratory disease
AU2016350816B2 (en) * 2015-11-03 2020-06-25 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
US20200223843A1 (en) * 2015-11-03 2020-07-16 Topivert Pharma Limited Kinase inhibitors
WO2017077283A1 (en) * 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
CN108349972A (en) * 2015-11-03 2018-07-31 施万生物制药研发Ip有限责任公司 Jak kinase inhibitor compound for treating respiratory disorder
US11718616B2 (en) 2015-11-03 2023-08-08 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
EP3712152A1 (en) 2015-11-03 2020-09-23 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
WO2017077288A1 (en) * 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
US10100049B2 (en) 2015-11-03 2018-10-16 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
TWI710560B (en) * 2015-11-03 2020-11-21 美商施萬生物製藥研發Ｉｐ有限責任公司 Jak kinase inhibitor compounds for treatment of respiratory disease
EP3865481A1 (en) 2015-11-03 2021-08-18 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
EP3831830A1 (en) 2015-11-03 2021-06-09 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
US20180319791A1 (en) * 2015-11-03 2018-11-08 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
US10526330B2 (en) 2015-11-03 2020-01-07 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
US10913740B2 (en) 2015-11-03 2021-02-09 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
US10183942B2 (en) 2015-11-03 2019-01-22 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
US10882859B2 (en) 2015-11-03 2021-01-05 Topivert Pharma Limited Kinase inhibitors
US10851097B2 (en) 2015-11-03 2020-12-01 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
WO2017089390A1 (en) 2015-11-23 2017-06-01 F. Hoffmann-La Roche Ag Janus kinases inhibitors, compositions thereof and use thereof
WO2017140825A1 (en) 2016-02-18 2017-08-24 F. Hoffmann-La Roche Ag Therapeutic compounds, compositions and methods of use thereof
WO2017191098A1 (en) 2016-05-05 2017-11-09 F. Hoffmann-La Roche Ag Pyrazole derivatives, compositions and therapeutic use thereof
EP4198036A1 (en) 2016-09-06 2023-06-21 F. Hoffmann-La Roche AG 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a] pyridinyl compounds, compositions and methods of use thereof
WO2018046409A1 (en) 2016-09-06 2018-03-15 F. Hoffmann-La Roche Ag 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
WO2018122212A1 (en) 2016-12-29 2018-07-05 F. Hoffmann-La Roche Ag Pyrazolopyrimidine compounds and methods of use thereof
CN110382498B (en) * 2017-03-09 2022-07-12 施万生物制药研发Ip有限责任公司 Fused imidazole-piperidine JAK inhibitors
TWI779016B (en) * 2017-03-09 2022-10-01 美商施萬生物製藥研發 Ip有限責任公司 Fused imidazo-piperidine jak inhibitors
US11878977B2 (en) 2017-03-09 2024-01-23 Theravance Biopharma R&D Ip, Llc JAK inhibitors containing a 4-membered heterocyclic amide
WO2018165395A1 (en) * 2017-03-09 2018-09-13 Theravance Biopharma R&D Ip, Llc Fused imidazo-piperidine jak inhibitors
WO2018165392A1 (en) * 2017-03-09 2018-09-13 Theravance Biopharma R&D Ip, Llc Jak inhibitors containing a 4-membered heterocyclic amide
US10519153B2 (en) 2017-03-09 2019-12-31 Theravance Biopharma R&D Ip, Llc Fused imidazo-piperidine JAK inhibitors
CN110461839A (en) * 2017-03-09 2019-11-15 施万生物制药研发Ip有限责任公司 JAK inhibitor containing 4 membered heterocyclic amides
US10550118B2 (en) 2017-03-09 2020-02-04 Theravance Biopharma R&D Ip, Llc JAK inhibitors containing a 4-membered heterocyclic amide
US11667637B2 (en) 2017-03-09 2023-06-06 Theravance Biopharma R&D Ip, Llc Fused imidazo-piperidine JAK inhibitors
KR20190127796A (en) * 2017-03-09 2019-11-13 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 JAK inhibitors including 4-membered heterocyclic amides
KR102533646B1 (en) 2017-03-09 2023-05-17 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 JAK inhibitors comprising 4-membered heterocyclic amides
CN110382498A (en) * 2017-03-09 2019-10-25 施万生物制药研发Ip有限责任公司 Condensed imidazole-piperidines JAK inhibitor
IL268689B2 (en) * 2017-03-09 2023-02-01 Theravance Biopharma R& D Ip Llc Fused imidazo-piperidine jak inhibitors
EA037261B1 (en) * 2017-03-09 2021-03-01 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Jak inhibitors containing a 4-membered heterocyclic amide
US10392386B2 (en) 2017-03-09 2019-08-27 Theravance Biopharma R&D Ip, Llc JAK inhibitors containing a 4-membered heterocyclic amide
IL268689B (en) * 2017-03-09 2022-10-01 Theravance Biopharma R& D Ip Llc Fused imidazo-piperidine jak inhibitors
US11453668B2 (en) 2017-03-09 2022-09-27 Theravance Biopharma R&D Ip, Llc JAK inhibitors containing a 4-membered heterocyclic amide
US10954237B2 (en) 2017-03-09 2021-03-23 Theravance Biopharma R&D Ip, Llc JAK inhibitors containing a 4-membered heterocyclic amide
US11254669B2 (en) 2017-03-09 2022-02-22 Theravance Biopharma R&D Ip, Llc Fused imidazo-piperidine JAK inhibitors
US10208040B2 (en) 2017-03-09 2019-02-19 Theravance Biopharma R&D Ip, Llc Fused imidazo-piperidine JAK inhibitors
AU2018231035B2 (en) * 2017-03-09 2021-09-09 Theravance Biopharma R&D Ip, Llc Fused imidazo-piperidine JAK inhibitors
AU2018231032B2 (en) * 2017-03-09 2021-08-19 Theravance Biopharma R&D Ip, Llc JAK inhibitors containing a 4-membered heterocyclic amide
EA037748B1 (en) * 2017-03-09 2021-05-18 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Fused imidazo-piperidine jak inhibitors
US10196393B2 (en) 2017-03-09 2019-02-05 Theravance Biopharma R&D Ip, Llc JAK inhibitors containing a 4-membered heterocyclic amide
WO2018166993A2 (en) 2017-03-14 2018-09-20 F. Hoffmann-La Roche Ag Pyrazolochlorophenyl compounds, compositions and methods of use thereof
AU2018261593B2 (en) * 2017-05-01 2021-08-26 Theravance Biopharma R&D Ip, Llc Fused imidazo-piperidine JAK inhibitor compound
US10406148B2 (en) 2017-05-01 2019-09-10 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
KR20190140062A (en) * 2017-05-01 2019-12-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Treatment Methods Using JAK Inhibitor Compounds
US11786517B2 (en) 2017-05-01 2023-10-17 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
KR102568333B1 (en) 2017-05-01 2023-08-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Methods of Treatment Using JAK Inhibitor Compounds
CN110603255A (en) * 2017-05-01 2019-12-20 施万生物制药研发Ip有限责任公司 Crystalline forms of a JAK inhibitor compound
WO2018204238A1 (en) * 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Fused imidazo-piperidine jak inhibitor compound
KR102550225B1 (en) 2017-05-01 2023-07-03 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Fused imidazo-piperidine JAK inhibitor compounds
WO2018204236A1 (en) * 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Crystalline forms of a jak inhibitor compound
KR20190142389A (en) * 2017-05-01 2019-12-26 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Fused Imidazo-piperidine JAK Inhibitor Compounds
US10493077B2 (en) 2017-05-01 2019-12-03 Theravance Biopharma R&D Ip, Llc Fused imidazo-piperidine JAK inhibitor compound
AU2018261591B2 (en) * 2017-05-01 2021-09-02 Theravance Biopharma R&D Ip, Llc Crystalline forms of a JAK inhibitor compound
US10548886B2 (en) 2017-05-01 2020-02-04 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
US11160810B2 (en) 2017-05-01 2021-11-02 Theravance Biopharma R&D Ip, Llc Fused imidazo-piperidine JAK inhibitor compound
US11160800B2 (en) 2017-05-01 2021-11-02 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
RU2764979C2 (en) * 2017-05-01 2022-01-24 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Methods for treatment using jak inhibitor compound
RU2790535C2 (en) * 2017-05-01 2023-02-22 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Crystal forms of jak inhibitor compound
WO2018204233A1 (en) * 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
US10251874B2 (en) 2017-05-01 2019-04-09 Theravance Biopharma R&D Ip, Llc Crystalline forms of a JAK inhibitor compound
CN110603255B (en) * 2017-05-01 2023-02-10 施万生物制药研发Ip有限责任公司 Crystalline forms of a JAK inhibitor compound
JP2020518579A (en) * 2017-05-01 2020-06-25 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Treatment methods using JAK inhibitor compounds
JP7153031B2 (en) 2017-05-01 2022-10-13 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Methods of treatment using JAK inhibitor compounds
WO2018215390A1 (en) 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
WO2018215389A1 (en) 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
WO2019139714A1 (en) 2018-01-15 2019-07-18 Genentech, Inc. Pyrazolopyrimidine compounds as jak inhibitors
WO2020051105A1 (en) * 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Dimethyl amino azetidine amides as jak inhibitors
US11713315B2 (en) 2018-09-04 2023-08-01 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as JAK inhibitors
US10836763B2 (en) 2018-09-04 2020-11-17 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as JAK inhibitors
TWI791886B (en) * 2018-09-04 2023-02-11 美商施萬生物製藥研發 Ip有限責任公司 Dimethyl amino azetidine amides as jak inhibitors
US10844057B2 (en) 2018-09-04 2020-11-24 Theravance Biopharma R&D Ip, Llc Process for preparing JAK inhibitors and intermediates thereof
US11634419B2 (en) 2018-09-04 2023-04-25 Theravance Biopharma R&D Ip, Llc Dimethyl amino azetidine amides as JAK inhibitors
US10947229B2 (en) 2018-09-04 2021-03-16 Theravance Biopharma R&D Ip, Llc Dimethyl amino azetidine amides as JAK inhibitors
RU2786361C2 (en) * 2018-09-04 2022-12-20 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Method for production of jak inhibitors and their intermediate compounds
US10968222B2 (en) 2018-10-29 2021-04-06 Theravance Biopharma R&D Ip, Llc 2-azabicyclo hexane JAK inhibitor compound
US11629148B2 (en) 2019-02-25 2023-04-18 Henan Medinno Pharmaceutical Technology Co., Ltd. Substituted pyrrolo[3,4-d]imidazoles as JAK inhibitors
EP3932919A4 (en) * 2019-02-25 2022-12-14 Henan Medinno Pharmaceutical Technology Co., Ltd. Jak inhibitor compound and use thereof
RU2820445C2 (en) * 2019-02-25 2024-06-03 Хенан Мединно Фармасьютикал Текнолоджи Ко., Лтд. Jak inhibitor compound and use thereof
WO2020257145A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof
WO2020257143A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
WO2020257142A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
WO2021136345A1 (en) * 2019-12-30 2021-07-08 路良 Jak inhibitor compound and use thereof
US11702415B2 (en) 2020-03-02 2023-07-18 Theravance Biopharma R&D Ip, Llc Crystalline hydrate of a JAK inhibitor compound
WO2022272020A1 (en) * 2021-06-25 2022-12-29 Theravance Biopharma R&D Ip, Llc Imidazolo indazole compounds as jak inhibitors
US12122773B2 (en) 2023-05-31 2024-10-22 Theravance Biopharma R&D Ip, Llc Crystalline hydrate of a JAK inhibitor compound

Also Published As

Publication number Publication date
TN2014000033A1 (en) 2015-07-01
CN103717599A (en) 2014-04-09
CA2841882A1 (en) 2013-01-31
CN103717599B (en) 2015-11-25
US8895544B2 (en) 2014-11-25
IL230662A0 (en) 2014-03-31
BR112014001801A2 (en) 2017-02-14
JP2014522865A (en) 2014-09-08
DOP2014000016A (en) 2014-07-15
UY34220A (en) 2013-02-28
JP5579351B1 (en) 2014-08-27
EA201490357A1 (en) 2014-05-30
MD20140002A2 (en) 2014-06-30
NI201400005A (en) 2014-04-23
CO6862160A2 (en) 2014-02-10
EP2736907B1 (en) 2015-10-07
US20140024634A1 (en) 2014-01-23
MA35285B1 (en) 2014-07-03
UA108442C2 (en) 2015-04-27
ECSP14013222A (en) 2014-03-31
MX2014001004A (en) 2014-05-13
AR087348A1 (en) 2014-03-19
CL2014000122A1 (en) 2014-08-18
AU2012288491A1 (en) 2014-01-30
CU20140009A7 (en) 2014-03-26
CR20140042A (en) 2014-03-19
TWI462922B (en) 2014-12-01
AP2014007372A0 (en) 2014-01-31
TW201313712A (en) 2013-04-01
GT201400016A (en) 2015-02-19
PE20141059A1 (en) 2014-08-30
US8575336B2 (en) 2013-11-05
US20130029968A1 (en) 2013-01-31
EP2736907A1 (en) 2014-06-04
KR20140026627A (en) 2014-03-05

Similar Documents

Publication Publication Date Title
EP2736907B1 (en) Indazoles
JP6663857B2 (en) Pyrazolopyridine and pyrazolopyrimidine
EP3573987B1 (en) Tyrosine amide derivatives as rho- kinase inhibitors
US9193722B2 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
WO2009153721A1 (en) Nicotinamide derivatives
MX2011002340A (en) Pyrazolopyrimidines and their use for the treatment of cns disorders.
EP2300478A1 (en) 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators
WO2011018495A1 (en) New compounds for the treatment of cns disorders
CA2585557C (en) Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors
US20230099344A1 (en) Compounds and methods for the targeted degradation of irak-4
OA16848A (en) Indazoles
US20240174647A1 (en) Kinase modulators and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12756557

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2841882

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 20140002

Country of ref document: MD

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A 2014 0002

Country of ref document: MD

WWE Wipo information: entry into national phase

Ref document number: 2014000122

Country of ref document: CL

ENP Entry into the national phase

Ref document number: 20147001773

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13360

Country of ref document: GE

Ref document number: MX/A/2014/001004

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2014522177

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14015917

Country of ref document: CO

Ref document number: 000128-2014

Country of ref document: PE

Ref document number: 2012756557

Country of ref document: EP

Ref document number: CR2014-000042

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2012288491

Country of ref document: AU

Date of ref document: 20120711

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201490357

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014001801

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014001801

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140124